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Introduction
Since the first description of Alzheimer’s disease (AD) by Aloïs Alzheimer in 1906,1 there 
has been a steady increase in the incidence and prevalence of dementia due to AD.2 
Although current predictions for future incidence of dementia in Europe now do show a 
stabilization3 rather than the previously anticipated continuous increase,2 dementia is 
already among the most common causes of death.4 Not surprisingly, AD currently has and 
will remain to have a significant impact on the total health care budget.5
 Consequently, with the increasing incidence of AD, there has also been an overwhelming 
increase in research to AD (Figure 1). Nevertheless, the pathophysiological processes 
underlying AD are still poorly understood.5 One of the currently dominant paradigms is 
the amyloid cascade hypothesis, where the aggregation of the protein amyloid-β in the 
brain is thought to be root of the disease.6, 7 Although it is likely that the amyloid-β has a 
(key) role in the disease progress, the linear cascade is probably too simplistic. There is 
growing evidence and acceptance that a complex interaction of many different factors 
contribute to Alzheimer’s disease.8 This is supported by the (so far) negative outcomes of 
many interventions that have focused on intervening in the amyloid-β cascade. 9, 10
 Contrasting with the negative results of the amyloid-β driven interventions, the 
effective prevention and treatment of cardiovascular diseases is probably the most 
important contributor to the currently observed stabilization of AD incidence.11, 12 Yet, 
cerebrovascular changes in AD are frequently regarded to result from the amyloid-β 
aggregation, rather than having a disease modifying effect in itself,13, 14 but this is 
shifting.15, 16 For example, the observed decrease in cerebral blood flow (CBF) in patients 
with AD, showed association with the histopathological damage in AD,17 but also 
corresponded with diminishing cognitive capacities.18 Yet, the underlying reasons for this 
decline in CBF are not completely understood. 
Determinants of cerebral blood flow
To be able to understand AD-related changes in CBF, first it is required to understand on 
which factors global CBF depends in healthy humans. There are three main determinants 
for global CBF, which are all influenced by different factors and regulation mechanisms 
(Figure 2).19 The total CBF is the net result of the difference in cerebral perfusion pressure 
(CPP) and intracranial pressure (ICP) divided by the cerebrovascular resistance (CVR):
The CVR is a result of vessel diameter, branching pattern, vascular tone and arterial, 
arteriolar or capillary obstructions, whereas ICP is the result of pressure from brain tissue 
and cerebrospinal fluid. There are only few conditions, i.e. traumatic brain injury, in which 
ICP is elevated. The CPP, which is the arterial blood pressure at the height of the head is a 
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function of cardiac output (Stroke volume (SV) × Heart rate (HR)) and total peripheral 
resistance (TPR):
To ensure homeostasis of CBF, the human body has several short-term (seconds to 
minutes) and long-term (hours to days) feedback mechanisms that act on CVR and CPP. 
A selection of these mechanisms is shown in Figure 2. For CVR, the regulating mechanisms 
mainly act on the vascular tone. Although regulation of CVR is an integrative process, 
roughly three main regulation mechanisms can be distinguished. These are the neuro- 
vascular unit (NVU), cerebral vasomotor reactivity (CVMR) and cerebral autoregulation 
(CA).20 The NVU is a local mechanism that adapts resistance in response to increased 
demand of glucose and oxygen in specific brain regions, thus coupling the CBF and neural 
activity.21 The CVMR changes resistance in response to PaCO2; with high arterial CO2 levels 
the vessels dilate.22 
 CA is a mechanism that maintains global cerebral blood flow over a range of blood 
pressures by adjusting the vascular tone.23 CA functions both for rapid and slow changes 
in BP. For the slow changes, Figure 3 shows the range of blood pressures at which cerebral 
blood flow is traditionally thought to be maintained. This mechanism is referred to as 
‘steady-state cerebral autoregulation’ (sCA). For the rapid changes in BP, CA can be 
Figure 1 Yearly number of publications in PubMed on the specified topics. Search performed on 
26-03-2018 on pubmed.gov with keywords: Cancer; Alzheimer’s disease; Alzheimer’s disease AND vascular 
factors.
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modeled as a high-pass filter with a cut-off around 0.3 Hz.24 Thus, oscillations in blood 
pressure (below 0.3 Hz) are dampened, e.g. after standing up, preventing periods of hypo- 
or hyperperfusion. This mechanism is referred to as ‘dynamic cerebral autoregulation’ 
(dCA).23
 CPP is regulated through an interplay between cardiac output and peripheral resistance. 
For slow changes, through the renin-angiotensin-aldosterone system (RAAS), the circulating 
volume is adjusted to maintain cardiac output. For short-term regulation the baroreflex, 
a reflex loop of the autonomous nerve system, which involves cardiac, vascular and 
cerebral components has an important role.25 The baroreceptors, stretch-sensitive fibers 
embedded in the carotid arteries and aorta, sense changes in blood pressure. Via the 
brainstem and sympathetic and parasympathetic nerve fibers these sensed changes 
result in adjustments of HR, SV and peripheral vascular tone to restore blood pressure.26  
Figure 2  Overview of determinants of CBF with the respective influences and regulation mechanisms. 
Figure adopted and modified from Donnelly et al.19 Abbreviations: CBF, cerebral blood flow; CPP, cerebral 
perfusion pressure; CVR, cerebrovascular resistance; ICP, intracranial pressure; SV, stroke volume; HR, heart rate; TPR, 
total peripherial resistance; CBV, cerebral blood volume; CSF V, cerebrospinal fluid in ventricles; RAAS, 
 renin-angiotensin-aldosterone system; NVU, neurovascular unit; CVMR, cerebral vasomotor reactivity.
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CBF in Alzheimer’s disease
Amyloid-β and CBF have a two-way interaction. There is evidence that cerebrovascular 
changes decrease clearance of amyloid-β and hence contribute to plaque formation.27 
But amyloid-β also affects CBF, as is shown in Figure 2. Amyloid-β plaques directly increase 
CVR by obstructing blood vessels. Also, these plaques are vaso-active, resulting in vaso-
constriction in the microcirculation.28 Moreover, neuronal death caused by amyloid 
aggregation, results in decreased demand of oxygen and glucose, leading to possibly 
even more vasoconstriction and hence increased CVR. 
 There are also indications that CBF regulating mechanisms are affected in AD, e.g. 
a recent study showed that orthostatic hypotension is associated with an increased risk 
on developing dementia.29 There is evidence for autonomic dysfunction in AD, which 
could also result in a worsened baroreflex.30 Yet, a reduced baroreflex has been found in 
only two studies, both with a relatively small sample-size.31, 32 Thus, evidence for an impaired 
baroreflex is still weak. Animal models of AD showed a severely impaired CA,33-35 but in 
humans these findings are not yet replicated.36-38 Hence, evidence on whether, and how 
the regulating mechanisms are affected is still inconclusive. 
Figure 3 Cerebral autoregulation curve (solid line) through adjustments of cerebro vascular resistance 
(dashed line). Abbreviations: CBF, cerebral blood flow; CPP, cerebral perfusion pressure; CVR, cerebrovascular 
resistance.
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All these effects together result in a net decrease of global CBF in AD. The magnitude of this 
decrease in CBF, which is already observed in an early stage of the disease,39 is predictive 
for progression and cognitive functioning.40 There have been only few studies that have 
the restoration of CBF as a starting hypothesis, e.g. the DANTE study, where an increase of 
CBF was expected through discontinuation of antihypertensive drugs (and hence increasing 
CPP).41 However, the anticipated improved cognitive functioning was not observed.42
Problem description
Vascular factors in AD and the role of a diminished CBF receive increasing attention in 
research, but still have a minor role in the total body of AD-research (Figure 1). Specifically, 
there has been very little attention to the possible disturbances of CBF regulation 
mechanisms. Moreover, interventions that focus on reducing CBF deficits are mostly 
absent, despite the proven importance of these CBF deficits in disease progression.39, 40
Therefore the central questions of this thesis are 
(1)   Is there evidence for dysfunctioning of short-term regulation mechanisms of CBF in patients 
with AD and if so, does this dysfunction contribute to the observed decrease in CBF? 
and 
(2)   Can CBF deficits in patients with AD be reduced by treating patients with nilvadipine 
(dihydropiridine calcium antagonist)? 
Clinical relevance
A better understanding of the pathophysiology in Alzheimer’s disease can, in the long 
run, contribute to finding treatment targets. However, a less distant application of 
knowledge on regulation of CBF in AD  relates to antihypertensive treatment in AD patients. 
Untreated hypertension is a major risk factor for developing AD, thus the use of anti-
hypertensive drugs is strongly advised, specifically in patients with high cardiovascular 
risks.43 Yet, when a subject converts to AD dementia, there is controversy in whether or 
not to start antihypertensive treatment. This controversy rises from different observational 
studies where a faster cognitive decline was observed in the group using antihyper-
tensives.44, 45 Contrasting, other studies show a delay in cognitive decline when using 
antihypertensives, possibly caused by the vasodilatory effects, leading to better 
perfusion.46 Given the high prevalence of hypertension in AD (at least 45%),47 more 
information that could guide the physician in treatment decisions is required and a direct 
incentive for this research project.  
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Thesis outline
Part 1. Assessment of cerebral perfusion regulation in older persons
Assessment of CA is challenging and not yet feasible in clinical practice, which impedes 
the clinical use of this concept. In Part 1 some of the present challenges in the research 
methodology of cerebral autoregulation assessment in older persons are investigated, 
which serve as a background for the final research objectives. 
 Chapter 2 presents a study which describes the impact of one of the undesired 
sources of variation: the measurement artifacts. Although a gold standard is lacking for 
assessment of dynamic CA there is a range of methods, varying from fitting the best CBF 
response on a sudden change in BP (autoregulatory index) to estimating the high-pass 
filter properties (in gain and phase) in the frequency domain (transfer function analysis). 
Yet, all these measures suffer from a large within and between subject variation. 
With recommendations to minimize the effect of artifacts on outcome measures, this 
chapter contributes to reduce the non-physiological variation in CBF measurement 
methodology. 
 Chapter 3 aims to disentangle the relationship between steady-state and dynamic 
CA in an aged population. For assessment of steady-state CA the challenge is to induce 
long-term BP changes, without directly affecting cerebrovascular resistance. Compared to 
assessment of dynamic CA, these measurements are complex. Although steady-state and 
dynamic CA are conceptually closely related, it is not clear whether and how strong they 
are correlated and whether dynamic CA measurements could replace steady-state CA 
measurements. Therefore, a better understanding of the relation between these concepts 
is required, to which chapter 3 contributes. 
Part 2: Changes in cerebral perfusion in Alzheimer’s disease
Applying the knowledge of the previous chapters to optimize assessment of cerebral 
regulation mechanisms, in this part of the thesis regulation mechanisms for a homeostatic 
CBF are assessed within patients with AD and hence provide an answer to the defined 
research aims. 
 Chapter 4 assesses the baroreflex in healthy older persons and patients with mild 
cognitive impairment (the disease stage prior to dementia), and relates this to white 
matter integrity and executive functioning. Although the impact of CBF on disease 
progression in AD has previously been shown, there is little understanding of whether 
and how functioning of CBF regulation mechanisms can affect brain functioning. This 
chapter studies one of these regulating mechanisms and correlates this with differences 
in brain structure and brain functioning.  
 Chapter 5 addresses the functioning of blood pressure regulation and dynamic CA 
in patients in different stages of AD, compared to healthy controls. Elaborating on the 
previous chapter, where the central topic was how dysfunction of CBF regulating 
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 17
Introduction | 17
1
mechanisms would affect the brain, this chapter seeks an answer to whether these 
regulating mechanisms dysfunction in AD. 
 Chapter 6 describes the effects of nilvadipine on CBF in an AD population. Whereas 
there is some research on decline of CBF in AD, research to reduce these CBF deficits is 
largely absent. In the sub study of a randomized controlled trial, presented in this chapter, 
the effects of nilvadipine (calcium antagonist as potential drug for AD) on CBF are evaluated. 
 Chapter 7 provides a summary and discussion of the results and answers the overall 
research questions.
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Abstract
Cerebral autoregulation (CA) is the mechanism that aims to maintain adequate cerebral 
perfusion during changes in blood pressure (BP). Transfer function analysis (TFA), the most 
reported method in literature to quantify CA, shows large between-study variability in 
outcomes. The aim of this study is to investigate the role of measurement artifacts in this 
variation. Speciﬁcally, the role of distortion in the BP and/or CBFV measurement on TFA 
outcomes was investigated. The inﬂuence of three types of artifacts on TFA outcomes was 
studied: loss of signal, motion artifacts, and baseline drifts. TFA metrics of signals without 
the simulated artifacts were compared with those of signals with artifacts. TFA outcomes 
scattered highly when more than 10% of BP signal or over 8% of the CBFV signal was lost, 
or when measurements contained one or more artifacts resulting from head movement. 
Furthermore, baseline drift aﬀected interpretation of TFA outcomes when the power in 
the BP signal was 5 times the power in the LF band. In conclusion, loss of signal in BP and 
loss in CBFV, aﬀects interpretation of TFA outcomes. Therefore, it is vital to validate signal 
quality to the deﬁned standards before interpreting TFA outcomes. 
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Introduction
Cerebral autoregulation (CA) is the mechanism that aims to maintain adequate cerebral 
perfusion during changes in blood pressure (BP). Its clinical importance lies in the 
protection of the brain from hypo- and hyperperfusion. The quantiﬁcation of CA can be 
helpful in understanding pathophysiology and in monitoring and management of 
diﬀerent diseases, for example stroke or traumatic brain diseases.1, 2 
 Currently, transfer function analysis (TFA) is the most used method in the literature to 
quantify dynamic CA from spontaneous oscillations in BP and cerebral blood ﬂow velocity 
(CBFV). In these publications, a large variability in TFA outcomes is observed between 
diﬀerent studies.3 A possible explanation is the lack of a standard signal processing 
method for TFA. Meel-van den Abeelen et al. showed that it is possible to reduce the 
variability in TFA outcomes by standardizing signal processing methods.4
 Another possible cause of the large variations in TFA outcomes lies in the quality 
of measurement of BP and CBFV. Very few studies5-7 have investigated the eﬀect of the 
measurement quality on the CA transfer function outcomes. Lorenz et al. studied the 
consequences of poor insonation conditions on TFA parameters for CA and found that 
poor bone windows can cause considerable bias in TFA outcomes.7 Furthermore, Deegan 
et al. (2011) studied the eﬀect of signal loss in BP or CBFV measurements and found 
detrimental changes in TFA outcomes when using time series waveforms as input signal. 
However, when the raw data was transformed to beat-to-beat data and that data was 
used as input data for TFA the changes in TFA outcomes were, although still signiﬁcant, 
much smaller.5 Whether these signiﬁcant changes also change the interpretation of the 
TFA outcomes between normal cerebral autoregulation and impaired cerebral auto- 
regulation has not been explored. 
 At this moment, no standard quality requirements for the transcranial Doppler (TCD) 
measurements are available, except for some qualitative descriptions on signal depth, 
velocity, and wave characteristics, which are not suitable to quantify quality of placement.8 
Next to CBFV, BP measurements may also be subjected to external artifacts. External noise 
decreases signal quality, which may inﬂuence TFA outcomes. The aim of this study was to 
investigate whether diﬀerent types of distortion in both the BP and/or CBFV measurements 
change the interpretation of the transfer function outcome metrics between good and 
impaired cerebral autoregulatory functioning.
Methods
Blood pressure and cerebral blood flow velocity measurement
Fifteen young healthy subjects participated in this study. The study was approved by 
the local Medical Ethics Committee and all participants gave written informed consent. 
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BP was measured noninvasively at the middle ﬁnger of the right hand using Finapres 
(Finapres Medical Systems, Amsterdam, the Netherlands). It has been shown that BP 
measured indirectly in a ﬁnger by arterial volume clamping is similar to auscultatory 
measurements.9 It also closely corresponds to intra-arterial recordings.10 The subjects 
underwent several minutes of acclimatization and the servo-adjust mechanism was 
turned oﬀ prior to each recording.
 CBFV was obtained in the left middle cerebral artery (MCA) by TCD (Multi-Dop, 
Compumedics DWL, Germany). The TCD probe was placed on the left temporal window. 
After identiﬁcation of the MCA according to signal depth, velocity, and wave characteristics8 
the signal was further optimized by adjusting place, insonation angle, and depth. During 
data collection, the probe was locked at a constant angle and position with a customized 
headband (Spencer technologies, Seattle, Wa., USA). Both BP as CBFV were recorded at 
200 Hz.
Transfer function analysis
TFA assesses the dynamic relationship between BP and CBFV based on spontaneous 
oscillations in these variables. To obtain beat average BP and CBFV values the raw BP and 
CBFV data were ﬁltered using a 4th order low-pass Butterworth ﬁlter with a cut-oﬀ frequency 
of 0.5 Hz (forward and reverse direction for a zero-phase response). The consecutive series 
were resampled to 10 Hz, which is the most common signal type for input in TF-analysis 
on cerebral autoregulation.3 Transfer function gain, phase, and coherence were estimated 
using the cross-spectral method which has been described in detail previously.11, 12 
The 5-minute time series of mean BP and CBFV were subdivided into ﬁve segments of 
950 samples with 50% overlap for spectral estimation. Fast Fourier transforms were 
implemented with each Hanning-windowed segment and averaged to quantify the 
transfer function. The gain, phase, and coherence were quantiﬁed as the mean for the 
following frequency bands: very low frequency (VLF): 0.02-0.07Hz; low frequency (LF): 
0.07-0.15Hz; high frequency (HF): 0.15-0.4Hz.11 In this article we have emphasized the LF 
results, because this frequency band includes the major frequency range of CA.13, 14 
Results for the VLF and HF are presented in the online supplemental material. 
Effects of artifacts
Measurements obtained by the Finapres and TCD can be inﬂuenced by various types of 
artifacts which reduce signal quality. We studied the inﬂuence of three types of artifacts 
on transfer function outcomes: 1) loss of signal, 2) motion artifacts, and 3) baseline drift. 
A brief discussion of each type of artifact and methods for approximating these artifact 
types are discussed below.
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 29
Effect of measurement artifacts on TFA | 29
2
Loss of signal 
TCD measurements are often subject to loss of the CBFV signal due to probe movement 
and several mechanisms may cause interruptions of BP recordings. Therefore, recordings 
of both techniques can be subject to periods of unusable data of varying number and 
duration. 
 To investigate the eﬀects of signal loss on TFA outcomes, random sections of the 
5-minute BP and/or CBFV signal were removed and replaced by the mean of the previous 
ten seconds (Figure 1A). The length and number of missing segments were varied, either 
in the BP or CBFV signal or in both. For each length of data loss (1, 2, 3, 4, 5, 10, 20, 30, 40, 
and 50 seconds) the number of segments was varied over a range of 1 to 5. In the case of 
loss in both signals, length and number of segments were similar, but the moment in time 
where data loss occurred diﬀered. To avoid potentially misleading results caused by a 
speciﬁc timing of the data loss, each of the 150 conditions was repeated 10 times and the 
results were averaged per condition.
Motion artifacts
Motion artifacts may occur, either during movement of the subject or of the TCD probes. 
Spencer et al. reported these artifacts to be bidirectional and to have a wider frequency 
spectrum, displaying the highest energy in the lower frequencies.15 Motion artifacts were 
simulated by multiplying short CBFV segments (3 seconds) with a motion template, which 
was deduced from an observed motion (Figure 1B). The number of simulated motion 
artifacts ran from 1 to 16 single motions, which were randomly placed in the 5-minute 
Figure 1A  Example of signal loss in CBFV signal. The grey line shows the original CBFV signal and the 
black line shows the CBFV signal with the signal loss.
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CBFV signal. Avoiding the potential for some misleading results based on the speciﬁc 
timing of the movement artifact, each of the 16 conditions was repeated 10 times and the 
results were averaged per condition.
Baseline drift
Stokes et al. described that unexplained pressure variations over time may emerge when 
using the Finapres.16, 17 These variations may lead to baseline drifts (Figure 1C) which may 
inﬂuence TFA results. Such baseline drifts might also inﬂuence the CBFV signal. The eﬀect 
of baseline drift was studied by adding low-pass ﬁltered white noise signal with a 
frequency range of 0-0.008 Hz to the BP or CBFV signal. The noise power varied from 0.01 
to 10000 times the power in the LF spectrum of the corresponding signal (Figure 1C).
Analysis
The TFA metrics - gain, phase and coherence in three frequency bands (VLF, LF and HF) - 
were calculated for each of the simulated signals. For the loss of signal and motion artifacts 
the mean and standard deviation of the 10 repetitions for each condition were pooled 
over the 15 subjects, giving the pooled mean and pooled standard deviation. With these 
pooled data the pooled mean shows the average bias caused by the artifacts. The scatter 
was calculated by determining 95%-ranges (1.96 times the pooled standard deviation), 
meaning that 95% of the data variation lies within this range. Baseline drift scatter was 
calculated by determining the standard deviation between the 15 subjects.  
Figure 1B  Example of the artiﬁcial generation of head movement in CBFV signal. The graph represents 
the eﬀect of the motion template on an original CBFV signal. The CBFV signal before (grey line) and 
after (black line) adding the motion template are shown.
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 In a systematic review3 of the TFA literature (which includes details on search strategy 
and study inclusion) results of multiple studies were combined to investigate the inter- 
study variability in CA values for healthy subjects. To obtain normal values for CA, the 
authors of the review combined all the retrieved values and calculated the pooled mean 
and pooled standard deviation by weighting the individual values with the sample size of 
the corresponding study. For our study we considered the values between mean ± 
standard deviation as normal values. When the 95% range crosses the limits of these 
normal values, scatter is  considered relevant.
Results
Loss of signal
In the LF-bands, all subjects had TFA values which were within the limits of the normal 
values for TFA. A higher percentage of signal loss in BP resulted in higher scatter in TFA 
values compared to the initial values (Figure 2). The average values for gain and coherence 
decreased, while values for phase remained fairly constant. Figure 3 shows that the eﬀect 
of the percentage of missing data on the TFA outcomes did not depend on whether the 
missing data consisted of one continuous block or consisted of diﬀerent shorter segments 
throughout the data. 
Figure 1C  Examples of the eﬀect of a baseline drift on CBFV signal. The light grey lines represent 
original CBFV and dark grey lines the CBFV signal with baseline drift with a power of 0.1 (left) and 5 
(right) times the power of the power in the LF-band.
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Table 1 shows the percentages of data loss which causes relevant scatter of the transfer 
function outcomes. Missing data segments in BP covering more than 10 % of the total 
data length resulted in scatter of the LF-phase values. Signal loss in CBFV covering more 
than 8% of the total data length resulted in scatter of the LF phase.
 When both BP and CBFV contain loss of signal LF phase show scatter when 3% or 
more of the data is missing, such that in more than 5% of the cases deviations were outside 
Figure 2  The eﬀect of missing segments in the ‘BP’, ‘CBFV’ and ‘BP and CBFV’ signal on LF gain, phase, 
and coherence values. X-axes show the total percentage of missing segments. Graph A, B, C represent 
the eﬀect of missing segments in BP on gain, phase, and coherence, respectively. Graph D, E, F represent 
the eﬀect of missing segments in CBFV and graph G, H, I show the eﬀect of missing segments 
in both BP and CBFV. Grey area shows the borders of normal values. Each point represents the 
pooled average for the total percentage of missing segments represented on the X-axes. The error 
bars represent 1.96 times the pooled standard deviation (95%-range).
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the boundaries. Figure 2 depicts the deviations in LF-gain, -phase, and -coherence values 
caused by missing segments in the ‘BP’, ‘CBFV’ and ‘BP and CBFV’ signal. For VLF and HF 
see supplementary data.
Motion artifacts
With an increase in the number of motions, gain shows a positive bias (Figure 4). For each 
transfer function parameter, the number of head movements related to scatter is shown 
in Table 1. When one head movement is presented LF-phase shows scatter (for VLF and HF 
see supplementary data).
Baseline drift
A drift in BP scattered the LF-gain when the power of the baseline-drift was 5, 100, and 
1000 times the power of the LF band, respectively (Figure 5, Table 1) (for VLF and HF see 
supplementary data).
Table 1  Percentage of dataloss, number of motions and power of drift causing relevant 
deviations in transfer function outcomes.
Gain Phase Coherence
BP loss VLF 50% 10% 17%
LF 7% 10% 27%
HF 0.7% 0.3% 27%
CBFV loss VLF 10% 8% 17%
LF 10% 8% 30%
HF 10% 0.7% 30%
BP and CBFV loss VLF 10% 7% 10%
LF 4% 3% 17%
HF 1% 0.3% 17%
motion (n) VLF 9 1 3
LF 3 1 4
HF 2 1 3
BP drift (power) VLF 5 2 100
LF 100 100 1000
HF 100 100 1000
CBFV drift (power) VLF 5 100 100
LF 1000 1000 1000
HF 100 - 1000
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Figure 3  The eﬀect of missing data on LF gain (A), phase (B), and coherence (C) with a distinction 
between number of missing segments and total length of missing data. Grey area shows the borders 
of normal values. The error bars represent 1.96 times the pooled standard deviation (95%-range).
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Figure 4  The eﬀect of head movements on LF gain (A), phase (B), and coherence (C). X-axes show 
number of head movements. Grey area shows the borders of normal values. The error bars represent 
1.96 times the pooled standard deviation (95%-range).
0
0.5
1
1.5
2
0 5 10 15
)g
H
m
m/s/
mc( FL nia
G
number of movements
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 5 10 15
Ph
as
e 
LF
 (r
ad
)
number of movements
0
0.2
0.4
0.6
0.8
1
0 5 10 15
C
oh
er
en
ce
 L
F 
number of movements
A  
B
C
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 36
36 | Chapter 2
Figure 5  The eﬀect of baseline drifts on TFA outcomes. The graphs A, C, E represent the eﬀect of 
baseline drifts in BP on LF gain, phase, and coherence, respectively. The graphs B, D, F represent the 
eﬀect of baseline drifts in CBFV. X-axes show the power of the baseline drifts. Grey area shows the 
borders of normal values. The error bars represent the standard deviation.
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Discussion
The main ﬁnding of our study is that motion and reduced signal quality leads to bias and 
scatter in TFA outcomes with the potential to mislead interpretation. The extent to which 
the TFA outcomes are inﬂuenced by the artifacts diﬀers per TFA-parameter. The phase- 
parameters are most prone to misinterpretation. As CA is a key protective mechanism 
of the brain, adequate assessment of CA may be of great importance for understanding 
pathophysiology and in monitoring and managing many clinical conditions, such as 
ischemic stroke and traumatic brain injury.1, 2
 Motion artifacts showed a considerable inﬂuence on TFA outcomes. Already one 
motion may aﬀect the LF-phase parameter in such a way that there is potential for mis-
inter pretation. The LF-gain is less sensitive to these motions, although the inter- measurement 
variability increases. A limitation for the head motion variation used in this study, is that only 
one kind of eﬀect (probe movement) has been taken into account while the movement 
of the head may also induce a change in BP via activation of the baroreceptors.18, 19
 There is a general bias from the original LF values with increasing data loss, together 
with an increasing scatter (Figure 2). This complicates the decision regarding data 
acceptability; in some subjects the distortion is limited, in others there is a large distortion. 
To give a suggestion for standardized decisions, we assessed the general tendency and 
reject data when the 95%-scatter range exceeds the range for normal values as set by 
Meel-van den Abeelen et al., (2014).3 However, it is still recommended to report exactly 
which range of data loss was accepted in research publications. 
 Regarding signal loss in BP, it was found that missing data segments can be inter - 
polated as long as the total length of missing segments in BP do not exceed 7 % (~21 s) of the 
total signal length. However, when there is signal loss in both BP and CBFV, already from 
3% (~9 s) data loss results in relevant scatter of LF-TFA outcomes. The higher the percentage 
of missing data segments, the greater the scatter in TFA outcomes. Data loss in CBFV 
showed slightly less scatter in TFA outcomes. 
 Deegan et al. already showed that the data loss in BP or CBFV cause signiﬁcant changes 
in TFA outcomes.5 Although they showed that data loss aﬀects TFA outcomes, they did 
not show how the data loss aﬀects interpretation of the TFA metrics. To complement their 
ﬁndings, we focused on relevant changes in TFA outcomes and found that loss of CBFV 
has less inﬂuence on gain, but more inﬂuence on phase, than loss of BP signal. This may be 
explained by the way the transfer function is calculated. The transfer function is estimated 
by dividing the cross spectra between BP and CBFV by the auto spectra of the blood 
pressure. In contrast to CBFV, BP is thus incorporated in both the numerator and 
denominator.  
 Baseline drifts in the BP or CBFV signal only resulted in deviations in TFA outcomes for 
very large drifts. Although magnitude of drift is diﬃcult to assess, in practice, drifts of such 
magnitude are not realistic (see Figure 1C). However, drifts with slightly higher frequencies, 
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e.g. because of slow loss of BP signal because of cold hands, may be of inﬂuence. Therefore 
one should still be aware of causes of baseline drift and try to minimize them. 
 Overall, this study showed that head movements and loss of signal in BP and CBFV 
have a considerable impact on TFA outcomes, but that the eﬀects of baseline drifts are 
minimal. The consequence of tolerating artifacts exceeding the thresholds will be that 
unreliable estimates of the cerebral autoregulation are obtained, leading to false-positive 
and false-negative results. The observed changes in phase and gain indicate a risk for 
erroneously assuming intact autoregulation. The observed decrease in gain may lead to 
falsely concluding depressed autoregulation. Depending on the nature of study and 
choice for parameters, coherence might be used as a threshold for data quality. This may 
help in identifying datasets which are subjective to noise. 
 However, rejecting data when the set thresholds are not exceeded may also have 
pernicious consequences. It may induce bias in research as patients with more unstable 
signals are excluded. In the clinic, the assessment of a patient can be unjustly denied. 
 In addition, there is no gold standard for diﬀerent stages of cerebral autoregulation 
performance. Although in hypercapnia there is clearly depressed autoregulation, diﬀerences 
between healthy and diseased subjects are more subtle. Therefore, any threshold for 
accepting or rejecting data is arbitrary and should depend on the purpose of the study. 
For this study we chose to use the mean +/- standard deviation values based on an earlier 
review,3 since this gives at least insight in the normal values for ‘healthy’ cerebral auto- 
regulation. 
 Some methodological issues regarding this study should be mentioned. First of all, 
the eﬀects of artifacts on TFA outcomes were tested using simulated artifacts, which possibly 
do not represent the full complexity of real artifacts. However, using simulated artifacts 
makes it possible to investigate diﬀerences in TFA outcomes which can be fully attributed 
to the artifacts and not inﬂuenced by temporal changes caused by physiological changes 
(i.e. eﬀects of hypocapnia due to hyperventilation). Secondly, we only investigated the 
eﬀect of artifacts on TFA parameters. Despite TFA being the most widely used method to 
investigate CA from spontaneous oscillations in BP and CBFV, it is not known whether 
it is the best method to investigate CA. An important disadvantage of TFA is that the 
method assumes a linear relationship between BP and CBFV, although, rigorously, CA is a 
nonlinear phenomenon due to the modulation of cerebrovascular resistance. Since we 
did not investigate other methods than TFA, it is possible that other methods (i.e. nonlinear 
methods) are less inﬂuenced by artifacts.
 Third, we did not take the inter-subject variability into account as we pooled the data. 
Only for baseline drift this pooling was not possible; since the drift was applied on the 
entire signals there was no possibility for random placement of the drift. Therefore, 
in studying the baseline drift a smaller scatter range was presented (standard deviation), 
as otherwise the inter-subject variability would  be the main determinant. Although the 
inter-subject variability is known to be quite high for cerebral autoregulation quantiﬁcation 
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using transfer function analysis, this was not in the scope of this research. It will require 
further study to assess the eﬀects of the inter-subject variability. 
 In summary, it can be concluded that motion artifacts and data loss are a serious 
concern when performing and interpreting TFA to assess CA. It is therefore of great 
importance to formulate standard  requirement regarding the signal quality of both CBFV 
as BP. Ensuring good signal quality, for which the criteria presented in Table 2 can be used, 
will possibly reduce the variability in TFA outcomes and makes it easier to compare 
diﬀerent studies. 
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Table 2  Criteria for the exclusion of data for 5-minute segments.
Exclude
VLF LF HF
BP signal loss [time in s] ≥30 ≥21 ≥1
CBFV signal loss [time in s] ≥24 ≥24 ≥1
BP and CBFV signal loss [time in s] ≥21 ≥9 ≥1
Head movements [n] ≥1 ≥1 ≥1
BP baseline drift -- -- --
CBFV baseline drift -- -- --
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Supplementary Material
Figure S1  The eﬀect of missing segments in the ‘BP’, ‘CBFV’ and ‘BP and CBFV’ signal on VLF gain, 
phase, and coherence values. X-axes show the total percentage of missing segments. Graph A, B, C 
represent the eﬀect of missing segments in BP on gain, phase, and coherence, respectively. Graph 
D, E, F represent the eﬀect of missing segments in CBFV and graph G, H, I show the eﬀect of missing 
segments in both BP and CBFV. Grey area shows the borders of normal values. Each point represents 
the pooled average for the total percentage of missing segments represented on the X-axes. The error 
bars represent 1.96 times the pooled standard deviation (95%-range).
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Figure S2  The eﬀect of missing segments in the ‘BP’, ‘CBFV’ and ‘BP and CBFV’ signal on HF gain, 
phase, and coherence values. X-axes show the total percentage of missing segments. Graph A, B, C 
represent the eﬀect of missing segments in BP on gain, phase, and coherence, respectively. Graph 
D, E, F represent the eﬀect of missing segments in CBFV and graph G, H, I show the eﬀect of missing 
segments in both BP and CBFV. Grey area shows the borders of normal values. Each point represents 
the pooled average for the total percentage of missing segments represented on the X-axes. The error 
bars represent 1.96 times the pooled standard deviation (95%-range).
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Figure S3  The eﬀect of head movements on VLF gain (A), phase (B), and coherence (C). X-axes show 
number of head movements. Grey area shows the borders of normal values. The error bars represent 
1.96 times the pooled standard deviation (95%-range).
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Figure S4  The eﬀect of head movements on HF gain (A), phase (B), and coherence (C). X-axes show 
number of head movements. Grey area shows the borders of normal values. The error bars represent 
1.96 times the pooled standard deviation (95%-range).
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Figure S5  The eﬀect of baseline drifts on TFA outcomes. The graphs A, C, E represent the eﬀect of 
baseline drifts in BP on VLF gain, phase, and coherence, respectively. The graphs B, D, F represent the 
eﬀect of baseline drifts in CBFV. X-axes show the power of the baseline drifts. Grey area shows the 
borders of normal values. The error bars represent the standard deviation.
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Figure S6  The eﬀect of baseline drifts on TFA outcomes. The graphs A, C, E represent the eﬀect of 
baseline drifts in BP on HF gain, phase, and coherence, respectively. The graphs B, D, F represent the 
eﬀect of baseline drifts in CBFV. X-axes show the power of the baseline drifts. Grey area shows the 
borders of normal values. The error bars represent the standard deviation.
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Abstract
The purpose of this study was to investigate the relationship between dynamic (dCA) and 
steady-state cerebral autoregulation (sCA). In 28 healthy older adults, sCA was quantiﬁed 
by a linear regression slope of proportionate (%) changes in cerebrovascular resistance 
(CVR) in response to proportionate (%) changes in mean blood pressure (BP) induced by 
stepwise sodium nitroprusside (SNP) and phenylephrine (PhE) infusion. Cerebral blood 
ﬂow (CBF) was measured at the internal carotid (ICA) and vertebral (VA) artery and cerebral 
blood ﬂow velocity (CBFV) at the middle cerebral artery (MCA). With CVR=BP/CBF, 
Slope-CVRICA, Slope-CVRVA and Slope-CVRiMCA were derived. dCA was assessed (i) in 
supine rest, analyzed with transfer function analysis (gain and phase) and autoregulatory 
index (ARI) ﬁt from spontaneous oscillations (ARIBaseline), (ii) with transient changes in BP 
using a bolus injection of SNP (ARISNP) and PhE (ARIPhE). Comparison of sCA and dCA 
parameters (using pearson’s r for continuous and Spearman’s  ρ for ordinal parameters) 
demonstrated a lack of linear correlations between sCA and dCA measures. However, 
comparisons of parameters within dCA and within sCA were correlated. For sCA 
slope-CVRCA with Slope-CVRi MCA (r=0.45, p<0.03); for dCA ARISNP with ARIPhE (ρ=0.50, 
p=0.03), ARIBaseline (ρ=0.57, p=0.03), and PhaseLF (ρ=0.48, p=0.03); GainVLF with GainLF 
(r=0.51, p=0.01). Conclusions: In contrast to the commonly held assumption based on an 
earlier study, there was no linear correlations between sCA and dCA. As an additional 
observation, there was strong inter-individual variability, both in dCA and sCA, in this 
healthy group of elderly, in a range from low to high CA eﬃciency.
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Introduction
The brain has an important role in maintaining homeostasis of the human body.1, 2 
However, the brain lacks energy reserve and therefore depends on a stable blood ﬂow to 
maintain its own function.3 Consequently, the brain has local mechanisms to maintain 
adequate perfusion when systemic blood pressure (BP) homeostasis is disrupted. This 
mechanism is captured in the concept of cerebral autoregulation (CA): the intrinsic ability 
of the brain to maintain an adequate perfusion during BP changes.4-6
 Research into CA has roughly led to two approaches in quantiﬁcation: dynamic CA 
(dCA) and steady-state or static CA (sCA).7-12 The dynamic models, which require high temporal 
resolution measurements, study the transient relationship between BP and CBF, and thus 
assess how a transient change in BP would aﬀect CBF, e.g. during orthostatic hypotension.7, 11-13 
In contrast, the static models approach the steady-state outcome of CBF following 
a persistent change in BP, for example when BP increases over time due to hypertension, 
or when BP is reduced over time, following treatment of hypertension.9, 12, 14
 Although dCA and sCA both model the functioning of CA, there are theoretical diﬀerences 
between these concepts. Whereas dCA parameters quantify the gain (damping) and latency 
(response delay) of the transient changes in BP and CBF, sCA parameters quantify the ﬁnal 
equilibrium of BP and CBF.6, 13, 15-17 Despite these conceptual diﬀerences, it has been widely 
assumed that estimates of dCA correlate with estimates of sCA.18 To date, little evidence 
exists as to the relationship between dCA and sCA. In adults, one study found a robust 
linear correlation (r=0.93, P<0.0001) between measures of sCA and dCA, measured during 
isoﬂurane and propofol anesthesia.8 In this study in a small sample (n=10) of young, 
otherwise healthy, patients undergoing orthopedic surgery (mean age 35 years), CA was 
measured during propofol anesthesia and during high-dose isoﬂurane anesthesia. Since 
isoﬂurane is known to impede sCA and dCA by causing cerebral vasodilatation,19 and 
propofol has a limited eﬀect on cerebrovasculature (from no eﬀect to a small vasocon-
strictive eﬀect),20 the anesthesia protocol in this study served to induce variation in CA 
measures. In a similar study, under high dose of isoﬂurane both dCA and sCA were 
impaired.21 However, with low dose isoﬂurane only dCA was impaired. It remains unknown 
whether dCA and sCA are correlated under conditions outside anesthesia with pharmaco-
logically impaired CA. 
 Understanding the relationship between dCA and sCA could yield important clinical 
applications for patient management. For example, in the treatment of an elderly 
hypertensive person, it would be of great beneﬁt when an assessment of dCA (which can 
safely be obtained during a 5-10 min recording in seated or supine position, without the 
need for any intervention) would reﬂect their sCA, i.e. how CBF is aﬀected by BP lowering 
following antihypertensive treatment. The assessment of dCA could so inform what level 
of BP reduction would be safe (intensive versus conservative)? Similarly, in a patient in the 
ICU, assessments of dCA could inform safe BP targets.
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 52
52 | Chapter 3
The main purpose of this study was to investigate this relationship between dCA and 
sCA to better understand the homeostatic control of brain perfusion under rapid and 
steady-state changes in blood pressure. 
Methods
Subjects and ethical approval
Twenty-eight healthy older adults (67±7, 13 women) were recruited from the local 
community in Dallas. Exclusion criteria included tobacco use, neurological disease (e.g., 
clinical diagnosis of stroke, traumatic brain injury and dementia), carotid and vertebral 
arterial steno-occlusive disease, major medical and psychiatric disorders (e.g. schizophrenia, 
psychosis), unstable heart diseases (e.g. myocardial infarction, angina), uncontrolled 
hypertension, obstructive sleep apnea, and diabetes mellitus. Participants were asked to 
abstain from alcohol, caﬀeinated beverages and high intensity exercise at least 24 hours 
before the examinations. Participants underwent all examinations consecutively on the 
same day, starting with two procedures to assess dCA (baseline and bolus injection), 
followed by the procedure to assess sCA (stepwise drug infusion) (Figure 1). This study was 
conducted in accordance with the standards of the Declaration of Helsinki for medical 
research involving human subjects. All participants provided their written informed 
consent with the study protocol, which was approved by the Institutional Review Boards 
of the UT Southwestern Medical Center and Texas Health Presbyterian Hospital of Dallas.
Data collection
Study protocol for sCA
To assess sCA, stepwise changes in BP were induced using intravenous infusions of sodium 
nitroprusside (SNP) and phenylephrine hydrochloride (PhE).10 Measurements started 
with a 3-minute baseline. BP, using ﬁnger plethysmography (Finapres, Ohmeda, USA); 
CBFV in the middle cerebral artery (DWL Elektronische Systeme, Germany), three-lead ECG 
(GE Solar 8000M, USA) and end-tidal CO2 (EtCO2) (Capnogard, Novametrix, USA) were 
recorded continuously using a data acquisition system (Acqknowledge, BIOPAC Systems, 
USA). After baseline collection, SNP was started with an infusion rate of 0.25 μg/kg/min, 
incrementally increased with steps of 0.25 μg/kg/min until BP dropped with 20 mmHg or 
25% from baseline, whichever came ﬁrst. Afterwards there was a time interval of at least 
20 minutes, until hemodynamics restored to baseline. Then PhE started with an infusion 
rate of 0.5 μg/kg/min, incrementally increased with steps of 0.5 μg/kg/min until BP 
increased with 25 mmHg or 30% from baseline, whichever came ﬁrst. During each step of 
drug infusion, as soon as BP had stabilized, brachial arterial pressure was measured using 
a sphygmomanometer (Tango+, Suntech, USA). CBF was calculated using color-coded 
duplex ultrasonography (CX-50, Philips Healthcare, the Netherlands). Time-averaged 
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mean blood ﬂow velocity (TAMV) and the luminal area (over at least 5 beats) in the ICA 
(CBFICA) and VA (CBFVA) were recorded three times at each stage and CBF was calculated 
as CBF = TAMV * [(mean diameter/2)2 * π] * 60. Subsequently, ﬂow velocity in the MCA was 
calculated by averaging the MCBFV, as measured with the TCD, over 3 minutes of rest in 
each condition. 
Study protocol for dCA
The dCA was assessed by spontaneous oscillations of BP and CBFV as well as their rapid 
changes induced by bolus injections of vasoactive drugs. Spontaneous oscillations in BP 
were assessed during an 8-minute baseline measurement in the supine position. Dynamic 
‘step-like’ changes in BP were induced by the Modiﬁed-Oxford method, originally 
designed to assess baroreﬂex sensitivity.22 Participants received a 100 μg intravenous 
bolus of SNP to induce a rapid decrease in BP. Exactly one minute later, a bolus of 150 μg 
PhE was injected to induce a rapid increase in BP. 
Figure 1  A schematic overview of the procedure for data collection. The measurement procedure 
started with an eight minute baseline (BL) measurement, followed with an intravenous bolus of 
100 μg sodium nitroprusside (SNP) and one minute later with 150 μg phenylephrine (PhE). After 
a resting period without drugs in which hemodynamics restored to baseline, the measurements 
continued with a second BL. After this BL, SNP was started with an infusion rate of 0.25 μg/kg/min, 
incrementally increased with steps of 0.25 μg/kg/min until blood pressure dropped with 20 mmHg 
or 25% from baseline, whichever came ﬁrst. This was followed by an interval of at least 20 minutes, 
until hemodynamics restored to baseline. After a 3rd BL, PhE was started with an infusion rate of 0.5 
μg/kg/min, incrementally increased with steps of 0.5 μg/kg/min until blood pressure increased with 
25 mmHg or 30% from baseline, whichever came ﬁrst. During each step of drug infusion, as soon 
as BP had stabilized, brachial arterial pressure was measured using a sphygmomanometer (Tango+, 
Suntech, USA). CBF was measured using color-coded duplex ultrasonography (CDUS; CX-50, Philips 
Healthcare, the Netherlands).
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Data analysis
Steady-state cerebral autoregulation
Slope estimation method
The sCA was quantiﬁed by a linear regression slope (deﬁned as cerebral autoregulatory 
slope) of proportionate (%) changes in cerebrovascular resistance (CVR = BP/CBF) or cerebro-
vascular resistance index (CVRi = BP/CBFV) in response to proportionate (%) changes in 
BP relative to their baseline levels.10 Cerebrovascular resistance was calculated both for 
CBFICA as for CBFVA, cerebrovascular resistance index was calculated for CBFVMCA.
Dynamic cerebral autoregulation
Transfer function analysis
Approaches to assess dCA focus on quantifying magnitude and latency from BP to CBFV, 
while assuming a linear relationship. In transfer function analysis (TFA) this relationship is 
estimated in the frequency domain.23, 24 Every signal can be deconstructed in sine-waves 
from the frequency spectrum. With TFA, BP and CBFV are decomposed in sine-waves and 
the diﬀerence in magnitude (gain) and latency (phase) for each frequency is calculated. 
Typically, dCA is active in the range of 0.02-0.20 Hz changes.25 
 From the 8 min baseline measurement, a 5 minute data segment of artifact-free 
beat-to-beat mean CBFV and mean BP served as input for the TFA, using the CARNet 
Matlab script with the default settings (version 1, 2016, software downloaded from www.
car-net.org).25 In short, these methods encompass the use of 100s Hanning windows with 
50% overlap; spectral smoothing with a triangular moving average window and a 
coherence threshold of 0.34. Gain, phase and coherence were averaged over the following 
frequency bands: very low frequency (VLF): 0.02-0.07 Hz; low frequency (LF): 0.07-0.2 Hz. 
Autoregulatory index
The Autoregulatory Index (ARI) model uses a second order linear diﬀerential equation to 
model the transient response of CBFV to a step-like change in BP.8, 26 Ten template 
responses to the presented BP-change are constructed using three variables to model 
gain and latency (damping & time constant) and the best ﬁt is calculated. 
 With the modiﬁed-Oxford method step-like changes in BP were induced, which can 
be assessed in the time domain. For this study, the onset of the change in BP was 
determined based on visual inspection. The 10 second average before this change were 
used as control value for BP (cBP) and CBFV (cCBFV) and the 30 second response was used 
to model the CBFV response. The model (see Appendix) where the diﬀerence between 
the model and the measured CBFV response had the lowest standard error of the mean 
was regarded to be the best ﬁt. 
 ARI was also determined for the baseline recording (spontaneous oscillations but no 
induced BP changes). The frequency response from this baseline measurement served 
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as input for an inverse Fourier transform, used to calculate the step-response.27, 28 
Subsequently, the best ﬁt between the models and the step-response was calculated 
using the normalized mean standard error (NMSE). To improve the reliability of this 
method, ﬁts with NMSE>0.15 were rejected.27
Statistical analysis
All variables were tested for normality using the Shapiro-Wilk test and in case of 
non-normality a log-transformation was applied. The bivariate correlation among the 
diﬀerent sCA and dCA metrics was tested using Pearson’s correlation (r, for continuous 
variables) or Spearman’s rank correlation (ρ, for ordinal variables). Based on the tertiles of 
Slope-CVRICA subjects were categorized in low, normal and highly eﬃcient sCA.29 Gender 
diﬀerence in the CA measures and diﬀerences in dCA metrics between the low and highly 
eﬃcient sCA groups were tested using the non-parametric Mann-Whitney-U test. There 
was no correction for multiple comparisons to prevent ﬁltering out weak correlations. 
Statistical signiﬁcance was assumed when p<0.05. Data were analyzed using SPSS 22 (IBM 
SPSS Inc, USA). 
Results
The baseline characteristics of the participants are provided in Table 1. 
Steady-state cerebral autoregulation
Figure 2 provides an overview of the experiments to assess sCA, including a representative 
time series of BP and CBFV from one of the participants. An overview of individual sCA 
estimates is presented in Figure 3. The average sCA values obtained were within the 
normal ranges in ICA (1.1±0.4), VA (1.1±0.8) and MCA (1.0±0.2), indicating normal sCA in this 
healthy population (Table 2). However, there was a high inter-individual variability leading 
to a wide range of values between low (almost absent) and highly eﬃcient sCA (Figure 3). 
Slope-CVRICA and Slope-CVRiMCA which both represent the anterior circulation, were 
correlated (r=0.45, p=0.03), while Slope-CVRVA (representing the posterior circulation) did 
not correlate with sCA estimates from the anterior circulation (Table 3). 
Dynamic cerebral autoregulation
Transfer function analysis
Figure 4 shows the transfer function estimates of dCA determined from the baseline 
measurement, presented in frequency plots for gain, phase and coherence. For the beneﬁt 
of comparison with sCA, these plots of dCA have been divided into groups with highest 
versus lowest tertile for sCA based on Slope-CVRICA. Figure 4 shows that gain is low and 
phase is high in the low frequencies, with gain increasing and phase decreasing with 
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higher frequencies. This observation is consistent with the expected ‘high-pass ﬁlter’ 
behavior observed with TFA in a healthy population.24, 30 With an average GainLF of 0.80 
(± 0.31) and PhaseLF of 0.70 (± 0.32) in the LF band (Table 2), the observed values were 
within the expected range for TFA studies as established recently.31 The range was wide, 
however, and would indicate variance from low (almost absent) to highly eﬃcient CA 
(similar as described above for the observations for sCA). Within these TFA parameters, 
GainVLF correlated with GainLF (for both absolute and normalized gain), but gain estimates 
did not correlate with phase estimates (Table 3). 
ARI
Representative time series from two participants are shown in Figure 5. Note, a lower 
absolute MCBFV is common in aging subjects.32 The ARI estimate for a decrease in BP 
(ARISNP) was on average 4.7 (±2.3), whereas ARI for an increase in BP (ARIPhE) was slightly 
higher 5.6 (± 1.8, p=0.04) (Table 2). These mean values are within the range observed in 
Table 1  Baseline characteristics.
Men/women 13/15
Age (years) 67 ± 6
Height (cm) 170 ± 8
Body mass (kg) 78 ± 15
BMI (kg/m2) 27 ± 4
HR 60 ± 9
SBP(mmHg) 122 ± 15
DBP (mmHg) 75 ± 9
MAP (mmHg) 90 ± 10
EtCO2 (mmHg) 37 ± 4
FlowICA (cm3/min) 232 ± 61
FlowVA (cm3/min) 76 ± 32
ØICA (mm) 4.6 ± 0.7
ØVA (mm) 3.1 ± 0.6
SCBFV (cm/s) 82 ± 26
MCBFV (cm/s) 53 ± 17
DCBFV (cm/s) 32 ± 10
Legend: Values presented as mean ± SD, body-mass index (BMI), HR (heart rate), SBP (systolic blood pressure), 
DBP (diastolic blood pressure), EtCO2 (end-tidal CO2), MAP (mean arterial pressure), FlowICA (ﬂow right internal 
carotid artery), FlowVA (ﬂow right vertebral artery), ØICA (diameter right internal carotid artery), ØVA (diameter 
right vertebral artery), SCBFV (systolic cerebral blood ﬂow velocity in MCA), MCBFV (mean cerebral blood ﬂow 
velocity in MCA) and DCBFV (diastolic cerebral blood ﬂow velocity in MCA).
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Figure 2  Representative data of cerebral blood ﬂow and cerebrovascular resistance index (MAP/
MCBFV) in response to steady-state changes in blood pressure (left) and the method to estimate 
steady-state cerebral autoregulation (right). A progressive, sustained decrease in blood pressure was 
induced by continuous infusion of SNP (sodium nitroprusside) with a step-wise increasing dose 
(black arrows) over a period of 40 min. After a recovery interval, a progressive, sustained increase 
in blood pressure was induced by continuous infusion of PhE (phenylephrine) with a step-wise 
increasing dose (light-grey arrows). The light grey bars indicate the segments used for calculation 
of MCBFV (mean cerebral blood ﬂow velocity). The dark-grey bars indicate within which time span 
MAP (mean arterial pressure) and FV in the ICA (internal carotid artery) and VA (vertebral artery) 
were measured. From these values the CVR (MAP/CBF) and CVRi (MAP/MCBFV) were calculated and 
using linear regression the Slope-CVRICA (0.74), Slope-CVRVA (0.23) and Slope-CVRiMCA (0.80) were 
calculated (see plots on the right).
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earlier studies using ARI in a healthy population, but again (as for sCA and for dCA TFA) 
the individual subjects showed a wide range from low to normal to highly eﬃcient CA 
(Figure 6). The ARI-response estimated from the baseline-measurement (see Methods; 
ARIBaseline) was 3.4 (± 2.3, p=0.02) which is below the range for normal CA. ARISNP correlated 
both with ARIPhE (ρ=0.50, p=0.03), and ARIBaseline (ρ=0.57, p=0.03), whereas ARIPhE and 
ARIBaseline did not correlate (ρ=0.42, p=0.15) (Table 3). 
Correlation between the dCA methods TFA and ARI
ARIBaseline and ARISNP and ARIPhE were compared with the 6 TFA parameters (gain, 
gain-norm and phase in the two frequency bands). There were correlations between 
PhaseLF and ARISNP and ARIPhE (ρ=0.48; p=0.03 and ρ=0.67; p<0.01), but not between ARI 
and Gain-parameters or PhaseVLF. 
Correlation between steady-state and dynamic cerebral autoregulation
In Table 3, correlations between sCA parameters and the TFA parameters are presented. 
GainVLF correlated with sCA, but this correlation was positive, i.e. indicating incongruity 
and not correspondence: high Gain (indicating poor dCA) correlated with high sCA 
(indicating eﬃcient sCA). This non-physiological correlation was the strongest for sCA 
estimates in the posterior circulation (VA; r=0.44; p=0.03), and borderline signiﬁcant for the 
anterior circulation (ICA; r=0.40; p=0.05). This can also be observed in Figure 4, where gain 
in the VLF-band diﬀers between the low and high sCA groups.
 Phase did not correlate with sCA. There was no correlation between the ARI and the 
sCA parameters, which is in line with the absence of diﬀerence between the ARI for the 
low and high sCA groups (Figure 6).
Figure 3  Scatter plot of the individual sCA outcomes, showing the variation of Slope-CVR or Slope-
CVRi from the average values of approximately 1. For each column, each dot represents one subject. 
Y-axis represents the Slope-CVR, calculated using ΔCVR(%)/ΔMAP(%) for the Slope-CVRICA and 
Slope-CVRVA, but ΔCVRi(%)/ΔMAP(%) for the Slope-CVRiMCA. The dashed lines represent the tertile 
boundaries for the ICA, at 0.84 and 1.34.
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Figure 4  Transfer function analysis frequency plots. Frequency plots showing the mean TFA response 
with the SEM of gain, phase and coherence for the group divided in the upper tertile for Slope-
CVRICA ( > 1.34, High sCA, n = 8) and lower tertile (< 0.84, Low sCA, n = 8). The gain plot increases with 
increasing frequency, and the phase plot shows the characteristic decrease in phase with increasing 
frequency as expected from the high-pass ﬁlter model of dynamic cerebral autoregulation. 
* indicates p<0.05 between the two groups in that frequency band, using the Mann-Whitney-U test.
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Figure 5  Two individual examples of the response of cerebral blood ﬂow to rapid, transient changes 
in blood pressure to estimate dynamic cerebral autoregulation. A decrease in blood pressure was 
induced by a bolus intravenous infusion of SNP (sodium nitroprusside; dark arrow) followed one 
minute later by a bolus of PhE (phenylephrine; light arrow), inducing an increase in blood pressure. 
Subject A shows a weak autoregulatory response (ARISNP= 1 and ARIPhE = 1); MCBFV (mean cerebral 
blood ﬂow velocity) appears to passively follow the MAP (mean arterial pressure). Subject B has a 
good autoregulatory response (ARISNP= 5 and ARIPhE =7); mFV is less inﬂuenced by the MAP.
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Discussion
This study examined if estimates of sCA, obtained in both the anterior and posterior 
circulation, were related to estimates of dCA, derived from both spontaneous and induced 
BP changes, in a population of healthy older participants. The two key ﬁndings of this 
study are: (1) the obtained indices of dCA as well as sCA showed a large variation in this 
group of healthy older subjects who were expected to have normal CA, indicating a range 
from low (almost absent) to highly eﬃcient CA. (2) Although there were correlations 
between diﬀerent measures of dCA, and between diﬀerent measures of sCA, there was 
a lack of correlations between indices of dCA and sCA.
 The large variation in the diﬀerent indices of dCA and sCA (Figures 3,4,6 and Table 2) 
is not a new ﬁnding. In previous research in animals, sCA varied from highly eﬃcient to 
absent, and only after averaging all animals the classical autoregulatory pattern was 
observed.33 In humans, the high variation in sCA in the population studied here has 
recently been reported by Liu et al.,(2016). The heterogeneity of dCA in subjects has also 
been acknowledged34 and several studies have addressed this variability.31, 35, 36 However, 
this was from the perspective of reproducibility; the implicit assumption was that the 
underlying CA mechanisms were relatively stable among individuals, and that variability 
may be driven by methodological issues rather than physiology.
 The majority of studies on CA averaged autoregulatory indices to report comparisons 
between groups; thus the presence of large individual autoregulatory indices suggesting 
either highly eﬃcient CA or absence of CA has been neglected. These factors may explain 
Figure 6  Scatter plot of the individual ARI outcomes, showing the variation of ARISNP and ARIPhE, 
categorized on the tertiles of the functioning of the sCA. Each dot represents one subject, showing 
their autoregulatory index (ARI) after a bolus of sodium nitroprusside (SNP) and after a bolus of 
phenylephrine (PhE). Subjects were divided in the lower tertile Slope-CVRICA < 0.84 (low sCA), the 
upper tertile Slope-CVRICA > 1.34 (high sCA) and middle tertile 0.84<Slope-CVRICA<1.34 (normal 
sCA).
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why thus far, the attention paid to the individual variations in CA has been minimal. Before we 
discuss the possible underlying mechanisms and consequences of this variation in CA, 
we will ﬁrst address the question whether the observed variability could be a result of 
inaccuracy in measurements. For the sCA measurements, the method used to assess sCA 
was robust when compared to previous studies on sCA, because for each slope-CVR 
calculation at least 3 data-points were used (Figure 2).8, 9, 16, 21, 37 Also, CBF measurements 
were repeated three times to reduce the eﬀects of intrinsic CBF oscillations (e.g. respiratory 
cycle) as well as to minimize the inﬂuence of random noise. 
 For dCA, the observed inter-individual variability in the estimates of ARI and TFA are 
in line with the variations observed in other work.27, 36, 38 Statistical criteria such as the 
coherence and NMSE threshold were applied to increase the reliability of the measures.25, 
27 Indeed, even though the three ARI measures were estimated from diﬀerent segments 
of the data, the correlation between these diﬀerent ARI-measures indicates intra-person 
reliability. In addition, the slightly higher ARIPhE compared to ARISNP is consistent with 
previous suggestions of hysteresis in CA.39-42 The absence of a relationship between the 
ARI and TFA measures, with exception of the PhaseLF, is in line with the ﬁndings of Tzeng 
et al.,(2012). Nevertheless, a correlation might have been expected, because for the ARI 
indices that were derived from a second-order linear model, the information from transfer 
function gain and phase were combined.
 In summary, the high inter-individual variations of CA measures we observed are in 
line with previous studies, and the intra-individual correlations found within sCA measures 
and within dCA measures suggest that these inter-individual variations are likely to 
represent ‘true’ physiological variations rather than simply measurement errors. 
 This inter-individual CA variations can have diﬀerent origins. It may originate from 
non-stationary behavior of CA, which is receiving increased attention in literature.6, 13 This 
non-stationary behavior is caused by processes which may inﬂuence both BP and CBF. For 
dCA, spontaneous oscillations in blood pressure are partly of unknown origin (because of 
autonomic neural control, vaso-active peptide activity or cardiac-vascular coupling). 
Some factors may aﬀect only BP, others only CBF.43 For example, the role of autonomic 
neural control in CA is not well understood, since in humans the sympathetic and para-
sympathetic cerebral blood vessel innervation cannot be studied in isolation.39 Similarly, 
BP may not be the only origin of oscillations in CBF, which may be related in part to the 
spontaneous oscillatory vasomotor or neuronal activity.44 These and other confounding 
factors (e.g. arterial pCO2, cerebral vasomotion) may contribute to CA variability. 
 The inter-individual variation may also indicate strong CA heterogeneity between 
individuals, with some having a highly eﬃcient and others a nearly absent CA. Several 
factors might contribute to this heterogeneity, including gender, age and clinical 
condition.45, 46 Although the group in this study is too small to show signiﬁcant diﬀerences 
in gender, it does seem to contribute to the variability (Table 2). Previous studies have 
shown that biological variability increases with aging,46, 47 but it cannot be determined in 
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this study whether the large individual CA variability observed in healthy older adults 
reﬂects eﬀects of age. The clinical correlates of this large heterogeneity in CA are unknown 
as all participants met criteria for healthy aging. 
 The primary aim of this study was to investigate the relationship between dCA and 
sCA, by assessing the correlation between multiple indices for both dCA and sCA. A 
prerequisite for studying correlations is that there is suﬃcient variability within the 
population studied which was the case for CA observed in this study. Despite this, there 
were no correlations between sCA and dCA with the exception of GainVLF with 
Slope-CVRVA. However, this correlation was discordant, i.e. low gain (indicating good dCA) 
correlated with low Slope-CVRVA (indicating poor sCA) and would not remain signiﬁcant 
after correction for multiple comparisons. In addition to correlation analysis we divided 
participants in two groups, eﬃcient versus poor sCA, and compared dCA indices between 
the groups. In line with the absence of correlations, there were no diﬀerences between 
the groups (Figures 4&6). 
 The absence of correlation between the sCA and dCA measures is in contrast with 
the observations from Tiecks et al, where the correlation between sCA and dCA was 
highly signiﬁcant (r=0.93, P<0.0001).8 However, the eﬀects of the chosen methodology on 
the observed correlation may have been underestimated. The variability of sCA and dCA 
was pharmacologically induced using isoﬂurane (which impairs CA measures), possibly 
inducing a coupling between the two. The currently presented study used the variability 
present in an aging population. With multiple dCA measures and with a methodological-
ly improved assessment of sCA (CBF instead of CBFV and using multiple equilibriums 
instead of only baseline and PhE-induced MAP increase of ~20 mmHg), evidence is 
pointing towards the lack of correlation between sCA and dCA. This is in line with the 
observed dissociation between dCA and sCA in speciﬁc conditions, such as during 
anesthesia,21 in sepsis48 and type-2-diabetes49 patients. Also in other studies that assessed 
both sCA and dCA there was no linear association between the two.16, 17, 21, 37
 Theoretically, a direct linear correlation between sCA and dCA variables may not exist. 
As illustrated by Tzeng & Ainslie (2014), the implicit conceptual paradigm for sCA and dCA 
consists of both ﬁxed and variable resistance.40 For sCA, it assesses the steady-state BP-CBF 
relationship over the time scales from minutes to hours or even days and is quantiﬁed 
generally by static linear regressions. For dCA, the variable resistances or impedances are 
frequency-dependent, with resistance or impedance changing at diﬀerent frequency 
bands, e.g. at the LF band (f=0.07-0.2Hz). In other words, dCA describes the dynamic 
BP-CBF relationship over the time scales from seconds to minutes and is assessed by the 
transfer function gain and phase. In summary, the mechanisms responsible for changes in 
cerebrovascular resistance or impedance over diﬀerent time scales are likely to be diﬀerent, 
and could explain the lack of linear correlations between sCA and dCA.
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Strengths and limitations
One of the limitations is the use of drugs to manipulate BP, which have possible cerebro-
vascular eﬀects. These eﬀects could be (1) general vasoconstriction leading to reduced 
CBF with PhE and vasodilation with increased CBF with SNP, or (2) more proximal eﬀects 
only on for example the MCA, which would aﬀect CBFV. There is evidence from several 
studies that PhE and SNP do not aﬀect the cerebral vasculature,8, 21, 50-52 although  some 
suggest otherwise.53 The correlation between the ARIBaseline and ARISNP also suggest that 
any eﬀects, if present, were only modest and cannot explain the lack of correlation or the 
large variability. 
 The induced BP changes also led to subtle changes in breathing pattern, which 
resulted in small elevations and reductions in EtCO2 (group average ranges from -1.4 
mmHg to +0.7 mmHg compared to baseline). Because even small changes in EtCO2 can 
have strong eﬀects on CBF (3-7 % CBF / mmHg EtCO2),54, 55 independent from the eﬀects 
of BP, this may have contributed to the variability in estimates. Since the sensitivity diﬀers 
among individuals, we did not apply these group averages to correct the potential eﬀects 
of EtCO2 on CBF. 
 The major strength of this study is the extensiveness of measurements, indices and 
analyses. In this study diﬀerent techniques were used for the assessment of CBF(V) and BP. 
One of the major limitations of CBFV measurements is the uncertainty of a constant 
diameter of the vessel, in most cases the MCA. Sympathetic activation due to exercise can 
induce a 2% change in the cross-sectional area of the MCA,56 which has only a very small 
eﬀect on CBFV estimates. The eﬀects of sympathetic activation or inactivation associated 
with changes in BP on the cross-sectional area of the MCA under supine resting conditions is 
likely to be minimal since a good correlation between Slope-CBFICA and the Slope-CBFV MCA 
was observed in this study. 
 In addition, multiple indices were assessed, based on both spontaneous and induced 
BP oscillations. These linear parameters are most conventional to study, although there is 
a movement towards more non-linear models.13, 57 These non-linear methods may be 
better able to handle the physiological variability in dCA. However, the correlation 
between the diﬀerent linear dCA estimates was reasonable, therefore, application of 
non-linear dCA methods would be unlikely to alter the main ﬁndings of this study. 
 Lastly, diﬀerent statistical approaches to study the relationship between sCA and dCA 
indices were used. Comparison of dCA between groups, based on sCA quality, showed 
the absence of a linear relationship between sCA and dCA (Figure 4&6). In addition, 
correlation analysis was performed (Table 3). Although correlations are sometimes 
misused for comparing quantitative methods, correlations can be used to study the 
presence or absence of a relationship between indices.58 Indeed, in this study the absence 
of correlations is in line with the group-comparison we performed. 
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Implications
The potential beneﬁt of a strong relationship between sCA and dCA would be that it 
makes prediction of sCA from dCA measures possible, which could change clinical routine. 
This study showed that such predictions are presently not possible, mainly for two reasons. 
First, sCA and dCA are not linearly related to each other, as indicated by the absence of 
correlation. Second, there is high variation in estimates of CA functioning in healthy older 
subjects, showing that a ﬁnding of almost absent CA can occur in healthy older subjects. 
 The absence of correlation between diﬀerent measures as shown in this study and in 
previous studies,36 indicates that careful consideration of measures is required. Most 
studies dealing with CA choose one measure to assess CA. Thus, investigators must be 
aware that instead of assessing overall CA, actually they assess only one element of CA. 
Depending on purpose and hypothesis, the choice for steady-state or dynamic measures 
and for TFA or ARI measures should be weighed carefully. 
 The high variation in the diﬀerent CA measures also has considerable consequences 
for future research design. However, the consequences do depend on the underlying 
cause of the high variability. There are two possible explanations.
 One, the non-stationarity of the CA is high, i.e. within a subject CA-eﬃciency may 
vary over time. This aspect may be highly underestimated. A study for investigating the 
variability of CA within participants on a day-to-day basis would therefore be recommended. 
If there is indeed a high non-stationary CA, this would advocate for averaging CA over 
several measurements. 
 Two, CA is stationary, but there is a high inter-subject variability, ranging from poor 
to good CA even in healthy subjects. This would limit studies that aim to use CA as a 
biomarker for disease, especially for elderly. Precisely in this group the diseases that may 
aﬀect CA, such as stroke, diabetes, or neurodegenerative disease, have the highest 
prevalence. CA assessment can however still be used to study diﬀerences in physiology 
between health and disease state, but groups need to be suﬃciently large. 
 Thus, for estimating eﬀects of prolonged changes in BP, assessment of dynamics of 
the CA system is not adequate as these measures are unable to predict more steady-state 
eﬀects of the systems. This implies that use of long term monitoring of CA cannot be 
replaced by short measurement-procedures; long-term monitoring of cerebral perfusion 
pressure and CBF remains required. 
Conclusion
There was a high variation in dCA and sCA parameters, indicating a wide range of CA 
functioning in this aged population. Although there were moderate to strong correlations 
within sCA and within dCA parameters, there were no linear correlations between sCA 
and dCA. In fact, when the groups were ranked based on sCA functioning, this did not 
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translate to diﬀerences in dCA functioning. With this, this study showed that the gain and 
latency of transient responses of CBF to dynamic changes in BP are not related to the 
steady-state responses of CBF to steady-state changes in BP.
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Appendix
The ARI-templates are calculated using a second order linear diﬀerential equation
where dP is the normalized change in mean arterial pressure (MAP) relative to the control 
value (cBP) adjusted for the estimated critical closing pressure (CrCP; equal to 12 mmHg), 
x2 and x1 are state variables (equal to 0 at baseline), mV is modeled mean velocity, and 
cMCBFV is baseline MCBFV, f is the sampling frequency (10Hz) mV values generated from 
10 predeﬁned combinations (see Table S1) of the time constant (T), dampening factor (D), 
and autoregulatory gain (K) were ﬁtted to the actual MCBFV recording within a 30-s 
window to identify the best-ﬁt model associated with the minimum quadratic error. 
Table S1  Parameters for calculation of autoregulatory indices.
ARI T D K
0 2 0 0
1 2 1.60 0.20
2 2 1.50 0.40
3 2 1.15 0.60
4 2 0.90 0.80
5 1.9 0.75 0.90
6 1.6 0.65 0.94
7 1.2 0.55 0.96
8 0.87 0.52 0.97
9 0.65 0.50 0.98
ARI, autoregulatory index; T, time constant, D, damping factor, K, autoregulatory dynamic gain.
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Abstract
Cerebral hypoperfusion elevates the risk of brain white matter (WM) lesions and cognitive 
impairment. Central artery stiﬀness impairs baroreﬂex, which controls systemic arterial 
perfusion, and may deteriorate neuronal ﬁber integrity of brain WM. The purpose of 
this study was to examine the associations among brain WM neuronal ﬁber integrity, 
baroreﬂex sensitivity (BRS), and central artery stiﬀness in older adults. Fifty-four adults 
(65±6 years) with normal cognitive function or mild cognitive impairment (MCI) were 
tested. The neuronal ﬁber integrity of brain WM was assessed from diﬀusion metrics 
acquired by diﬀusion tensor imaging. BRS was measured in response to acute changes in 
blood pressure induced by bolus injections of vasoactive drugs. Central artery stiﬀness 
was measured by carotid-femoral pulse wave velocity (cfPWV). The WM diﬀusion metrics 
including fractional anisotropy (FA) and radial (RD) and axial (AD) diﬀusivities, BRS, and 
cfPWV were not diﬀerent between the control and MCI groups. Thus, the data from both 
groups were combined for subsequent analyses. Across WM, ﬁber tracts with decreased 
FA and increased RD were associated with lower BRS and higher cfPWV, with many of 
the areas presenting spatial overlap. In particular, the BRS assessed during hypotension 
was strongly correlated with FA and RD when compared with hypertension. Executive 
function performance was associated with FA and RD in the areas that correlated with 
cfPWV and BRS. These ﬁndings suggest that baroreﬂex-mediated control of systemic 
arterial perfusion, especially during hypotension, may play a crucial role in maintaining 
neuronal ﬁber integrity of brain WM in older adults.
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Introduction
Cardiovascular aging and disease are associated with an elevated risk for structural and 
functional abnormalities in the brain.1, 2 In particular, white matter (WM) lesions, a strong 
risk factor for cognitive impairment, have consistently been shown to correlate with 
central artery stiﬀness.3, 4 WM lesions may develop from hypoperfusion and/or ischemia.5, 6 
Under normal conditions, arterial perfusion pressure, especially those of short-term 
variability in seconds and minutes, is controlled by arterial baroreﬂex.7 Arterial baroreceptors, 
a type of mechanoreceptor located in the central elastic arteries, monitor changes in transmural 
pressure via the vessel wall distortion.8 With age and/or presence of cardiovascular disease 
risk factors, a reduction in central arterial compliance attenuates baroreﬂex sensitivity for a 
given change in blood pressure.9, 10 As a result, the depressed baroreﬂex sensitivity (BRS) 
may impair cardiovascular regulation of systemic arterial perfusion.11, 12 To date, there have 
been no studies investigating the relation between brain WM structural integrity and BRS.
 Diﬀusion tensor imaging (DTI) can quantitatively assess microstructural changes in 
WM neuronal ﬁber tracts that manifest with aging or neurodegenerative disease.13, 14 
Measuring the anisotropic property of water molecule diﬀusions in a WM ﬁber tract, DTI 
provides several key metrics, including fractional anisotropy (FA) and radial and axial 
diﬀusivities (RD and AD respectively).15 FA reﬂects WM neuronal ﬁber integrity that is 
determined by density, directional coherence, and myelination level of WM ﬁbers.16 RD 
and AD further provide structural information about WM neuronal ﬁbers. Histological 
studies suggested that higher RD indicates axonal demyelination, while lower AD reﬂects 
axonal loss.17 Importantly, alterations in these diﬀusion metrics correlate with neuro-
cognitive performance, especially executive function.18
 Dementia manifests at the end of a pathological spectrum, extending from age- 
related cognitive decline and functional impairment.19, 20 Mild cognitive impairment (MCI) 
represents an intermediate disease stage which may be a suitable target to alter the 
pathological trajectory via life-style and/or pharmacological interventions.21 Therefore, 
physiological understanding of the mechanisms linking cardiovascular and cognitive 
health in MCI is crucial. The main aim of the present study was to determine the impact of 
central artery stiﬀness and BRS on WM neuronal ﬁber integrity in older adults with or 
without MCI. Speciﬁcally, we hypothesized that: 1) central artery stiﬀness and depressed 
BRS would be associated with the lower levels of WM neuronal ﬁber integrity as assessed 
by DTI, and these abnormalities are exacerbated in MCI when compared with normal 
older adults, and 2) executive function performance would be associated with WM 
neuronal ﬁber integrity in the area(s) that correlates with central artery stiﬀness and BRS. 
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Materials and Methods
Study Participants
Fifty-four participants (18 cognitively normal and 36 MCI subjects) were recruited through 
a community-based advertisement using local newspapers, senior centers, and the 
University of Texas Southwestern Medical Center Alzheimer’s Disease Center. The diagnosis 
of MCI was based on the Petersen criteria,22, 23 as modiﬁed by the Alzheimer’s Disease 
Neuroimaging Initiative project (http://adni-info.org). Clinical evaluation was performed 
based on the recommendations from Alzheimer’s Disease Cooperative Study (http://
adni-info.org). Inclusion criteria were men and women aged 55-80 years who were 
diagnosed with MCI or judged to be cognitively normal. Exclusion criteria included major 
psychiatric disorders, major or unstable medical conditions, uncontrolled hypertension, 
diabetes mellitus, current or a history of smoking within the past 2 years, or chronic 
inﬂammatory diseases. Individuals with a pacemaker or any metal in their body which 
precluded magnetic resonance imaging were excluded. Subjects engaging in regular 
aerobic exercise in the past 2 years were excluded because physical activity may alter 
brain structure and function, independently of vascular disease and risk factors.24 All 
subjects signed the informed consent approved by the Institutional Review Boards of 
University of Texas Southwestern Medical Center and Texas Health Presbyterian Hospital 
of Dallas.
Measurements
Magnetic Resonance Imaging (MRI)
All MRI measurements were acquired by a 3-Tesla scanner (Philips Medical System, Best, 
The Netherlands) using a body coil for radiofrequency transmission and 8-channel head 
coil with parallel imaging capability for signal reception. Three MRI sequences were 
performed: DTI, ﬂuid-attenuated-inversion-recovery (FLAIR), and 3D magnetization-pre-
pared rapid acquisition gradient echo (MPRAGE). DTI was acquired using a single-shot 
echo-planar-imaging (EPI) sequence with a sensitivity encoding (SENSE) parallel imaging 
scheme (reduction factor=2.2). The imaging matrix was 112×112 with ﬁeld of view (FOV) 
=224×224 mm2 (nominal resolution of 2 mm), which was ﬁlled to 256×256. Axial slices of 
2.2 mm thickness (no gap) were acquired parallel to the anterior-posterior commissure 
line. A total of 65 slices covered the entire hemisphere and brainstem. Echo Time (TE)/
Repetition Time (TR) was 51/5630 ms. The diﬀusion weighing was encoded along 30 
independent orientations and the b value was 1000 s/mm2. The scan duration was 4.3 
minutes. Automated image registration was performed on the raw diﬀusion images to 
correct distortions caused by motion artifacts or eddy currents. All subjects underwent 
two consecutive scans of DTI acquisitions. 
 FLAIR images were acquired in the transverse plane using the following parameters: 
FOV=230×230 mm2, resolution=0.65 (anterior-posterior) ×0.87 (right-left) mm2, number of 
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slices=24, thickness=5 mm, gap=1 mm, TR/Inversion Time/TE=11000/2800/150 ms, and 
scan duration=3.6 minutes. MPRAGE images were acquired using the following parameters: 
TE/TR=3.7/8.1 ms, ﬂip angle=12°, FOV=256×256 mm, number of slices = 160 (no gap), 
resolution=1×1×1 mm3, SENSE factor=2, and scan duration=4 minutes.
Cardiovascular Assessments
All physiological measurements were performed in an environmentally controlled laboratory 
after resting in the supine position for ≥15 minutes. All subjects abstained from alcohol, 
caﬀeinated beverages, and intense physical activity for ≥12 hours prior to data collection. 
Brachial blood pressure was measured intermittently using an electrosphygmomanometer 
(Suntech, Morrisville, NC, USA). Central artery stiﬀness was measured by carotid-femoral 
pulse wave velocity (cfPWV) using applanation tonometry which was sequentially placed 
on the common carotid and femoral arteries (SphygmoCor 8.0; AtCor Medical, West Ryde, 
NSW, Australia). Arterial pulse of >10 cardiac cycles was recorded to calculate cfPWV. 
 BRS was assessed via the modiﬁed Oxford protocol in which we performed a 
sequential intravenous bolus injections of sodium nitroprusside (100 μg) followed 60 
seconds by phenylephrine hydrochloride (150 μg). All subjects experienced a decrease 
and increase in systolic blood pressure of at least 15 mmHg. Three-lead electrocardiogram 
(ECG) and beat-by-beat arterial blood pressure using ﬁnger plethysmography (Finapress; 
Ohmeda, Boulder, CO, USA) were continuously recorded with a sampling frequency of 
1,000 Hz and analyzed oﬄine using data analysis software (Acqknowledge, BIOPAC 
Systems, Goleta, CA, USA).
Neurocognitive Assessments
Clinical Dementia Rating (CDR),25 Mini-mental State Examination (MMSE),26 Wechsler 
Memory Scale-Revised (WMS-R),27 California Verbal Learning Test-second edition 
(CVLT-II),28 and Trail Making Test parts A and B29 were administered and scored using 
standard criteria. The diagnosis of MCI was determined by a global CDR of 0.5 with a score 
of 0.5 in the memory category, objective memory loss as indicated by education-adjusted 
scores on the Logical Memory subtest of the WMS-R, and MMSE score between 24 and 30. 
CVLT-II Long Delay Free Recall and Trail Making Test part B minus A (i.e., to focus more 
upon the executive function components of the test by subtracting the psychomotor 
speed aspect) were selected a priori as the primary measures of memory and executive 
function, respectively.30, 31
Data Analyses
DTI Preprocessing and Analysis
DTI data were preprocessed using the FMRIB Diﬀusion Toolbox (FDT) included as a part of 
the FMRIB Software Library (FSL) program (http://www.fmrib.ox.ac.uk/fsl, Oxford Center 
for Functional MRI of the Brain, Oxford University, UK) (version 5.0). First, 2 scans of DTI data 
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 82
82 | Chapter 4
were merged in the temporal order, corrected for eddy currents and head motion, and 
averaged over the scans to increase signal-to-noise ratio. Second, a brain mask was created 
using Brain Extraction Tool (BET). Finally, the diﬀusion tensor was calculated by ﬁtting a 
diﬀusion tensor model to the preprocessed DTI data using the DTIﬁt program included in 
FDT.32 To minimize partial volume eﬀects from grey matter and cerebrospinal ﬂuid, we set 
a threshold for voxels with FA value greater than 0.20. Individual subjects’ images with FA, 
RD, and AD were visually inspected and used in the voxelwise and region-of-interest (ROI) 
analyses. 
 Voxelwise statistics were performed by tract-based spatial statistics (TBSS) (version 
1.2),33 a part of the FSL program.34 All subjects’ FA data were ﬁrst aligned into a common 
space using the FMRIB’s nonlinear image registration tool (FNIRT), which uses a b-spline 
representation of the registration warp ﬁeld.35 We used JHU-ICBM-FA template as a 
common space in order to correspond the results from voxelwise and ROI analyses. Next, 
the mean FA image was created and thinned to generate a mean FA skeleton which 
represents the centers of all tracts common to all subjects. Each subject’s aligned FA, RD, 
and AD data were projected onto this skeleton and the resulting data were fed into 
voxelwise and ROI-based cross-subject statistics. 
 ROI analysis that is limited to the TBSS skeleton was performed using the deep WM 
atlas (ICBM-DTI-81 white-matter atlas) developed by the Johns Hopkins University.36 Mean 
values of a diﬀusion metric for selected ROI segmentations were extracted from each 
participant.
WM Lesion Volume. 
Total brain volume of WM hyperintensities were measured in FLAIR images using a 
procedure described in detail elsewhere.37 First, a ROI corresponding to WM hyperintensity 
was created using a semi-automated technique which applies individually determined 
intensity thresholding. Second, gross manual outlining of WM hyperintensities was 
performed to create ROI maps. Third, the intersection of ROIs created from the 1st and 2nd 
steps were identiﬁed, visually inspected, and produced the ﬁnal WM hyperintensity 
volume. To account for individual diﬀerences in head size, total brain volume of WM 
hyperintensity was normalized to the intracranial volume and reported in percentage.
Baroreflex Sensitivity
Cardiovagal BRS was analyzed using the procedure described in detail elsewhere.38, 39 
Brieﬂy, individual raw data showing the relation between R-R interval and systolic blood 
pressure was ﬁrst plotted to visually identify and exclude the saturation and threshold 
regions. Next, the values of R-R interval were pooled and averaged every 2 mmHg bin of 
systolic blood pressure to minimize the inﬂuence of respiration. A least squares linear 
regression was applied to the relation between changes in systolic blood pressure and 
R-R interval of the preceding cardiac cycle to account for baroreﬂex delays. BRS was 
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determined by a slope of the linear regression, with a correlation coeﬃcient greater than 
0.80. BRS was calculated from the entire sequence of the modiﬁed Oxford protocol as well 
as hypo- and hypertensive episodes separately. 
Central Artery Stiffness 
Carotid-femoral PWV was calculated by dividing arterial pulse traveling distance by the 
transit time, and expressed in meters per second. The traveling distance was measured as 
a straight distance on body surface between the carotid and femoral arteries using a tape 
ruler. The arterial pulse transit time was calculated by subtracting a time diﬀerence between 
the R-wave of ECG to a foot of femoral artery pressure waveform minus a time diﬀerence 
between the R-wave of ECG to a foot of carotid artery pressure waveform. The transit time 
was averaged over >10 cardiac cycles. 
Brain Volume
Global and regional brain volumes were measured using FreeSurfer software (https://
surfer.nmr.mgh.harvard.edu/fswiki). Global brain volume (i.e., total parenchyma, and grey 
and white matters) was normalized to intracranial volume whereas regional brain volume 
(i.e., medial temporal lobe and hippocampus) was corrected for total parenchyma volume 
in order to estimate regional tissue loss, independent of the global eﬀect.40
Statistical Analysis
All participants completed the study protocol. Voxelwise analysis of DTI data was 
performed by general linear model, a part of the FSL-randomise program. Diﬀusion 
metrics were ﬁrst compared between the groups of normal and MCI subjects. Then, the 
associations with cfPWV and BRS were examined. To further explore the impact of hypo- 
and hypertension on the brain structure, we performed an additional TBSS analysis using 
BRS to separately assess the eﬀects of blood pressure reduction and elevation. Correction 
for multiple comparisons was performed using threshold-free cluster enhancement 
(TFCE) with 5,000 permutations. Corrected statistical maps were further thresholded by 
P<0.05. Anatomical assignments of the WM skeleton voxels that survived correction of 
multiple comparisons and P-value thresholding were identiﬁed using the WM atlas. We 
speciﬁcally focused on the major WM ﬁber tracts in the deep and periventricular area 
which may be susceptible for cerebral hypoperfusion and/or ischemia.6 These WM ﬁber 
tracts included corpus callosum, corona radiate, internal capsule, external capsule, and 
superior longitudinal fasciculus. Finally, the mean values of diﬀusion metrics were 
extracted from the signiﬁcant WM skeletons resulting from the TBSS analysis. 
 The groups of normal and MCI subjects were compared by the Mann-Whitney U test. 
Simple correlations among continuous variables were examined by the Pearson’s product- 
moment correlation. Multiple linear regression was used to examine the association of 
diﬀusion metrics with cfPWV and BRS, including covariates. All models were adjusted for 
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age, sex, education level, systolic blood pressure, and correlates of cfPWV, BRS, and 
diﬀusion metrics in this sample. Partial correlation was used to test the association 
between diﬀusion metrics and cognitive function. The covariates included in this analysis 
were age, sex, education level, systolic blood pressure, and correlates of cognitive function 
in this sample. 
 Normality of continuous variables was examined by the Shapiro-Wilk test as well as 
the visual inspection of histograms and Q-Q plots. Total brain volume of WM hyperintensity 
was log-transformed due to a skewed distribution of the raw data. Sex was dummy-coded 
(men=0 and women=1). Statistical signiﬁcance was set a priori at P<0.05 for all tests. Data 
are reported as mean ± standard deviation. Statistical analyses were performed using 
SPSS 21.0 (SPSS inc., Chicago, IL).
Results
Table 1 shows a group comparison of the normal and MCI subjects. Age, sex, education 
level, and MMSE scores did not diﬀer between groups. Compared with the normal group, 
MCI subjects demonstrated lower performance in memory and executive function, 
as evidenced by the lower scores on CVLT-II Long Delay Free Recall and the longer time 
in Trail Making Test B-A respectively. In contrast, there was no group diﬀerence in the 
measures of diﬀusion metrics, brain volume, and cardiovascular function including cfPWV 
and BRS. Accordingly, all subjects’ data were combined to perform the association analyses. 
 Consistent with the literatures,9, 10 higher cfPWV correlated with lower BRS (r=-0.34, 
P=0.01), assessed particularly during hypotension (r=-0.45, P=0.001) compared with 
hypertension (r=-0.26, P=0.06). The greater volume of WM hyperintensity correlated with 
lower BRS (r=-0.35, P=0.01) and higher cfPWV (r=0.68, P<0.001). 
Associations among central artery stiffness, BRS, and WM neuronal  
fiber integrity
In Figure 1, TBSS maps exhibit WM ﬁber tracts that associated with cfPWV and BRS. 
Speciﬁcally, 46.6 cm3 and 43.1 cm3 of the WM ﬁber tracts with decreasing FA were 
associated with higher cfPWV and lower BRS, respectively. Similarly, 48.8 cm3 and 31.9 cm3 
of the WM ﬁber tracts with increasing RD were associated with higher cfPWV and lower 
BRS, respectively. When BRS was analyzed separately during hypo- and hypertension, 
the former was associated with the greater volume of WM ﬁber tracts with FA (43.0 vs. 
21.8 cm3) and RD (36.0 vs. 0.08 cm3) when compared with the latter, while the directions 
of associations remained the same as the combined BRS (Figure 2). WM ﬁber tracts with 
AD did not correlate with either cfPWV or BRS.
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Table 1  Sample characteristics of all, cognitively normal, and MCI subjects.
 All Normal MCI P-value
Men/Women (n) 26/28 10/8 16/20 0.44
Age (years) 65 ± 6 65 ± 6 66 ± 7 0.59
Education (years) 16 ± 2 17 ± 2 16 ± 2 0.29
Height (cm) 170 ± 8 171 ± 9 170 ± 8 0.64
Body mass (kg) 80 ± 14 80 ± 16 80 ± 13 0.89
Body mass index (kg/m2) 27 ± 4 27 ± 4 28 ± 4 0.50
Neurocognitive measures           
Mini-Mental State Exam 29 ± 1 29 ± 1 29 ± 1 0.46
CVLT Short Delay Free Recall 10 ± 3 11 ± 2 9 ± 2 <0.01
CVLT Long Delay Free Recall 10 ± 3 12 ± 2 10 ± 3 <0.01
Trail Making Test part A 28 ± 10 29 ± 11 27 ± 9 0.80
Trail Making Test part B 72 ± 25 62 ± 18 77 ± 26 0.01
Trail Making Test part B-A 44 ± 21 33 ± 16 49 ± 21 <0.01
Cardiovascular measures           
Systolic BP (mmHg) 124 ± 14 125 ± 14 124 ± 14 0.82
Diastolic BP (mmHg) 74 ± 8 74 ± 9 74 ± 8 0.82
Heart rate (bpm) 61 ± 10 63 ± 10 60 ± 11 0.34
Carotid-femoral PWV (m/sec) 11.0 ± 2.7 11.2 ± 2.2 11.0 ± 2.9 0.54
BRS (ms/mmHg) 4.99 ± 2.33 5.09 ± 2.80 4.94 ± 2.10 0.91
Brain volumetric measures           
Total grey matter volume (%ICV) 39.7 ± 2.4 40.3 ± 2.1 39.4 ± 2.6 0.23
Total white matter volume (%ICV) 34.7 ± 3.1 34.7 ± 2.3 34.7 ± 3.5 0.83
Medial temporal lobe volume (%TB) 1.62 ± 0.13 1.63 ± 0.13 1.62 ± 0.12 0.73
Hippocampus volume (%TB) 0.69 ± 0.08 0.69 ± 0.06 0.69 ± 0.09 0.93
Total WMH volume (%ICV) 0.27 ± 0.44 0.25 ± 0.39 0.29 ± 0.46 0.79
Bold: P-value<0.05 between normal vs. MCI subjects. Values are mean ± standard deviation. BP=blood 
pressure, BRS=baroreflex sensitivity, CVLT=California Verbal Learning Test, ICV=intracranial volume, MCI= 
mild cognitive impairment, PWV=pulse wave velocity, TB=total brain volume, and WMH=white matter 
hyperintensity. %ICV and %TB represent brain volume normalized to intracranial and total brain volumes 
respectively.
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The WM ﬁber tracts that associated with cfPWV and BRS exhibited a large spatial overlap. 
Speciﬁcally, 25.0 cm3 and 21.6 cm3 of the voxels with FA and RD were associated with both 
cfPWV and BRS, respectively (bottom of the Figure 1). This accounts for ~50% of the WM 
ﬁber tracts that correlated with either cfPWV or BRS, and may suggest the presence of a 
common underlying mechanism by which central artery stiﬀness and low BRS deteriorate 
WM neuronal ﬁber integrity or they may contribute independently to the neuronal ﬁber 
deterioration in these regions. To explore these possibilities, we extracted the mean 
values of individual FA and RD from the spatial overlapped regions and further examined 
their associations with cfPWV and BRS. Figure 3 shows the scatter plots of cfPWV 
and BRS in relation to FA and RD extracted from the global WM skeletons. Multivariate 
adjusted regression revealed signiﬁcant associations of the global WM skeletons with 
cfPWV and BRS after controlling for age, sex, education level, systolic blood pressure, and 
WM hyperintensity volume (Tables 2 and 3). 
Figure 1  Tract-based spatial statistic (TBSS) maps exhibit white matter (WM) ﬁber tracts with fractional 
anisotropy (left) and radial diﬀusivity (right) that associated with carotid-femoral pulse wave velocity 
(PWV) (top) and baroreﬂex sensitivity (BRS) (middle). The color bar illustrates the directionality and 
P-value of the associations. The bottom images show spatial overlap of the WM ﬁber tracts (green) 
that associated with both carotid-femoral PWV and BRS.
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Similar to the global WM analysis, many of the WM ﬁber tracts in the deep and periventric-
ular area showed spatial overlap in terms of their associations with cfPWV and BRS. 
Multivariate adjusted regression revealed that both cfPWV and BRS independently 
associated with FA and RD in the posterior corona radiata (PCR) (Tables 2 and 3). In addition, 
BRS independently associated with FA and RD in the splenium of corpus callosum and 
the retrolenticular part of internal capsule.
Association between WM neuronal fiber integrity and cognitive function
Better executive function performance, as assessed by Trail Making Test B-A, was 
associated with the higher levels of FA and the lower levels of RD in the global WM 
skeletons that correlated with both cfPWV and BRS (Figure 4). Partial correlation analysis 
further revealed that FA and RD measured from the global WM (r=-0.32 with P=0.03; r=0.31 
with P=0.04, respectively) and RD measured from the PCR (r=0.29 with P=0.048) remain to 
be correlated with executive function performance after controlling for age, sex, education 
level, systolic blood pressure, WM hyperintensity volume, and cognitive status (i.e., healthy 
or MCI group).
Figure 2  Tract-based spatial statistic (TBSS) maps exhibit white matter ﬁber tracts with fractional 
anisotropy (left) and radial diﬀusivity (right) that associated with baroreﬂex sensitivity (BRS), as assessed 
separately during hypotension (top) and hypertension (bottom). The color bar illustrates the directionality 
and P-value of the associations.
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Figure 3  Scatter plots show simple correlations of carotid-femoral pulse wave velocity (PWV) (left) and 
baroreﬂex sensitivity (right) with fractional anisotropy (FA) (top) and radial diﬀusivity (RD) (bottom). 
Mean values of FA and RD were extracted from the global WM skeleton that associated with both 
carotid-femoral PWV and baroreﬂex sensitivity (see the bottom of Figure 1).
Figure 4  Scatter plots show simple correlations of fractional anisotropy (FA) (left) and radial diﬀusivity 
(RD) (right) with the scores from the Trail Making Test B-A index. Mean values of FA and RD were 
extracted from the global WM skeleton that associated with both carotid-femoral PWV and baroreﬂex 
sensitivity (see the bottom of Figure 1).
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Table 2  Multivariate adjusted relations of central artery stiﬀness and baroreﬂex sensitivity 
with microstructural tissue integrity of global and regional white matter ﬁber tracts, 
as assessed by fractional anisotropy.
White matter regions Carotid-femoral PWV Baroreflex sensitivity
β ± SE P-value β ± SE P-value
Global white matter -0.37 ± 0.11 <0.01 0.39 ± 0.10 <0.001
Corpus callosum genu -0.29 ± 0.18 0.12 0.15 ± 0.15 0.32
 body -0.90 ± 0.17 0.59 0.03 ± 0.14 0.86
 splenium -0.32 ± 0.19 0.10 0.32 ± 0.16 0.049
Corona radiata anterior -0.13 ± 0.16 0.40 0.12 ± 0.13 0.37
 superior -0.25 ± 0.19 0.20 0.20 ± 0.16 0.23
 posterior -0.46 ± 0.15 <0.01 0.40 ± 0.13 <0.01
Internal capsule anterior limb -0.26 ± 0.15 0.10 0.14 ± 0.13 0.29
 posterior limb -0.27 ± 0.14 0.07 0.06 ± 0.12 0.63
 retrolenticular part -0.34 ± 0.18 0.06 0.32 ± 0.15 0.04
External capsule -0.19 ± 0.16 0.25 0.27 ± 0.14 0.053
Superior longitudinal fasciculus -0.32 ± 0.18 0.09 0.25 ± 0.15 0.10
Bold: P-value<0.05. The mean values of fractional anisotropy were extracted from the global and regional 
white matter fiber tracts that associated with both carotid-femoral PWV and baroreflex sensitivity (see the 
bottom left of Figure 1). All models adjusted for age, sex, education level, systolic blood pressure, and total 
brain volume of white matter hyperintensity. Total brain volume of white matter hyperintensity was log-
transformed before entered in the model. β=standardized regression coefficient, PWV=pulse wave velocity, 
and SE=standard error.
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Discussion
The major ﬁndings from this study are as follows. First, central artery stiﬀness and 
depressed BRS were independently associated with the deterioration of WM neuronal 
ﬁber integrity, as reﬂected by the decreases in FA and increases in RD. In addition, a large 
portion of the WM ﬁber tracts with FA and RD that correlated with arterial stiﬀness and 
BRS showed spatial overlap. Second, WM neuronal ﬁber integrity was correlated more 
strongly with BRS assessed during hypotension than hypertension. Third, executive 
function performance was associated with WM neuronal ﬁber integrity, speciﬁcally in the 
areas correlated with arterial stiﬀness and low BRS. Below we further discuss the potential 
mechanism(s) and clinical implications of these ﬁndings.
Table 3  Multivariate adjusted relations of central artery stiﬀness and baroreﬂex sensitivity 
with microstructural tissue integrity of global and regional white matter ﬁber tracts, 
as assessed by radial diﬀusivity.
White matter regions Carotid-femoral PWV Baroreflex sensitivity
β ± SE P-value β ± SE P-value
Global white matter 0.38 ± 0.12 <0.01 -0.39 ± 0.10 0.001
Corpus callosum genu 0.32 ± 0.17 0.07 -0.24 ± 0.14 0.10
 body 0.31 ± 0.16 0.055 -0.12 ± 0.13 0.37
 splenium 0.36 ± 0.18 0.055 -0.39 ± 0.15 0.01
Corona radiata anterior 0.30 ± 0.14 0.03 -0.30 ± 0.11 0.01
 superior 0.28 ± 0.15 0.07 -0.28 ± 0.13 0.04
 posterior 0.47 ± 0.15 <0.01 -0.32 ± 0.12 0.01
Internal capsule anterior limb 0.18 ± 0.17 0.29 -0.16 ± 0.14 0.25
 posterior limb 0.24 ± 0.16 0.14 -0.04 ± 0.13 0.78
 retrolenticular part 0.37 ± 0.17 0.03 -0.28 ± 0.14 0.047
External capsule 0.29 ± 0.16 0.07 -0.24 ± 0.13 0.08
Superior longitudinal fasciculus 0.38 ± 0.17 0.04 -0.23 ± 0.15 0.13
Bold: P-value<0.05. The mean values of radial diffusivity were extracted from the global and regional 
white matter fiber tracts that associated with both carotid-femoral PWV and baroreflex sensitivity (see the 
bottom right of Figure 1). All models adjusted for age, sex, education level, systolic blood pressure, and total 
brain volume of white matter hyperintensity. Total brain volume of white matter hyperintensity was log-
transformed before entered in the model. β=standardized regression coefficient, PWV=pulse wave velocity, 
and SE=standard error.
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The role of baroreflex in the link between central artery stiffness and 
WM neuronal fiber integrity
Central artery stiﬀness was associated with abnormal structural changes in the brain WM, 
as assessed by both WM hyperintensity and DTI. The cross-sectional association between 
aortic PWV and WM hyperintensity volume has consistently been reported in the 
literature,41 and our study also conﬁrmed this association (r=0.68, P<0.001). Furthermore, 
our data adds to the literature by demonstrating the independent association of higher 
cfPWV with lower FA and higher RD in the global and regional WM ﬁber tracts after 
controlling for WM hyperintensity volume. These ﬁndings suggest an involvement of 
central artery stiﬀness in the pathogenesis of WM lesions because the lower levels of FA 
in the WM tissue have been shown to precede the development and progression of WM 
hyperintensity.13
 Hemodynamic mechanisms underlying the association between central artery stiﬀness 
and WM lesions are likely to be multifactorial. Aortic stiﬀness increases left ventricular 
afterload and also leads to an early return of arterial wave reﬂections from the peripheral 
vascular bed.42 As a result, central pulse pressure increases due to the eﬀects of elevated 
forward and/or backward pressure waves.43, 44 Cerebral circulation has a high ﬂow, low 
vascular resistance and impedance which may facilitate the transmission of hemodynamic 
pulsatility.45 Age-related elevations in central artery stiﬀness and pulse pressure are 
independently associated with the higher levels of cerebral blood ﬂow pulsatility and 
WM lesion volume.46-49 Mechanistically, excessive pulsatile shear stress on cerebral micro-
circulations may damage vascular endothelium and blood-brain barrier whose integrity 
has been shown as a neuropathological correlate of WM lesions.50 Therefore, central 
artery stiﬀness may increase the risk of WM lesions via elevations in central and cerebral 
hemodynamic pulsatility.
 Central artery stiﬀness may also increase short-term variability in blood pressure 
which may predispose the brain to unstable supplies of oxygen and nutrients.51 In the 
current study, WM neuronal ﬁber integrity not only correlated with BRS in general, but 
also more closely with BRS assessed during hypotension than hypertension. Arterial 
baroreceptors, the stretch-sensitive mechanoreceptors located in the walls of aortic 
arch and carotid sinus, monitor moment-to-moment variability in arterial pressure. 
The baroreceptor reﬂex subsequently modulates cardiac output and total peripheral 
resistance and maintains a constant levels of systemic arterial pressure and perfusion.8 
With stiﬀening of the barosensory arteries, BRS decreases and may elevate the risk of 
cerebral hypoperfusion in the face of hypotension (e.g., orthostasis).52 Alternatively, 
attenuated increases in cardiac output that are accompanied by compensatory elevations 
in total peripheral resistance may also cause hypoperfusion, independent of arterial 
pressure.53 It has been shown that attenuated elevations in cardiac output during 
orthostasis correlate with cerebral hypoperfusion and cognitive impairment in heart 
failure patients.54 Therefore, these ﬁndings suggest that cardiovascular regulation of 
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arterial pressure and perfusion, especially during hypotension, may have signiﬁcant 
impact on the structural integrity of the brain WM.
 The lower levels of FA associated with arterial stiﬀening and decreasing BRS occurred 
with concurrent elevations in RD in many brain regions (Figures 1 and 2). DTI measures 
water diﬀusions in a WM ﬁber tract that are restricted by axonal membranes and myelin.15 
While FA provides an overall measure of WM neuronal ﬁber integrity, changes in RD, as 
measured by water diﬀusions perpendicular to the WM ﬁber tract, are likely to reﬂect 
myelin integrity. A series of histological experiments using the optic nerve exposed to 
retinal ischemia demonstrated that axonal demyelination is correlated with elevations in 
RD.17, 55 Therefore, ﬁndings from the present study suggest that cerebral hypoperfusion 
and/or ischemia associated with low BRS during hypotension may lead to myelin 
deterioration and manifest as reductions in WM FA.
The role of WM neuronal fiber integrity in cognitive function
Better executive function performance was correlated with higher FA and lower RD 
measured from the global and regional WM ﬁber tracts. The brain WM, which accounts for 
40%-50% of the parenchyma, comprises axons and myelin, connects distributed network 
of neurons, and facilitates complex cognitive task via structural and functional 
integrations.56 The conventional techniques of brain WM imaging (e.g., T1-weighted or 
FLAIR MRI) are limited by their sensitivity in detecting changes in cognitive function. In 
contrast, the diﬀusion metrics derived from DTI have consistently been shown to correlate 
with processing speed and executive function.57 For example, Vernooij et al. reported that 
higher FA measured from the global WM was related to better performance on tasks 
assessing information processing speed and global cognition.58 In this regard, our data 
also showed that higher FA and lower RD in the global WM correlated with better 
executive function performance, while total brain volume of WM or WM hyperintensities 
were unrelated to cognitive performance.
 WM neuronal ﬁber integrity, as assessed by FA and RD, correlated with executive 
function performance in all subjects. However, MCI subjects who have shown lower 
performance in executive function demonstrated similar levels of WM neuronal ﬁber 
integrity compared with healthy subjects. Such discrepancies in the results of group 
comparison versus association analyses may be explained by a few reasons. First, cognitive 
impairment has multifactorial causes, including but not only limited to brain WM 
deteriorations. The other potential causes include amyloid depositions, hypometabolism, 
and neurodegeneration, which may impact cognitive function independent of brain WM 
structural abnormalities.59, 60 Second, a recent meta-analysis suggested that the eﬀect of 
MCI or Alzheimer disease on WM microstructural integrity may depend on the level of 
global cognitive impairment (e.g., MMSE).61 Indeed, we also observed a trend towards a 
positive relation between MMSE scores and global FA and RD (Data Supplement Figure). 
In the current study, MCI participants as a group demonstrated the comparable MMSE 
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scores to healthy adults which in turn may have reﬂected the similar levels in FA and RD. 
Third, the metrics derived from DTI may not be speciﬁc and/or sensitive enough to detect 
the group diﬀerence in executive function. Finally, our study sample was relatively small 
and may be underpowered to detect group diﬀerences in the DTI metrics.
Strengths and Limitations
The major strength of this study is the multidisciplinary nature of the investigation. DTI 
assessed microstructural tissue properties of brain WM, while baroreﬂex-mediated control 
of systemic arterial perfusion was assessed by the modiﬁed Oxford technique which is 
currently considered the gold-standard method to quantify BRS.39 In addition, DTI 
quantiﬁes a continuous scale of WM structural characteristics as opposed to the 
conventional FLAIR-MRI, which only provides a dichotomous classiﬁcation of normal or 
abnormal WM tissues. Furthermore, our sample was enriched by heterogeneous levels of 
cognitive function. Since MCI is a common condition in older adults, understanding the 
physiological link between cardiovascular and cognitive health in this population may 
help with the development of strategies to prevent dementia later in life. 
 There are several limitations that need to be discussed. First, the baroreﬂex pathway 
involves neural circuits in the brainstem which may confound an interpretation of the 
association between BRS and WM neuronal ﬁber integrity.62 Indeed, we saw that BRS was 
associated with FA and RD of the brainstem where the cardiovascular regulatory center is 
located (Figure 1). However, a stronger correlation between WM neuronal ﬁber integrity 
and BRS assessed during hypotension than hypertension and the presence of the 
correlations in many other brain regions which may not relate to the baroreﬂex pathway 
make an argument that impairment in the BRS neural pathway alone cannot explain our 
observations. Second, anatomical orientation of the WM ﬁber tracts (e.g., crossing ﬁbers 
and diameter of axons) may alter the level of diﬀusion metrics independent of the ﬁber 
integrity.16 In this regard, TBSS may reduce such errors by analyzing the center of WM 
tracts common to all subjects. Third, our sample size was limited, and multiple statistical 
analyses were conducted, which tends to inﬂate Type II error. Finally, our MCI group was 
comprised of very mildly impaired subjects, and may not be generalizable to other 
populations. We did not have longitudinal data to conﬁrm the stability or progression of 
MCI symptoms, and the collection of data were spread out over ~3 months, which may 
further attenuate relationships of interest. 
Conclusions
Central artery stiﬀness and depressed BRS are independently associated with deterioration 
of WM neuronal ﬁber integrity in older adults. In particular, the BRS assessed during 
hypotension is strongly correlated with WM neuronal ﬁber integrity. These alterations in 
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 94
94 | Chapter 4
WM neuronal ﬁber are likely to be related to axonal demyelination. Finally, executive 
function performance is associated with WM neuronal ﬁber integrity, in the areas 
correlated with arterial stiﬀness and BRS. Therefore, these ﬁndings collectively suggest 
that cardiovascular dysregulation of systemic arterial perfusion may elevate the risk of 
brain WM lesions and cognitive impairment in older adults.
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Supplementary Figure
Figure S1  The distribution of individual fractional anisotropy (FA) and radial diﬀusivity (RD) in relation to 
the Mini-mental State Exam (MMSE) scores. A horizontal line at each of the MMSE scores represents the 
mean value of FA and RD across the subjects. The FA and RD values of individual subjects were extracted 
from the whole brain white matter skeletons.
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Abstract
Cerebral autoregulation and baroreﬂex sensitivity are key mechanisms that maintain 
cerebral blood ﬂow. This study assessed whether these control mechanisms are aﬀected 
in patients with dementia and mild cognitive impairment due to Alzheimer’s disease, as 
this would increase the risks of antihypertensive treatment. We studied 53 patients with 
dementia (73.1 [71.4-74.8] years), 37 patients with mild cognitive impairment (69.2 [66.4-72.0] 
years) and 47 controls (69.4 [68.3-70.5] years). Beat-to-beat blood pressure (photoplethysmo-
graphy), heart rate and cerebral blood ﬂow velocity (transcranial Doppler) were measured 
during 5 minutes rest (sitting) and 5 minutes of orthostatic challenges, using repeated 
sit-to-stand maneuvers. Cerebral autoregulation was assessed using transfer function 
analysis and the autoregulatory index. Baroreﬂex sensitivity was estimated with transfer 
function analysis and by calculating the heart rate response to blood pressure changes 
during the orthostatic challenges. Dementia patients had the lowest cerebral blood ﬂow 
velocity (P=0.004). During rest, neither transfer function analysis nor the autoregulatory 
index indicated impairments in cerebral autoregulation. During the orthostatic challenges, 
higher autoregulatory index (P=0.011) and lower transfer function gain (P=0.017), indicating 
better cerebral autoregulation, were found in dementia (4.56 [4.14-4.97] arb. unit; 0.59 
[0.51-0.66] cm/s/mmHg) and mild cognitive impairment (4.59 [4.04-5.13] arb. unit; 0.51 
[0.44-0.59] cm/s/mmHg) compared to controls (3.71 [3.35-4.07] arb. unit; 0.67 [0.59-0.74] 
cm/s/mmHg). Baroreﬂex sensitivity measures did not diﬀer between groups. In conclusion, 
the key mechanisms to control blood pressure and cerebral blood ﬂow are not reduced in 
two stages of Alzheimer’s disease compared to controls, both in rest and during orthostatic 
changes that reﬂect daily life challenges. 
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Introduction
While the prevalence of hypertension in patients with Alzheimer’s disease (AD) is high 
(at least 45%),1 there is controversy regarding the risk -beneﬁt ratio of antihypertensive 
treatment in these patients.2 Observational data have shown that antihypertensive 
treatment was associated with a faster rate of cognitive decline in patients with dementia 
or mild cognitive impairment (MCI) due to AD,3 raising the question whether blood 
pressure (BP) lowering could compromise cerebral blood ﬂow (CBF). This has become 
even more clinically relevant now that hypertension guidelines have shifted towards 
lower BP levels for both diagnostic and treatment targets.4
 Based on preclinical evidence, two mechanisms have been proposed to explain 
the potentially deleterious eﬀects of BP lowering on CBF.3, 5 First, animal studies have 
demonstrated severe impairment of cerebral autoregulation (CA) in AD, due to amyloid 
angiopathy, which could explain cerebral hypoperfusion when BP is lowered.6, 7 Second, 
autonomic dysfunction associated with AD pathology to the insular cortex (Braak stage III) 
could negatively aﬀect baroreﬂex-mediated BP control,8 increasing the risk of episodic 
hypotension. Together, these two mechanisms could substantially increase the risks that 
antihypertensive treatment will cause (episodic) hypotension and cerebral hypoperfusion 
in AD patients. However, whether or not CA and autonomic BP regulation (baroreﬂex 
sensitivity, BRS) are truly impaired in AD patients remains uncertain, as this has only been 
explored in very few studies with small sample sizes.9-12 Moreover, these mechanisms 
have never been studied together. 
 The primary aim of this study was to investigate both CA and BRS in a large sample 
of patients with dementia or MCI due to AD. 
Materials and Methods
The data that support the ﬁndings of this study are available from the corresponding 
author upon reasonable request.
Participants
In this case-control study, patients with dementia or MCI due to AD were compared with 
healthy elderly control subjects. Patient data were obtained from the baseline assessments 
of the NILVAD trial (for dementia patients; NCT02017340) and the NeuroExercise trial (for 
MCI patients; NCT02913053).13-15 Between July 2013 and September 2017 we included 
patients with a clinical diagnosis of dementia due to probable AD (NIA-AA criteria,16 
without requirement of positive biomarker evidence), with a Mini-Mental State Examination 
(MMSE) score between 12 and 26.17 In addition we included patients with a diagnosis of 
MCI due to AD (NIA-AA criteria18), with Montreal Cognitive Assessment (MoCA) score 
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between 18 and 26.19 All patients were aged >50 years and had no signiﬁcant medical 
conditions or cerebral abnormalities (based on medical history and MRI). Patients with 
uncontrolled hypertension or diabetes mellitus type II were excluded. The complete lists 
of inclusion and exclusion criteria can be found in the online-only Supplement. 
 Participants in the control group (NCT01417663) were recruited between July 2008 
and June 2011 and had no medical history of cardiovascular or cerebrovascular disease, 
were not receiving treatment from their general practitioner or a medical specialist and 
were not using any cardiovascular or psychotropic medication. Cognitive impairment was 
excluded by clinical screening by a geriatrician, including normal scores for age and 
education on the MMSE.
 All participants gave written informed consent. For the patients with dementia, 
written consent was obtained from the patients as well as their caregivers. The study was 
approved by the Medical Ethics Committee (CMO Arnhem-Nijmegen, no. 2017-3340) and 
was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. 
Experimental design
Demographics
Demographic and clinical characteristics, including the Clinical Dementia Rating,20 were 
assessed in all participants. Vascular co-morbidities, including hypertension at screening 
or use of antihypertensive medication, chronic heart failure, coronary heart disease, 
arrhythmias, cerebrovascular diseases, peripheral artery disease and chronic kidney disease 
were summarized into a vascular comorbidity score.3
Instrumentation
Continuous arterial BP was measured in the index or middle ﬁnger of the non-dominant 
hand using photoplethysmography (Finapres Medical Systems, Amsterdam). An arm sling 
was used to keep the hand at heart level. Cerebral blood ﬂow-velocity (CBFV) in the 
middle cerebral arteries was measured using transcranial Doppler ultrasonography (TCD). 
Two 2-MHz probes (Multi-Dop, Compumedics DWL, Germany) were placed over the 
temporal window and ﬁxed with a customized headband (Spencer Technologies, Seattle, 
WA, USA). Exhaled CO2 was monitored with a nasal cannula using capnography (BIOPAC 
Systems, Goleta, Ca., USA). All signals were recorded at 200 Hz using a data acquisition 
system (MP150, BIOPAC Systems, Goleta, Ca., USA).
Procedures
All patients and controls were tested in the same laboratory at the department of Geriatric 
Medicine, under supervision of one of the authors (JC). CA and BRS were assessed during 
rest and during orthostatic challenges. During rest, CA and BRS were estimated using 
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spontaneous hemodynamic ﬂuctuations (in BP, CBFV and heart rate [HR]). Data were 
recorded for 5 minutes with the participant sitting still and breathing spontaneously. 
In addition, repeated orthostatic challenges were used to enhance hemodynamic ﬂuctuations, 
thus improving the reliability of the estimates and mimicking clinically relevant perturbations in 
BP and CBF.21-23 The orthostatic challenges consisted of repeated sit-to-stand maneuvers 
(10 s sitting, 10 s standing) for 5 minutes, resulting in large repeated ﬂuctuations in BP and 
CBF around a frequency of 0.05 Hz. This represents the very low frequency range where 
CA is most active under normal circumstances. 
 In addition to CA, in dementia and MCI patients we assessed cerebral vasomotor 
reactivity (CVMR: the CBF response to changes in arterial CO2) as an estimate of cerebro-
vascular function and cerebrovascular disease.24, 25 This protocol consisted of inducing 
hypocapnia by hyperventilating at a frequency of 0.5 Hz (1 s breathing in, 1 s breathing 
out) for 30 s and was followed by inducing hypercapnia through inhalation of a gas 
mixture with increasing concentrations of CO2 (30 s 3%, 30 s 4%, 3 minutes 5%).
 Finally, in dementia and MCI patients, in addition to BRS we assessed recovery of SBP 
following a single orthostatic challenge as a measure of cardiovascular control.26-28 For 
the analysis of SBP recovery, patients performed three repetitions of the following 
protocol: 2 minutes sitting and 1 minute standing, during spontaneous breathing. 
Data analysis
Data were preprocessed and analyzed using custom-written Matlab scripts (version 
2014b, the MathWorks Inc., Natick, Massachusetts, USA). See online-only Supplement for a 
description of all preprocessing steps. 
Estimation of CA and BRS during rest
CA was estimated by determining the autoregulatory index (ARI) and gain, normalized 
gain and phase between mean arterial pressure (MAP) and mean CBFV (MCBFV) using 
transfer function analysis (TFA).
 For the TFA, the 5-minute recordings of MAP and MCBFV were the input for the 
CARNet Matlab script with default settings (version 1, 2016; www.car-net.org).29 The TFA 
output consists of gain, normalized gain, phase and coherence. Gain represents a measure 
of damping (lower gain indicates better CA), while phase is a measure of the time delay of 
cerebrovascular adaptation (higher phase indicates active adaptation as seen in normal 
CA). These parameters were averaged over the very low frequency (0.02-0.07 Hz) and low 
frequency (0.07-0.2 Hz) bands, where CA is most active, and visualized for the whole CA 
spectrum.
 The ARI is an extensively used quantitative measure for CA and ranges between 
theoretical values of zero (absence of CA) and nine (excellent CA).30, 31 An ARI between 
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four and six can be considered as normal CA. See online-only Supplement for a detailed 
description of TFA and ARI estimation.
 TFA between systolic BP (SBP) and R-R interval was performed to assess cardiac BRS 
during rest. BRS was estimated by averaging the gain over the frequency band 0.07- 
0.14 Hz, while using the CARNet Matlab script for TFA.29 Here, a higher gain indicates better 
cardiac BRS. 
Estimation of CA and BRS during orthostatic challenges
First, we calculated the average maximal induced changes in MAP and MCBFV during 
the repeated sit-to-stand maneuver as the diﬀerence between the maximal sitting value 
and the nadir after standing for each sit-to-stand cycle. The average of all cycles represents 
the maximal induced changes in absolute and relative MAP (ΔMAPmax, Δ%MAPmax) and 
absolute and relative MCBFV (ΔMCBFVmax and Δ%MCBFVmax).32
 For CA, the analysis of the ARI and TFA was similar to the analysis during rest, except 
that the TFA parameters were now estimated at the sit-to-stand frequency band around 
0.05 Hz (0.04-0.06 Hz), which contains the strong ﬂuctuations in BP and CBF induced by 
the sit-to-stand maneuver.22, 23
 BRS during orthostatic challenges was calculated using the same methodology as 
employed before,33 and resulted in separate values for BP increases (BRSUP) and decreases 
(BRSDOWN). In addition, similar to the analysis at rest, cardiac BRS was estimated using TFA, 
by averaging gain over the frequency band 0.04-0.06 Hz. See online-only Supplement for 
a detailed description of BRS estimation.
Estimation of CVMR 
The CVMR was expressed using the cerebrovascular conductance index (CVCi, the ratio of 
MCBFV to MAP) to account for confounding eﬀects of CO2 on BP.34 CVMR was derived 
as the diﬀerence between maximal CVCi during hypercapnia and minimal CVCi during 
hypocapnia, divided by the mean CVCi during normocapnia. See online-only Supplement 
for a detailed description and mathematical equations. 
Estimation of orthostatic SBP recovery
SBP recovery 50-60 s after standing was expressed as percentage from baseline. To increase 
reliability the results of the three repetitions performed by one participant were averaged. 
See online-only Supplement for a detailed description and mathematical equations.
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Statistical analysis
Data were analyzed using IBM SPSS Statistics 22.0 (SPSS, Inc, Chicago, IL, USA). All data were 
inspected for outliers using z-scores and outliers were replaced with a score corresponding 
to three standard deviations from the mean.35 Missing data were not imputed. Participant 
characteristics were compared between groups using ANOVA with post hoc pairwise 
mean comparisons (Bonferroni corrected) or independent samples t-test for continuous 
variables and Pearson χ2 test for categorical variables. Analysis of covariance was used for 
between-group comparisons of all CA and BRS variables, with age as covariate and post 
hoc Bonferroni-corrected pairwise mean comparisons. Diﬀerences between parameters 
during rest and during challenges were tested with independent samples t-test. For AD 
dementia and MCI patients, CVMR and SBP recovery were categorized into tertiles. CA and 
BRS parameters were compared between the highest and the lowest tertiles using 
independent samples t-test. For all analyses two-sided testing and an alpha level of 0.05 
were used. In sensitivity analyses, we corrected for age and compared patients with and 
without antihypertensive treatment. Outcomes are reported as mean and 95% CI.
Sample size 
We calculated the required sample size for ARI and BRS-gain during rest. For ARI, the 
calculation is based on the ability to detect a clinically relevant diﬀerence of 1.0 ± 1.6 arb. 
unit, with the standard deviation based on previous reported ARI results.31 For BRS, we 
deﬁned a clinically relevant diﬀerence as 1.64 ± 2.31 ms/mmHg, based on previously 
reported diﬀerences between middle aged and old men and women.36 This resulted in 
eﬀect sizes (Cohen’s f ) of 0.29 and 0.33 respectively. Using alpha=0.05 and two-sided 
testing this resulted in a total sample size of n=117 for ARI (n=39 per group) and n=90 for 
BRS (n=30 per group) to achieve power of 0.80.
Results
Participant characteristics
92 AD patients (54 with dementia, 38 with MCI) and 48 healthy controls were enrolled. 
Complete datasets could not be obtained in all participants, due to absence of BP or TCD 
signal or not meeting the quality criteria set for analysis as described in the Methods. 
This resulted in slightly diﬀerent ﬁnal samples sizes for each type of analysis (Figure 1). 
Three participants (one dementia, one MCI, one control) were excluded because of 
missing outcomes for all analyses. Figure S1 presents representative recordings of BP 
(MAP) and TCD (MCBFV) for the diﬀerent parts of the protocol.
 Participant characteristics are shown in Table 1. Dementia patients were older (mean 
[95% CI], 73.1 [71.4-74.8] years) compared to both MCI (69.2 [66.4-72.0] years) and controls 
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(69.4 [68.3-70.5] years, P=0.003). As expected based on selection of healthy controls, 
vascular co-morbidities were more prevalent in MCI and dementia compared to controls. 
Antihypertensive drugs were used by 30.2% and 37.8% of dementia and MCI patients, 
respectively. Patients with MCI had a higher brachial systolic BP (P=0.024,) and diastolic BP 
(P=0.009) during screening. Participant characteristics of the ﬁnal sample sizes for each 
type of analysis were not signiﬁcantly diﬀerent from those presented in Table 1 (Table S1).
CBF and cerebrovascular resistance in AD
MCBFV was much lower in patients with dementia (38.8 [36.0-41.6] cm/s) compared to 
controls (46.6 [44.1-49.2] cm/s, P<0.001) (Table 2A). There was a signiﬁcant eﬀect of group 
on CVR index (P=0.016) with the lowest CVR index observed in controls. Speciﬁcally, CVR 
Figure 1  Flow diagram showing the ﬁnal sample sizes for each type of analysis. The ﬁnal sample 
sizes are shown for each part of the protocol (“rest”, “challenges”, “CVMR” and “recovery”) and type 
of analysis (“TFA”, “ARI” and “BRS”) per group. Data could be missing for one of the following reasons: 
measurement was not done (“not done”), BP or TCD signal was missing (“no signal”) or the outcome 
was not passing the quality criteria set a priori for an analysis as described in the methods section 
(“no outcome”). Three participants (one dementia patient, one MCI patient, one control) had missing 
outcomes (“no signal” or “no outcome”) on all analyses. MCI = mild cognitive impairment; TFA = 
transfer function analysis; ARI = autoregulatory index; BRS = baroreﬂex sensitivity; CVMR = cerebral 
vasomotor reactivity; TCD = transcranial Doppler.
Dementia 
n=54 
Rest: n=54 
TFA: n=41 
n=9 no signal  
n=4 no outcome 
ARI: n=36 
n=9 no signal  
n=9 no outcome 
BRS: n=36 
n=1 no signal  
n=17 no outcome 
Challenges : n=53 
n=1 not done 
TFA: n=39 
n=10 no signal  
n=4 no outcome 
ARI: n=39 
n=10 no signal  
n=4 no outcome 
BRS: n=50 
n=1 no signal  
n=2 no outcome 
CVMR: n=32 
n=5 not done 
n=10 no signal  
n=7 no outcome 
Recovery: n=52 
n=2 no signal  
MCI 
n=38 
Rest: n=38 
TFA: n=31 
n=6 no signal  
n=1 no outcome 
ARI: n=29 
n=6 no signal  
n=3 no outcome 
BRS: n=25 
n=1 no signal  
n=12 no outcome 
Challenges : n=36 
n=2 not done 
TFA: n=31 
n=5 no signal  
ARI: n=31 
n=5 no signal  
BRS: n=35 
n=1 no signal  
CVMR: n=22 
n=57not done 
n=5 no signal  
n=4 no outcome 
Recovery: n=32 
n=3 not done 
n=3 no signal  
Controls 
n=48 
Rest: n=48 
TFA: n=41 
n=6 no signal  
n=1 no outcome 
ARI: n=39 
n=6 no signal  
n=3 no outcome 
BRS: n=41 
n=1 no signal  
n=6 no outcome 
Challenges : n=42 
n=6 not done 
TFA: n=37 
n=5 no signal  
ARI: n=36 
n=5 no signal  
n=1 no outcome 
BRS: n=38  
n=4 no outcome 
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Table 1  Participants characteristics.
Characteristics Dementia MCI Controls P 
n 53 37 47
Age, years 73.1 (71.4-74.8) 69.2 (66.4-72.0) 69.4 (68.3-70.5) 0.003
Female, % 52.8 (28) 35.1 (13) 42.6 (20) 0.238
BMI, kg m-2 25.0 (24.0-26.0) 26.0 (24.8-27.3) 26.3 (25.3-27.2) 0.151
CDR, %    0 - - 100 (47) na
0.5 35.8 (18) 100 (37) -
1 49.1 (26) - -
2 15.1 (8) - -
MMSE score 20.6 (19.7-21.6) - 28.6 (28.2-29.0) <0.001
MoCA score - 22.9 (22.1-23.7) - na
Use of medication, % (n):
AHD 30.2 (16) 37.8 (14) - 0.500
≥2 AHD 3.8 (2) 18.9 (7) - na
ACE inhibitor 13.2 (7) 10.8 (4) - na
ARB 9.4 (5) 13.5 (5) - na
Diuretic 11.3 (6) 10.8 (4) - na
Beta blocker - 16.2 (6) - na
CCB - 13.5 (5) - na
Statin 15.1 (8) 29.7 (11) - 0.094
VCS, %      0 26.4 (14) 18.9  (7) 72.3 (34) 0.687
1 41.5 (22) 45.9 (17) 27.7 (13)
2 24.5 (13) 21.6 (8) -
3 7.5 (4) 13.5 (5) -
SBP, mmHg 138.3 (134.9-141.8) 142.3 (135.4-149.2) 133.2 (129.7-136.8) 0.024
DBP, mmHg 78.0 (76.3-79.8) 83.7 (79.7-87.7) 78.9 (76.4-81.4) 0.009
Values are presented as mean (95% CI) or % (n). Test statistics used is F-statistic for age, BMI, SBP and DBP and 
χ2-statistic for categorical data. P-value for use of AHD, VCS and statin results from comparison between 
dementia and MCI. P-value for MMSE results from comparison between dementia and controls. SBP and DBP 
were measured during screening in sitting position for dementia and MCI patients and supine for controls. 
MCI = mild cognitive impairment; BMI = body mass index; CDR = clinical dementia rating; MMSE = Mini-Mental 
State Examination; MoCA = Montreal Cognitive Assessment; AHD = antihypertensive drugs; ACE = angioten-
sin-converting-enzyme; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker; VCS = vascular 
comorbidity score; SBP = systolic blood pressure; DBP = diastolic blood pressure. 
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index was markedly elevated in MCI (2.38 [2.16-2.59] mmHg/cm/s) compared to controls 
(1.95 [1.79-2.11] mmHg/cm/s). 
CA and BRS during rest
Table 2A provides an overview of CA and BRS parameters assessed during rest, when CA 
and BRS were evaluated using spontaneous oscillations in BP, HR and CBF. In accordance 
with the observed higher brachial BP, MCI patients had higher ﬁnger MAP (97.3 [90.9-103.6] 
mmHg, P=0.001) and SBP (153 [140-166] mmHg, P=0.012).
Cerebral autoregulation
The ARI did not diﬀer between the groups as shown in Table 2A and Figure 2A. In addition, 
we found no diﬀerences between the groups for the TFA parameters phase and gain in 
the very low and low frequency bands where CA is active, except for normalized gain 
(normalized because of the baseline diﬀerences in MCBFV) in the low frequency band in 
the dementia group (1.64 [1.50-1.78] %/mmHg) compared to controls (1.41 [1.30-1.52] %/
mmHg, P=0.007). Figure 2 and Figure S2 show the gain, phase, normalized gain and 
coherence for the whole CA spectrum (0-0.5 Hz).
Baroreflex sensitivity
The transfer function gain between SBP and R-R interval in controls was comparable to 
recently published reference values for adults between 65-80 years.36 We observed no 
diﬀerence in BRS gain between groups, as displayed in Table 2A en Figure 3A. 
CA and BRS during orthostatic challenges
The multiple orthostatic challenges resulted in repeated substantial BP changes of 
approximately 25% (corresponding to 23 mmHg for MAP) in all groups (Table 2B). The 
resulting changes in MCBFV were largest for the healthy controls (17.5 [15.4-19.5] cm/sec, 
P<0.001or 38.2 [34.3-42.1] %, P<0.001) (Table 2B). We found a small decline in EtCO2 during 
the orthostatic challenges as compared to rest, consistent with previous reports,37 but this 
decline was not signiﬁcant, irrespective of group (-0.09 [-0.18 – 0.01] kPa, P=0.083) and was 
also not diﬀerent between groups (P=0.886).
Cerebral autoregulation
As expected, the orthostatic challenges with their stronger corresponding changes in BP 
and CBF led to an increased TFA coherence between MAP and MCBFV in the very low 
frequency band in all three groups (mean increase [95% CI], 0.30 [0.26-0.33] arb. unit, 
P<0.001) compared to rest, increasing the reliability of the transfer function gain and phase 
estimates.29 Phase did not diﬀer between the three groups at the sit-to-stand frequency 
(0.04-0.06 Hz) as shown in Table 2B and Figure 2F. Gain was higher in the control group 
(0.67 [0.59-0.74] cm/s/mmHg) compared to MCI patients (0.51 [0.44-0.59] cm/s/mmHg, 
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Figure 2  (A-B) Scatter plots of the autoregulatory index. (A) during rest (ARIrest); (B) during orthostatic 
challenges (ARIchallenge). (C-F) Outcome measures of transfer function analysis during rest and during 
orthostatic challenges. (C, D) normalized gain; (E, F) phase. Transfer function analysis outcomes 
during rest are visualized as frequency plot with 95% CI, for dementia patients (dotted line), MCI 
patients (dashed line) and controls (solid line). Outcomes during orthostatic challenges are presented 
as scatter plots at the sit-to-stand frequency (0.04-0.06 Hz). Scatter plots: each dot represents one 
participant and bars indicate the mean and 95% CI. Better cerebral autoregulation is indicated by 
higher autoregulatory index, lower gain and higher phase. MCI = mild cognitive impairment.
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P=0.017), while normalized gain was higher in dementia patients (1.47 [1.33-1.62] %/
mmHg) compared to MCI patients (1.23 [1.09-1.37] %/mmHg, P=0.027) (Table 2B, Figure 2D 
and Figure S2). ARI was lower in controls (3.71 [3.35-4.07] arb. unit) compared to both the 
dementia (4.56 4.14-4.97] arb. unit) and MCI patients (4.59 [4.04-5.13] arb. unit, P=0.011) 
(Table 2B, Figure 2B). 
Baroreflex sensitivity
Average SBP and HR were increased in all groups compared to rest (SBP increase: 13.4 
[9.5-17.2] mmHg, P<0.001; HR increase: 8.5 [7.4-9.5] beats/min, P<0.001). We found no 
signiﬁcant diﬀerences between the groups for both methods used to estimate cardiac 
BRS (Table 2B and Figure 3B). Again, the BRS gain was comparable to values found by Xing 
et al. in older adults.36 
 In sensitivity analyses, we corrected all models for sex and included the sex*group 
interaction term, since previous studies have reported sex diﬀerences for hemodynamic 
parameters.36, 38, 39 This did not alter the main results of the study (see Table S2). 
Furthermore, there were no diﬀerences in CA and BRS parameters between patients using 
antihypertensive drugs and patients not using antihypertensive drugs (see Table S3).
Relationship between CVMR and CA and BRS parameters
There was no diﬀerence in CVMR between dementia (46.7 [18.6-74.9]%) and MCI patients 
(45.5 [12.0-78.2]%, P=0.768), so they were pooled. Table 3A shows that neither ARI nor BRS 
diﬀered between the lowest (≤40.5%) and highest tertile (≥51.5%) of CVMR. Similarly, 
no association between any of the TFA parameters and CVMR was observed (see Figure S3 
and Table S4). 
Figure 3  Outcomes of baroreﬂex sensitivity. Scatter plots of the baroreﬂex sensitivity. (A) during rest 
(BRS-gainrest); (B) during orthostatic challenges (BRS-gainchallenge). Scatter plots: each dot represents 
one participant and bars indicate the mean and 95% CI. A higher gain indicates better baroreﬂex 
function. BRS = baroreﬂex sensitivity; MCI = mild cognitive impairment.
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Relationship between orthostatic SBP recovery and CA and BRS parameters
SBP recovery did not diﬀer between dementia (101.9 [99.5-104.2] %) and MCI patients 
(101.2 [98.9-103.4] %, P=0.694). As shown in Table 3B there were no diﬀerences in ARI or 
BRS outcomes between the lowest (≤98%) and highest tertile (≥105%) of SBP recovery. 
TFA parameters between tertiles are shown in Figure S4 and Table S5. When comparing 
the group with a partial SBP recovery (≤95%, n=18) to the group with full recovery (≥100%, 
n=50), no diﬀerences in any of the CA and BRS parameters were found (see Table S6).
Discussion
This case-control study of cerebrovascular physiology in AD investigated whether the key 
mechanisms to control the short-term stability of BP (i.e., BRS) and of CBF (i.e., CA) are 
aﬀected in this highly prevalent disease. Because any degree of impairment might depend 
on the extent of the underlying Alzheimer pathology, we investigated patients in both 
early (MCI) and more advanced (dementia) stages of AD and compared these to a group 
of controls. With a sample size that is large for studies on hemodynamic physiology, the 
study was powered to detect relevant between-group diﬀerences. Our ﬁndings indicate 
no reduced function of CA and BRS in AD compared to controls, both during rest and 
during a protocol aimed at inducing changes in BP with a magnitude that reﬂects daily life 
challenges to these two systems. Even when we subdivided AD patients in groups with 
high and low cerebrovascular or cardiovascular burden (based on CVMR and orthostatic 
BP recovery), we observed no diﬀerences in CA and BRS functioning. The same held true 
when we compared patients with and without antihypertensive treatment. 
 Our ﬁndings for CA are inconsistent with animal studies reporting severe impairments 
in CA in AD.6, 7, 40 However, these studies used models of quite extreme BP changes (i.e. 
a range of MAP values of 20-160 mmHg) which do not translate to changes that occur as 
a result of orthostatic changes, hypertension or antihypertensive treatment. BP changes 
of this magnitude are clinically only observed in situations such as hemorrhagic or septic 
shock or malignant hypertension. Conversely, our observations are consistent with earlier 
pilot studies in dementia9, 10, 32 and MCI that assessed CA during rest.41 
 Although in conditions such as acute ischemic stroke it was possible to detect 
reduced CA (e.g. ARI 3.2, compared to 4.5 in controls) using the spontaneously occurring 
changes in BP,42 it has been argued that the this method may provide insuﬃcient 
challenges to truly assess CA.43 Therefore, we also studied CA during much larger changes 
in BP (∆MAP of ≈ 25%) induced by repeated orthostatic challenges. Such changes are 
deemed clinically more relevant because they mimic (or even exceed) the magnitude of 
BP changes during daily life postural changes (orthostatic hypotension) and BP lowering 
treatment. Also under these conditions, we observed no reduced function of CA in AD 
compared to controls. This is again consistent with earlier pilot studies that investigated 
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CA during squat-to-stand manoeuvres,9 and during sit-to-stand manoeuvres.10 In the 
latter study only the relative maximal induced changes in MCBFV were larger in the 
patients (n=9, 27%) compared to controls (n=24, 22%), which might suggest reduced CA.32 
However, this was not reproduced in the present study with a much larger sample size. 
 Regulation of BP, expressed by BRS, was also preserved in AD in the current study. 
This is in contrast with earlier suggestions of autonomic dysfunction in AD44 and with 
pilot studies that found decreased BRS in patients with AD.11, 12 However, a study that 
explored BRS in patients with MCI using the current gold standard (the modiﬁed Oxford 
method), did not show impairment in BRS.45 Our present study extends those ﬁndings to 
a more advanced stage of AD (i.e. dementia). Like the modiﬁed Oxford method, our 
method to assess BRS during orthostatic challenges also uses large oscillations in BP 
(∆MAP of ≈ 25%) to obtain more reliable estimates. 
 In aging and AD there inherently is a large degree of heterogeneity,46, 47 possibly 
resulting in subgroups with diﬀerent degrees of cerebrovascular comorbidity. Therefore, we 
used CVMR as a marker of cerebrovascular disease and divided dementia and MCI patients 
into tertiles of CVMR.24, 25 There were no diﬀerences in BRS and CA estimates between 
these subgroups (Table 3). In a similar way, this heterogeneity applies to orthostatic BP 
recovery, which is a marker of overall cardiovascular disease and physical frailty,48 and has 
been suggested recently as a marker of increased dementia risk,49 associated with 
autonomic dysfunction.50 We therefore divided dementia and MCI patients into tertiles of 
orthostatic BP recovery, but found no diﬀerences in estimates of BRS or CA (Table 3). 
 In summary, integrating preclinical and clinical pilot studies with our present work, 
we conclude that CA and BRS are not reduced in AD, both at the MCI and dementia stage, 
compared to controls for transient BP changes that fall within a range of MAP ≈ 70-130 
mmHg. 
Cerebrovascular resistance in AD
Previous studies have assessed the relationship between CBF and AD. In accordance with 
our observations, these studies consistently report decreased CBF in AD.51 The importance 
of this decreased CBF is further demonstrated as it predicts development of AD, especially 
when BP is high52 and by its decline with disease progression.53 Moreover,  decreased  CBF 
is linked to amyloid accumulation54 and to cognitive deterioration.55 Recently it was 
suggested that increased CVR is an even stronger predictor than reduced CBF for disease 
progression in late onset AD, especially in the earlier stages of the disease.56 Increased 
CVR, such as we observed in MCI patients, preceded (and not followed) reductions in 
metabolic demand, brain atrophy, cognitive decline and even amyloid accumulation. 
Given these known eﬀects of decreased CBF and increased CVR in AD, it is essential that 
CBF is not further reduced in AD patients by antihypertensive treatment. This stresses why 
it is important to establish normal function of the mechanisms that control BP and CBF 
function in AD. 
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The evidence of  early abnormalities in CVR and CBF in AD raises the question how this can 
be reconciled with no reduced CA function. This might be explained by the locations in 
the cerebrovascular bed where CA operates and where AD pathology is located. Some 
evidence points to the arteriolar and capillary beds as the main contributors to determine 
resistance,57 while other evidence indicates the proximal vessels (carotid and vertebral 
arteries and the vessels in the circle of Willis).58 One hypothesis to explain our observations 
is that the increased CVR in AD is caused by amyloid-related microvascular changes, without 
aﬀecting the proximal vessels, which then remain able to adapt CVR to stabilize CBF 
(normal CA). An alternative hypothesis is that of enhanced cerebrovascular contractility, 
which has previously been shown in AD.59 Enhanced contractility will lead to an exaggerated 
vasoconstriction response to increases in BP, which will result in highly eﬀective CA for BP 
increases, at the cost of a chronic reduction in CBF if BP is chronically elevated (as is expected 
with aging, where >60% of the population is hypertensive).60 Our observation of no reduced 
CA for both increases and decreases in BP suggests that normal vasodilation is still retained in 
this scenario. 
Strengths and limitations
The major strength of this study compared to previous studies is the conjoint investigation 
of two cerebro-protective mechanisms within a range of measures, both during rest and 
during orthostatic challenges and in a large number of participants. All previous studies 
focused on only one mechanism on the heart-brain axis. However, CBF regulation relies 
on synchronization between general and local mechanisms. Especially during daily 
activities this synchronization is important to prevent periods of hypoperfusion. Precisely 
during these short-period BP oscillations BRS and CA are the most important mechanisms 
in maintaining CBF.61
 There is an ongoing debate regarding whether CA can best be studied during rest or 
during challenges.43 Therefore, the absence of diﬀerence in CA parameters in both 
situations strengthens the ﬁnding that this cerebro-protective mechanism still functions 
well in AD. Although there is no gold standard to assess CA at present, TFA using 
transcranial Doppler can be regarded as the reference standard. This technique is 
frequently and extensively used and a standardized method of assessment and analysis 
has recently been described in a consensus paper.29 Similarly, for our estimations of BRS 
we used a validated method that equals or even outperforms the current gold standard.33
 A possible limitation to this study is that, although AD MCI and dementia diagnoses 
were established according to the NIA-AA guidelines using clinical, cognitive and MRI 
biomarkers, the diagnosis was not conﬁrmed with amyloid biomarker evidence. However, 
the diagnostic accuracy of clinical AD is approximately 79%62 and the prevalence of 
amyloid positivity on PET-imaging in clinically diagnosed AD  patients in the age group 
we studied ranges between 78% (95% CI 71 – 84 %) for ApoE ε4 negative to 94% (92 - 96 
%) for ApoE ε4 positive patients.63 
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Changes in vessel diameter can aﬀect measurement accuracy of CBF with transcranial 
Doppler. In particular, during sit-to-stand maneuvers, sympathetic activation could induce 
up to a 2% decrease in cross-sectional area, leading to a small overestimation of CBF.64 
However, there is no evidence that this overestimation would diﬀer between dementia, 
MCI and controls. Moreover, such overestimation of CBF would only inﬂuence TFA gain 
and not phase. Techniques such as MR arterial spin labeling, SPECT and Xenon-CT would 
overcome this problem, since they assess ﬂow at the microcirculation level.65 Additionally, 
they provide regional information on CBF. However, their temporal resolution is currently 
too low to assess the dynamics of CA. 
 As shown in Figure 1, data were missing in this study due to absence of signal (e.g. 
no temporal window) or not meeting quality control criteria. These missing data were not 
related to disease severity, i.e. Clinical Dementia Rating score (Table S1). In many cases, 
signal loss was caused by an absent insonation window in the temporal bone, but this 
phenomenon is a random factor unrelated to CA. Irregular heart rhythms caused missing 
data for BRS assessed during rest, but not for BRS during the orthostatic challenges and 
missing data were not correlated to low or high BRS (Table S6). 
 The dementia patients were slightly older than the controls, which, if anything, would 
cause a bias towards decreased CA and BRS in dementia. The MCI patients had a higher 
BP, but hypertension most likely does not alter CA.66 Furthermore, by including a control 
group without cognitive problems and without cardiovascular history, the control group 
would be expected to be biased towards a better CA and BRS. Thus, any bias resulting 
from these between-group diﬀerences would have led to an overestimation of the level 
of impairment of CA and BRS in MCI and/or dementia and cannot have led to our current 
ﬁndings. 
 Although the lack of an intervention with an antihypertensive drug limits direct 
translation to clinical practice, the sensitivity analyses comparing those on and oﬀ antihy-
pertensive treatment (Table S3) did not show any diﬀerences in CA and BRS. This suggests 
that antihypertensive treatment itself will not aﬀect these dynamic control mechanisms.
 Finally, one of the inherent problems with case-control studies is that selection 
impedes generalization of the results. Patients with MCI and dementia who participate 
in clinical research are less frail than those seen outside a research setting. Nonetheless, 
our sample did include frail patients, i.e. dementia patients with Clinical Dementia Rating 2, 
and patients with co-morbidities. Also, the sub-group analyses based on markers for 
autonomic dysfunction and cerebrovascular disease showed no diﬀerence between 
those patients who were most and least aﬀected. 
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Conclusion
This study investigated the two main short-term cerebro-protective mechanisms, BRS and 
CA, in AD and controls. With a range of measures during both rest and orthostatic 
challenges, we found that these control mechanisms for BP and CBF were preserved in AD 
in diﬀerent stages of the disease.
Perspectives
The present study did not ﬁnd evidence to support the hypothesis that the mechanisms 
to control stability in BP and CBF are aﬀected in AD at the MCI or dementia stage. Although 
these ﬁndings of normal CA for short-term BP changes do not necessarily implicate that 
CBF remains stable during long-term changes in BP,67 it is in keeping with an earlier 
demonstration of maintaining CBF after BP reduction in a small group of MCI patients.68 
Conversely, this ﬁnding may explain why an increase in BP, through discontinuation of 
antihypertensives, in MCI patients did not result in improvements in CBF.69 Integrating 
these ﬁndings, we observe no evidence that AD patients have an inherently increased risk 
that lowering BP (with antihypertensive treatment) will lead to a (further) reduction in CBF 
or to BP instability, although this needs to be conﬁrmed in follow-up studies that measure 
the CBF response to long-term BP lowering with antihypertensive treatment. Previous 
observational studies have suggested that patients with MCI or dementia who are treated 
with antihypertensives fare worse than those who are not, in terms of cognitive function.3, 
70 Alternative hypotheses must be considered to explain these ﬁndings, because the 
hypothesis that this decline was due to failure of CA and BRS in AD was not conﬁrmed in 
our study. 
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Supplementary Material
Supplemental Methods
Box 1  In- and exclusion criteria for dementia patients.
Inclusion criteria
· Males and females ≥50 years
· Diagnosis of probable Alzheimer’s disease based on the National Institute of Neurological 
and Communicative Disorders and Stroke/Alzheimer’s disease and Related Disorders 
Association, Inc (NINCDS-ADRDA) criteria
· Mini-Mental State Examination score ≥12 and <27
· Stable dose (>3 months) of cholinesterase inhibitor or memantine, or not on cholinesterase 
inhibitors or memantine
· Oﬃce-based blood pressure values greater than 100/65 mmHg but less than 159/99 mmHg
· Capacity to provide written informed consent
· Dutch ﬂuency to complete study assessments
Exclusion criteria
· Comorbid dementia due to other neurological disorders (i.e. Parkinson’s disease, vascular 
dementia, Huntington’s disease, Pick’s disease, Creutzfeldt-Jakob disease, normal pressure 
hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural 
haematoma or multiple sclerosis)
· Other medical conditions known to interfere with cognition such as HIV disease, neurosyphilis, 
history of signiﬁcant head trauma with loss of consciousness followed by persistent 
neurological deﬁcits, known structural brain abnormalities
· A medical condition that, in the opinion of the clinician, precludes participation in the study 
such as, chronic heart failure, syncope within the past year, signiﬁcant valvular heart disease, 
that is, severe aortic and mitral stenosis, or symptomatic orthostatic hypotension within the 
last year
· Type 2 Diabetes Mellitus* 
· Abnormal ECG results that, in the opinion of the clinician, prevent participation in the study
· Clinically signiﬁcant laboratory blood test abnormality during screening
· Clinically signiﬁcant abnormalities on CT/MRI
· Signiﬁcant renal impairment (estimated glomerular ﬁltration rate: <30 mL/min)
· Severe hepatic impairment (liver cirrhosis)
· Use of a calcium channel blocker, β-blocker, α-agonist or nitrate 
· Use of the medical food Souvenaid 
· Current Axis I (DSM IV) diagnosis of schizophrenia, bipolar disorder or major depression
· Signiﬁcant history of alcoholism or drug abuse within the last year
· Known hypersensitivity to nilvadipine (Nivadil)
· Enrollment in investigational or other unapproved drug studies during 30 days or 5 half-lives, 
whichever is longer, prior to baseline
· Enrollment in other clinical research studies
* Not an exclusion criterium in the NILVAD trial, but an additional criterium for the current analyses
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Box 2  In- and exclusion criteria for MCI patients.
Inclusion criteria
· Males and females ≥50 years
· Diagnosis of MCI due to Alzheimer’s disease according to the Albert et al. criteria
· Montreal Cognitive Assessment score ≥18 and <27
· Capacity to provide written and dated informed consent
· If recruited from the community: education adjusted cut-oﬀs of -2 SD for low education, -1.5 
SD for the medium education and -1 SD for the high education, from the Logical Memory 
subtest of the Wechsler Memory Scale
· Stable medical condition for more than 6 months
· Stable medication for more than 3 months
· Adequate visual and auditory acuity to complete neuropsychological testing
· Electrocardiogram without signiﬁcant abnormalities that might interfere with the study
· Physical ability suﬃcient to allow performance of endurance exercise training
· Medical clearance to undergo a symptom-limited cardiopulmonary exercise test and 
extensive aerobic exercise training
Exclusion criteria
· Diagnosis of Alzheimer’s disease or other type of dementia
· History of familial early onset dementia
· Enrollment in any investigational drug study
· History in the past 2 years of epileptic seizures
· Any major psychiatric disorder
· Past history or MRI evidence of brain damage, including signiﬁcant trauma, stroke, 
hydrocephalus, mental retardation, or serious neurological disorder
· carotid stent or severe stenosis
· History of myocardial infarction within previous year
· Congestive heart failure (New York Heart Association Class II, III or IV)
· Uncontrolled hypertension (systolic blood pressure >200 mm Hg and/or diastolic blood 
pressure >110 mm Hg at rest)
· Unstable cardiac, renal, lung, liver, or other severe chronic disease
· Type 2 Diabetes Mellitus 
· Signiﬁcant history of alcoholism or drug abuse within last 10 years
· Engagement in moderate-intensity aerobic exercise training for more than 30 min, 3 times 
per week, during past 2 years
· History of vitamin B12 deﬁciency or hypothyroidism (stable treatment for at least 3 months is 
allowed)
· Serious or non-healing wound, ulcer, or bone fracture
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Box 3  In- and exclusion criteria for healthy controls.
Inclusion criteria
· Males and females ≥65 years
Exclusion criteria
· History of cardiovascular disease, including myocardial infarction, angina pectoris, arrhythmias, 
heart failure, valvular heart disease, congenital heart disease.
· History of cerebrovascular disease
· Mini-Mental State Examination score <25
· Diabetes Mellitus Type I or II 
· Blood pressure values above 170 mmHg systolic and/or 90 mmHg diastolic
· Hypercholesterolemia (deﬁned as fasting total cholesterol > 7.5 mmol/l, triglycerides >4 
mmol/l, LDL-cholesterol >5,5 mmol/l)
· Hyperglycemia (deﬁned as glycated hemoglobin >7 DCCT %)
· BMI > 33 kg/m2 
· Use of antihypertensive medication, statins, anticoagulents, diabetes medication and thyroid 
medication
· Abnormal resting ECG results
· Abnormal exercise ECG results
· Engagement in moderate to intensive exercise training for more than 1 hour per week on a 
regular basis
· Any orthopedic or neurological condition that hinders performance of exercise training
Data analysis
Preprocessing
Data was processed and analyzed using custom-written Matlab scripts (version 2014b, the 
MathWorks Inc., Natick, Massachusetts, USA). For a transfer function of the acquisition 
system, blood pressure and TCD signals, see Figure S5. First, systolic and diastolic BP (SBP 
and DBP) and CBF velocity (SCBFV and DCBFV) were automatically detected and manually 
corrected. Spikes in the signals were then linearly interpolated, followed by waveform 
integration for each beat (with diastolic BP as start and end point) to calculate mean 
arterial pressure (MAP) and mean CBF velocity (MCBFV). The SBP peaks were used to 
calculate the inter-beat interval (R-R interval) and heart rate (HR). Beat-to-beat values (for 
each cardiac cycle) were resampled to 10 Hz (for MAP and MCBFV) and 4 Hz (for SBP and 
R-R interval).1 Before further analysis was performed, data with ectopic beats (BRS analysis) 
and with poor MCBFV signal quality due to noise (CA analysis) was excluded after visual 
inspection.2 The cerebrovascular resistance index (CVR index) was calculated as the ratio 
of MAP to MCBFV. End-tidal CO2 (EtCO2) was calculated using automatic peak-detection 
of the exhaled CO2-signal followed by manual validation. 
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ARI estimation
To obtain the ARI the inverse Fourier transform of the frequency response (between 0-0.5 
Hz) was used to calculate the step response. The ARI template with the lowest normalized 
mean squared error (NMSE) on an 8 s segment was considered the best ﬁt with the step 
response.3 Fitting a parabola through the NMSE values of the best-ﬁt and neighbouring 
ARI models obtained the optimal ARI with two decimal places. Data was included when 
coherence between MAP and MCBFV in the low frequency band (0.07-0.2 Hz) was >0.19, 
NMSE was <0.07 and when the signal was classiﬁed as physiological response after visual 
inspection.
Baroreflex sensitivity during orthostatic challenges
Directional cardiac BRS was calculated for BP increases (BRSUP) and decreases (BRSDOWN) 
separately. For this method,  described before,4 the segments with BP increases and 
decreases are automatically selected and matched to the corresponding R-R interval 
segments. For each segment, using piecewise linear regression, the saturation and 
threshold regions were ﬁltered out and if the R-R interval was below 800 ms, a one-beat 
delay was used. The remaining data was averaged across 3 mmHg bins. Then the slope 
between R-R interval and SBP was estimated using least squares linear regression. Data 
was included when there were at least ﬁve underlying data points and the correlation 
coeﬃcient was >0.7. The median of all included segments resulted in BRSUP and BRSDOWN.
Estimation of cerebral vasomotor reactivity
The CVMR was expressed using the cerebrovascular conductance index (CVCi, the ratio of 
MCFBV to MAP) to account for confounding eﬀects of CO2 on BP (Equation 1).5 CVMR was 
derived as the diﬀerence between maximal CVCi during hypercapnia and minimal CVCi 
during hypocapnia, divided by the mean CVCi during normocapnia in rest (Equation 2). 
The CVCiREST was the average CVCi during rest. CVCiCO2 was estimated by ﬁtting a 
smoothing spline and estimate the 10s average CVCi around the maximum of that spline,6 
while CVCiHV was estimated for the mimimum of the spline.
Estimation of orthostatic SBP recovery
The SBP signal was ﬁltered using a moving average ﬁlter with a 5 s window. For all three 
sit-to-stand repetitions we extracted baseline SBP (mean 10-40 s before standing) and 
mean SBP 50-60 s after standing, which was subsequently expressed as percentage from 
baseline (Equation 3).7 To increase reliability the results of the three repetitions performed 
by one participant were averaged. 
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Supplemental Tables
Table S1  Participant characteristics with the ﬁnal sample sizes for each type of analysis.
Variable Dementia MCI Controls P Test 
statistic
A. During rest
 TFA
  n 41 31 41
  Age, years 72.1 (70.1-74.1) 69.4 (66.4-72.3) 69.1 (68.0-70.2) 0.053 3.023
  Female, % 51.2 (21) 22.6 (7) 36.6 (15) 0.045 6.201
  CDR, % 0 - - 100 (26)
 0.5 39.0 (16) 100 (24) -
 1 46.3 (19) - -
 2 14.6 (6) - -
  VCS, % 0 29.3 (12) 12.9 (4) 73.2 (30) 0.253 4.079
 1 36.6 (15) 48.4 (15) 26.8 (11)
 2 26.8 (11) 22.6 (7) -
 3 7.3 (3) 16.1 (5) -
 ARI
  n 36 29 39
  Age, years 72.0 (70.1-73.8) 69.0 (66.0-71.9) 69.3 (68.2-70.4) 0.052 3.048
  Female, % 52.8 (19) 24.1 (7) 35.9 (14) 0.057 5.739
  CDR, % 0 - - 100 (39)
 0.5 41.7 (15) 100 (29) -
 1 47.2 (17) - -
 2 11.1 (4) - -
  VCS, % 0 30.6 (11) 13.8 (4) 69.2 (27) 0.224 4.373
 1 36.1 (13) 51.7 (15) 30.8 (12)
 2 27.8 (10) 20.7 (6) -
 3 5.6 (2) 13.8 (4) -
BRS
  n 36 25 41
  Age, years 71.5 (69.4-73.6) 68.6 (65.4-71.9) 69.4 (68.2-70.6) 0.126 2.116
  Female, % 50.0 (18) 36.0 (9) 39.0 (16) 0.481 1.462
  CDR, % 0 - - 100 (41)
 0.5 41.7 (15) 100 (25) -
 1 41.7 (15) - -
 2 16.7 (6) - -
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Table S1  Continued.
Variable Dementia MCI Controls P Test 
statistic
  VCS, % 0 27.8 (1) 24.0 (6) 70.7 (29) 0.642 1.679
 1 38.9 (14) 52.0 (13) 29.3 (12)
 2 27.8 (10) 16.0 (4) -
 3 5.6 (2) 8.0 (2) -
B. During orthostatic challenges
 TFA
  n 39 31 37
  Age, years 72.4 (70.3-74.5) 68.8 (65.9-71.7) 69.2 (68.1-70.4) 0.029 3.659
  Female, % 46.2 (18) 25.8 (8) 37.8 (14) 0.217 3.060
  CDR, % 0 - - 100 (37)
 0.5 38.5 (15) 100 (31) -
 1 48.7 (19) - -
 2 12.8 (5) - -
  VCS, % 0 30.8 (12) 12.9 (4) 70.3 (26) 0.268 3.943
 1 35.9 (14) 51.6 (16) 29.7 (11)
 2 25.6 (10) 22.6 (7) -
 3 7.7 (3) 12.9 (4) -
 ARI
  n 39 31 36
  Age, years 72.5 (70.5-74.6) 68.8 (65.9-71.7) 69.0 (68.0-70.1) 0.015 4.341
  Female, % 46.2 (18) 25.8 (8) 38.9 (14) 0.215 3.074
  CDR, % 0 - - 100 (36)
 0.5 35.9 (14) 100 (31) -
 1 51.3 (20) - -
 2 12.8 (5) - -
  VCS, % 0 28.2 (11) 12.9 (4) 69.4 (25) 0.313 3.564
 1 35.9 (14) 51.6 (16) 30.6 (11)
 2 28.2 (11) 22.6 (7) -
 3 7.7 (3) 12.9 (4) -
BRS
  n 50 35 38
  Age, years 73.1 (71.3-74.9) 68.7 (65.8-71.5) 69.6 (68.4-70.8) 0.003 6.113
  Female, % 52.0 (26) 34.3 (12) 42.1 (16) 0.260 2.695
  CDR, % 0 - - 100 (38)
 0.5 38.0 (19) 100 (35) -
 1 48.0 (24) - -
 2 14.0 (7) - -
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Table S1  Continued.
Variable Dementia MCI Controls P Test 
statistic
  VCS, % 0 28.0 (14) 17.1 (6) 71.1 (27) 0.649 1.647
 1 40.0 (20) 48.6 (17) 28.9 (11)
 2 24.0 (12) 22.9 (8) -
 3 8.0 (4) 11.4 (4) -
Values are presented as mean (95% conﬁdence interval) or % (n). Test statistics is F-statistic for age and χ2 for 
sex and VCS. For VCS a comparison between dementia and MCI has been made. MCI = mild cognitive 
impairment; TFA = transfer function analysis; ARI = autoregulatory index; BRS = baroreﬂex sensitivity; CDR = 
clinical dementia rating; VCS = vascular comorbidity score.
Table S2  Between-group comparisons of CA and BRS variables corrected for age 
and sex.
Variable Group Sex Group * Sex
P F P F P F
A. During rest
 Cerebral autoregulation
  MAP, mmHg 0.004 5.80 0.746 0.105 0.965 0.04
  MCBFV, cm s-1 0.002 6.46 0.081 3.11 0.888 0.12
  CVRi, mmHg cm-1 s-1 0.042 3.28 0.397 0.72 0.968 0.03
  EtCO2, kPa 0.003 6.26 0.034 4.66 0.410 0.90
  ARI 0.141 2.00 0.218 1.54 0.470 0.76
  GainVLF, cm s-1 mmHg-1 0.386 0.96 0.632 0.46 0.446 0.56
  GainNORM-VLF, % mmHg-
1
0.068 2.76 0.012 6.50 0.577 0.55
  PhaseVLF, degrees 0.523 0.65 0.094 2.86 0.055 2.98
  GainLF, cm s-1 mmHg-1 0.951 0.05 0.509 0.44 0.218 1.55
  GainNORM-LF, % mmHg-1 0.006 5.30 0.396 0.73 0.294 1.24
  PhaseLF, degrees 0.157 1.88 0.551 0.36 0.295 1.24
 Baroreﬂex sensitivity
  SBP, mmHg 0.019 4.14 0.701 0.15 0.923 0.08
  HR, beats min-1 0.735 0.31 0.111 2.59 0.472 0.76
  BRSGAIN, ms mmHg-1 0.137 2.03 0.446 0.58 0.748 0.29
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Table S2  Continued.
Variable Group Sex Group * Sex
P F P F P F
B. During orthostatic challenges
 Cerebral autoregulation
  MAP, mmHg 0.432 0.85 0.736 0.11 0.539 0.62
  MCBFV, cm s-1 0.111 2.25 0.834 0.04 0.535 0.63
  CVRi, mmHg s-1 0.093 2.43 0.612 0.26 0.526 0.65
  EtCO2, kPa 0.329 1.13 0.577 0.31 0.245 1.43
  ΔMAP, mmHg 0.139 2.01 0.202 1.65 0.648 0.44
  ΔMAP, % 0.085 2.53 0.174 1.87 0.837 0.18
  ΔMCBFV, cm s-1 0.002 6.48 0.427 0.64 0.038 3.37
  ΔMCBFV, % 0.002 6.50 0.357 0.86 0.015 4.36
  ARI 0.015 4.38 0.280 1.8 0.874 0.14
  Gain, cm s-1 mmHg-1 0.054 3.01 0.201 1.66 0.668 0.41
  GainNORM, % mmHg-1 0.027 3.77 0.049 3.98 0.748 0.29
  Phase, degrees 0.074 2.67 0.923 0.01 0.696 0.36
 Baroreﬂex sensitivity
  SBP, mmHg 0.350 1.06 0.991 0.01 0.733 0.31
  HR, beats min-1 0.192 1.68 0.119 2.48 0.122 2.15
  BRSGAIN, ms mmHg-1 0.120 2.18 0.836 0.04 0.631 0.46
  BRSUP, ms mmHg-1 0.155 1.90 0.243 1.38 0.325 1.14
  BRSsDOWN, ms mmHg-1 0.287 1.27 0.970 0.01 0.481 0.74
F-statistic and corresponding P-values for the eﬀects of Group, Sex and Group*Sex interaction on all CA and 
BRS variables. All models are corrected for age. P-values in bold indicate <0.05.MAP = mean arterial pressure; 
MCBFV = mean cerebral blood ﬂow velocity; CVRi = cerebrovascular resistance index; EtCO2 = end-tidal CO2; 
ARI = autoregulatory index; VLF = very low frequency; LF = low frequency; NORM = normalized; SBP = systolic 
blood pressure; HR = heart rate; BRS = baroreﬂex sensitivity.
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Table S3  Comparison of all characteristics and CA and BRS variables between patients 
on and oﬀ antihypertensive treatment.
Variable On AHD Off AHD P Test 
statistic
n 30 60
Age, years 74.1 (71.7-76.5) 70.2 (68.3-72.2) 0.018 2.41
Female, % 40 (12) 48.3 (29) 0.454 0.56
BMI, kg m-2 26.3 (24.8-27.7) 25.0 (24.1-25.9) 0.114 1.60
CDR, %     0 0 (0) 0 (0) 0.929 0.15
                  0.5 63.3 (19) 61.7 (37)
                  1 26.7 (8) 30.0 (18)
                  2 10.0 (3) 8.3 (5)
VCS, %     0 0 (0) 35.0 (21) <0.001 25.04
                  1 40.0 (12) 45.0 (27)
                  2 33.3 (10) 18.3 (11)
                  3 26.7 (8) 1.7 (1)
SBP, mmHg 139.8 (133.3-146.3) 140.0 (135.9-144.1) 0.953 0.06
DBP, mmHg 81.1 (77.6-84.6) 80.0 (77.6-82.5) 0.611 0.51
A. During rest
 Cerebral autoregulation
  MAP, mmHg 87.3 (78.9-95.8) [24] 89.3 (83.9-94.8) [48] 0.957 0.01
  MCBFV, cm s-1 38.0 (33.9-42.1) [24] 41.9 (38.9-44.9) [48] 0.255 1.32
  CVRi, mmHg cm-1 s-1 2.42 (2.11-2.72) [24] 2.22 (2.04-2.40) [48] 0.249 1.35
  EtCO2, kPa 4.90 (4.64-5.15) [19] 5.00 (4.77-5.24) [39] 0.709 0.14
  ARI 5.07 (4.28-5.87) [20] 4.81 (4.32-5.29) [45] 0.453 0.57
  GainVLF, cm s-1 mmHg-1 0.44 (0.36-0.52) [21] 0.46 (0.42-0.50) [46] 0.715 0.13
  GainNORM-VLF, % mmHg-1 1.11 (0.97-1.26) [21] 1.10 (1.01-1.20) [46] 0.964 0.01
  PhaseVLF, degrees 56.0 (47.8-64.2) [19] 54.1 (47.5-60.7) [46] 0.461 0.55
  GainLF, cm s-1 mmHg-1 0.56 (0.47-0.64) [24] 0.66 (0.62-0.71) [48] 0.126 2.40
  GainNORM-LF, % mmHg-1 1.45 (1.31-1.59) [24] 1.62 (1.50-1.74) [48] 0.277 1.20
  PhaseLF, degrees 34.3 (25.4-43.2) [24] 34.1 (30.1-38.1) [48] 0.764 0.09
 Baroreﬂex sensitivity
  SBP, mmHg 151 (129-174) [15] 137 (129-145) [46] 0.110 2.63
  HR, beats min-1 61.3 (56.6-66.9) [15] 64.9 (62.4-67.7) [46] 0.167 1.96
  BRSGAIN, ms mmHg-1 5.43 (3.82-7.04) [15] 4.82 (4.04-5.60) [46] 0.409 0.69
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Table S3  Continued.
Variable On AHD Off AHD P Test 
statistic
B. During orthostatic challenges
 Cerebral autoregulation
  MAP, mmHg 94.5 (86.2-102.9) [24] 94.3 (89.3-99.4) [46] 0.843 0.04
  MCBFV, cm s-1 38.3 (34.6-42.1) [24] 41.9 (39.3-44.6) [46] 0.325 0.98
  CVRi, mmHg cm-1 s-1 2.60 (2.29-2.90) [24] 2.31 (2.16-2.46) [46] 0.152 2.10
  EtCO2, kPa 4.59 (4.31-4.87) [23] 4.74 (4.42-5.06) [33] 0.416 0.67
  ΔMAP, mmHg 21.8 (19.1-24.4) [24] 22.3 (20.3-24.3) [47] 0.503 0.45
  ΔMAP, % 23.6 (20.5-26.6) [24] 24.2 (21.9-26.5) [47] 0.467 0.53
  ΔMCBFV, cm s-1 12.1 (10.2-14.1) [24] 13.6 (12.0-15.2) [47] 0.310 1.05
  ΔMCBFV, % 31.9 (27.7-36.1) [24] 32.6 (29.3-35.9) [47] 0.621 0.25
  ARI 5.04 (4.49-5.59) [24] 4.32 (3.92-4.72) [46] 0.121 2.47
  Gain, cm s-1 mmHg-1 0.53 (0.44-0.62) [24] 0.57 (0.50-0.63) [45] 0.706 0.14
  GainNORM, % mmHg-1 1.37 (1.20-1.54) [24] 1.36 (1.23-1.50) [45] 0.968 0.01
  Phase, degrees 51.9 (45.6-58.1) [24] 46.4 (43.1-49.7) [45] 0.167 1.95
 Baroreﬂex sensitivity
  SBP, mmHg 156 (142-170) [28] 152 (144-161) [57] 0.814 0.06
  HR, beats min-1 69.6 (65.3-74.4) [28] 70.4 (68.1-73.0) [57] 0.718 0.13
  BRSGAIN, ms mmHg-1 3.45 (2.47-4.36) [20] 3.57 (3.02-4.11) [47] 0.724 0.13
  BRSUP, ms mmHg-1 5.06 (3.36-6.76) [25] 5.26 (4.37-6.15) [55] 0.515 0.43
  BRSsDOWN, ms mmHg-1 3.56 (2.56-4.57) [20] 3.54 (2.97-4.11) [50] 0.188 1.78
Values are presented as mean (95% conﬁdence interval) [n] or % (n). Test statistics is t-statistic for age, BMI, SBP 
and DBP and χ2-statistic for sex, CDR and VCS. For all CA and BRS parameters the test statistic is the F-statistic 
corrected for age. P-values in bold indicate <0.05. AHD = antihypertensive drugs; MCI = mild cognitive 
impairment; BMI = body mass index; CDR = clinical dementia rating; VCS = vascular comorbidity score; SBP = 
systolic blood pressure; DBP = diastolic blood pressure. MAP = mean arterial pressure; MCBFV = mean 
cerebral blood ﬂow velocity; CVRi = cerebrovascular resistance index; EtCO2 = end-tidal CO2; ARI = 
autoregulatory index; VLF = very low frequency; LF = low frequency; NORM = normalized; HR = heart rate; 
BRS = baroreﬂex sensitivity.
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Table S4  Comparison of CA and BRS variables between patients with the lowest and 
highest tertile of cerebral vasomotor reactivity.
Variable Lowest tertile Highest tertile P Test 
statistic
 CVMR, % 29.8   (26.0-33.7)   [18] 61.9   (57.5-66.4)   [18]
A. During rest
 Cerebral autoregulation
  MAP, mmHg 81.9 (73.6-90.3) [18] 92.6 (81.2-104.0) [17] 0.118 2.58
  MCBFV, cm s-1 38.4 (34.3-42.6) [18] 40.1 (35.6-44.6) [17] 0.576 0.32
  CVRi, mmHg cm-1 s-1 2.16 (1.96-2.36) [18] 2.39 (2.03-2.75) [17] 0.236 1.45
  EtCO2, kPa 4.74 (4.25-5.23) [15] 5.06 (4.76-5.35) [17] 0.225 1.53
  ARI 5.13 (4.16-6.10) [15] 4.55 (3.74-5.36) [17] 0.333 0.97
  GainVLF, cm s-1 mmHg-1 0.44 (0.36-0.52) [17] 0.46 (0.38-0.54) [17] 0.684 0.17
  GainNORM-VLF, % mmHg-1 1.12 (0.99-1.26) [17] 1.17 (0.98-1.35) [17] 0.654 0.20
  PhaseVLF, degrees 56.3 (45.2-67.5) [17] 51.5 (42.3-60.7) [17] 0.482 0.51
  GainLF, cm s-1 mmHg-1 0.61 (0.54-0.68) [18] 0.62 (0.54-0.70) [17] 0.797 0.07
  GainNORM-LF, % mmHg-1 1.59 (1.44-1.74) [18] 1.58 (1.39-1.76) [17] 0.885 0.02
  PhaseLF, degrees 41.5 (31.8-51.2) [18] 29.3 (24.9-33.7) [17] 0.024 5.59
 Baroreﬂex sensitivity
  SBP, mmHg 128.5 (111.4-145.6) [11] 149.9 (131.8-168.0) [17] 0.094 3.02
  HR, beats min-1 65.5 (57.9-73.1) [11] 63.6 (59.0-68.2) [17] 0.628 0.24
  BRSGAIN, ms mmHg-1 5.76 (3.20-8.32) ]11] 4.49 (3.65-5.33) [16] 0.243 1.43
B. During orthostatic challenges
 Cerebral autoregulation
  MAP, mmHg 94.1 (86.7-101.5) [17] 94.6 (84.8-104.3) [17] 0.939 0.01
  MCBFV, cm s-1 39.3 (35.5-43.0) [17] 40.1 (36.2-44.1) [17] 0.751 0.10
  CVRi, mmHg s-1 2.42 (2.21-2.63) [17] 2.39 (2.11-2.67) [17] 0.858 0.03
  EtCO2, kPa 4.54 (4.00-5.07) [13] 4.87 (4.49-5.26) [15] 0.272 1.26
  ΔMAP, mmHg 21.8 (18.6-24.9) [17] 23.4 (19.4-27.5) [17] 0.493 0.48
  ΔMAP, % 23.9 (19.4-28.4) [17] 25.3 (21.6-28.9) [17] 0.610 0.27
  ΔMCBFV, cm s-1 12.4 (10.6-14.2) [17] 13.3 (10.2-16.4) [17] 0.590 0.30
  ΔMCBFV, % 32.7 (26.7-38.5) [17] 33.1 (27.2-39.1) [17] 0.906 0.01
  ARI 4.40 (3.73-5.06) [17] 4.65 (4.11-5.19) [17] 0.542 0.38
  Gain, cm s-1 mmHg-1 0.54 (0.46-0.62) [16] 0.52 (0.42-0.61) [17] 0.702 0.15
  GainNORM, % mmHg-1 1.39 (1.20-1.58) [16] 1.30 (1.07-1.53) [17] 0.518 0.43
  Phase, degrees 48.4 (42.0-54.7) [16] 45.9 (40.1-51.8) [17] 0.553 0.36
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Table S4  Continued.
Variable Lowest tertile Highest tertile P Test 
statistic
 Baroreﬂex sensitivity
  SBP, mmHg 157.1 (143.2-170.9) [18] 153.1 (138.5-167.7) [18] 0.680 0.17
  HR, beats min-1 74.0 (68.7-79.3) [18] 71.1 (66.1-76.0) [18] 0.401 0.72
  BRSGAIN, ms mmHg-1 3.62 (1.87-5.37) [13] 3.19 (2.37-4.00) [16] 0.613 0.26
  BRSUP, ms mmHg-1 5.40 (2.87-7.93) [16] 4.10 (3.09-5.12) [17] 0.308 1.08
  BRSsDOWN, ms mmHg-1 3.77 (2.19-5.34) [14] 3.23 (2.20-4.26) [14] 0.540 0.39
Values are mean (95% conﬁdence interval) [n]. Test statistics is t-statistic. The lowest tertile of CVMR contains 
patients with CVMR ≤40.5%, the highest tertile CVMR contains patients with CVMR ≥51.5%. Data from 
dementia and MCI patients are pooled into one group. CVMR = cerebral vasomotor reactivity ; MAP = mean 
arterial pressure; MCBFV = mean cerebral blood ﬂow velocity; CVRi = cerebrovascular resistance index; EtCO2 
= end-tidal CO2; ARI = autoregulatory index; VLF = very low frequency; LF = low frequency; NORM = 
normalized; SBP = systolic blood pressure; HR = heart rate; BRS = baroreﬂex sensitivity.
Table S5  Comparison of all CA and BRS variables between patients with the lowest and 
highest tertile of systolic blood pressure recovery.
Variable Lowest tertile Highest tertile P Test 
statistic
 SBP recovery, % 93.8   (92.2-95.4)   [28] 109.4   (107.3-111.5)   [29]
A. During rest
 Cerebral autoregulation
  MAP, mmHg 88.1 (79.6-96.6) [24] 83.0 (74.1-91.9) [23] 0.398 0.73
  MCBFV, cm s-1 40.7 (36.8-44.6) [24] 41.6 (37.3-46.0) [23] 0.738 0.11
  CVRi, mmHg cm-1 s-1 2.24 (1.98-2.51) [24] 2.05 (1.83-2.27) [23] 0.256 1.32
  EtCO2, kPa 5.17 (4.79-5.55) [17] 4.76 (4.45-5.06) [20] 0.083 3.19
  ARI 4.81 (4.15-5.48) [19] 4.78 (4.05-5.52) [24] 0.870 0.03
  GainVLF, cm s-1 mmHg-1 0.48 (0.41-0.55) [22] 0.47 (0.40-0.54) [22] 0.888 0.02
  GainNORM-VLF, % mmHg-1 1.16 (1.00-1.31) [22] 1.12 (0.97-1.27) [22] 0.715 0.14
  PhaseVLF, degrees 57.25 (48.4-66.6) [22] 51.6 (43.2-60.0) [22] 0.324 1.00
  GainLF, cm s-1 mmHg-1 0.61 (0.54-0.69) [24] 0.64 (0.57-0.72) [23] 0.561 0.34
  GainNORM-LF, % mmHg-1 1.54 (1.35-1.72) [24] 1.56 (1.42-1.70) [23] 0.811 0.06
  PhaseLF, degrees 33.4 (24.9-41.9) [24] 34.5 (28.2-40.9) [23] 0.829 0.05
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 138
138 | Chapter 5
Table S5  Continued.
Variable Lowest tertile Highest tertile P Test 
statistic
 Baroreﬂex sensitivity
  SBP, mmHg 141 (127-154) [24] 143 (124-162) [19] 0.840 0.04
  HR, beats min-1 63.1 (59.3-66.9) [24] 67.0 (62.5-71.6) [19] 0.173 1.92
  BRSGAIN, ms mmHg-1 5.35 (4.02-6.69) [22] 4.48 (3.12-5.83) [18] 0.346 0.91
B. During orthostatic challenges
 Cerebral autoregulation
  MAP, mmHg 98.6 (89.7-107.6) [23] 87.7 (80.0-95.4) [22] 0.062 3.67
  MCBFV, cm s-1 42.3 (38.7-45.9) [23] 39.7 (36.1-43.3) [22] 0.293 1.13
  CVRi, mmHg s-1 2.39 (2.14-2.64) [23] 2.31 (2.03-2.58) [22] 0.639 0.22
  EtCO2, kPa 4.73 (4.27-5.19) [19] 4.51 (4.18-4.83) [19] 0.411 0.69
  ΔMAP, mmHg 22.7 (19.7-25.7) [23] 22.9 (19.8-26.0) [23] 0.921 0.01
  ΔMAP, % 23.3 (20.3-26.3) [23] 27.1 (23.2-31.0) [23] 0.112 2.64
  ΔMCBFV, cm s-1 13.4 (11.4-15.5) [23] 14.5 (12.4-16.7) [23] 0.460 0.56
  ΔMCBFV, % 31.9 (27.9-35.9) [23] 37.2 (31.9-42.5) [23] 0.102 2.79
  ARI 4.23 (3.58-4.87) [23] 4.87 (4.35-5.38) [23] 0.115 2.59
  Gain, cm sec-1 mmHg-1 0.56 (0.48-0.65) [23] 0.61 (0.50-0.72) [22] 0.507 0.45
  GainNORM, % mmHg-1 1.36 (1.17-1.55) [23] 1.52 (1.31-1.72) [22] 0.234 1.46
  Phase, degrees 44.2 (37.8-50.5) [23] 49.6 (45.0-54.2) [22] 0.161 2.03
 Baroreﬂex sensitivity
  SBP, mmHg 158 (146-168) [27] 159 (145-173) [28] 0.100 2.80
  HR, beats min-1 70.3 (66.1-74.4) [27] 74.6 (71.0-78.1) [28] 0.112 2.62
  BRSGAIN, ms mmHg-1 3.55 (2.69-4.42) [22] 3.38 (2.46-4.30) [22] 0.782 0.08
  BRSUP, ms mmHg-1 5.25 (3.65-6.84) [26] 4.38 (3.25-5.50) [27] 0.361 0.85
  BRSsDOWN, ms mmHg-1 3.41 (2.47-4.36) [22] 3.11 (2.16-4.06) [22] 0.641 0.22
Values are mean (95% conﬁdence interval) [n]. Test statistics is t-statistic. The lowest tertile of SBP recovery 
contains patients with recovery ≤98%, the highest tertile contains patients with SBP recovery ≥105%. Data 
from dementia and MCI patients are pooled into one group. SBP = systolic blood pressure; MAP = mean 
arterial pressure; MCBFV = mean cerebral blood ﬂow velocity; CVRi = cerebrovascular resistance index; EtCO2 
= end-tidal CO2; ARI = autoregulatory index; VLF = very low frequency; LF = low frequency; NORM = 
normalized; HR = heart rate; BRS = baroreﬂex sensitivity.
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Table S6  Comparison of all CA and BRS variables between patients with partial and full 
systolic blood pressure recovery.
Variable Partial recovery Full recovery P Test 
statistic
 SBP recovery, % 91.7 (89.9-93.6) [18] 106.3 (104.7-107.9) [50]
A. During rest
 Cerebral autoregulation
  MAP, mmHg 87.5 (77.9-97.0) [16] 85.7 (79.7-91.6) [39] 0.741 0.11
  MCBFV, cm s-1 40.3 (35.6-44.9) [16] 39.8 (36.5-43.1) [39] 0.870 0.03
  CVRi, mmHg cm-1 s-1 2.23 (1.93-2.53) [16] 2.27 (2.04-2.49) [39] 0.868 0.03
  EtCO2, kPa 5.39 (4.76-5.83) [11] 4.75 (4.55-4.95) [33] 0.017 6.13
  ARI 4.56 (3.66-5.46) [12] 4.96 (4.44-5.49) [39] 0.535 0.39
  GainVLF, cm s-1 mmHg-1 0.47 (0.39-0.55) [15] 0.44 (0.39-0.49) [37] 0.602 0.28
  GainNORM-VLF, % mmHg-1 1.16 (0.98-1.35) [15] 1.11 (1.00-1.21) [37] 0.546 0.37
  PhaseVLF, degrees 54.9 (43.8-66.0) [15] 52.9 (46.6-59.1) [37] 0.726 0.12
  GainLF, cm s-1 mmHg-1 0.60 (0.53-0.67) [16] 0.64 (0.58-0.69) [39] 0.444 0.59
  GainNORM-LF, % mmHg-1 1.51 (1.34-1.69) [16] 1.62 (1.49-1.74) [39] 0.353 0.88
  PhaseLF, degrees 36.3 (24.9-47.8) [16] 34.6 (29.9-39.4) [39] 0.735 0.12
 Baroreﬂex sensitivity
  SBP, mmHg 140 (124-157) [15] 143 (131-154) [36] 0.813 0.06
  HR, beats min-1 60.6 (55.7-65.4) [15] 65.9 (62.7-69.1) [36] 0.070 3.44
  BRSGAIN, ms mmHg-1 5.70 (4.03-7.36) [13] 4.97 (4.04-5.91) [33] 0.412 0.69
B. During orthostatic challenges
 Cerebral autoregulation
  MAP, mmHg 100.1 (88.8-111.4) [15] 91.3 (86.1-96.5) [39] 0.100 2.81
  MCBFV, cm s-1 42.8 (38.2-47.3) [15] 38.8 (36.1-41.5) [39] 0.118 2.52
  CVRi, mmHg s-1 2.38 (2.10-2.67) [15] 2.46 (2.25-2.67) [39] 0.679 0.17
  EtCO2, kPa 4.85 (4.04-5.66) [11] 4.57 (4.33-4.82) [34] 0.346 0.91
  ΔMAP, mmHg 22.2 (19.5-25.0) [15] 22.0 (19.7-24.2) [40] 0.886 0.02
  ΔMAP, % 22.6 (19.7-25.6) [15] 24.7 (22.1-27.4) [40] 0.366 0.83
  ΔMCBFV, cm s-1 13.3 (11.5-15.0) [15] 13.3 (11.5-15.0) [40] 0.983 0.00
  ΔMCBFV, % 31.5 (28.0-35.0) [15] 34.1 (30.4-37.8) [40] 0.412 0.68
  ARI 4.19 (3.33-5.05) [15] 4.92 (4.54-5.31) [39] 0.068 3.48
  Gain, cm s-1 mmHg-1 0.54 (0.46-0.62) [15] 0.56 (0.49-0.63) [39] 0.772 0.09
  GainNORM, % mmHg-1 1.29 (1.10-1.48) [15] 1.43 (1.29-1.57) [39] 0.245 1.38
  Phase, degrees 47.3 (38.8-55.8) [15] 50.9 (37.6-54.3) [39] 0.322 1.00
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 140
140 | Chapter 5
Table S6  Continued.
Variable Partial recovery Full recovery P Test 
statistic
 Baroreﬂex sensitivity
  SBP, mmHg 160 (142-179) [17] 149 (140-158) [49] 0.227 1.49
  HR, beats min-1 68.9 (63.2-74.6) [17] 73.0 (70.2-75.8) [49] 0.160 2.02
  BRSGAIN, ms mmHg-1 3.28 (2.07-4.49) [13] 3.51 (2.87-4.15) [40] 0.719 0.13
  BRSUP, ms mmHg-1 4.92 (3.20-6.64) [16] 4.92 (3.97-5.88) [46] 0.994 0.01
  BRSsDOWN, ms mmHg-1 3.28 (1.92-4.64) [13] 3.35 (2.72-4.00) [40] 0.914 0.01
Values are presented as mean (95% conﬁdence interval) [n]. Test statistics is t-statistic. Partial SBP recovery was 
deﬁned as ≤95% and full recovery as ≥100%. Data from dementia and MCI patients are pooled into one 
group. P-values in bold indicate <0.05. SBP = systolic blood pressure; MAP = mean arterial pressure; MCBFV = 
mean cerebral blood ﬂow velocity; CVRi = cerebrovascular resistance index; EtCO2 = end-tidal CO2; ARI = 
autoregulatory index; VLF = very low frequency; LF = low frequency; NORM = normalized; HR = heart rate; 
BRS = baroreﬂex sensitivity.
Table S7  Comparison of BRS during orthostatic challenges between participants with 
and without missing BRS during rest using Mann-Whitney test.
Variable BRS rest present BRS rest missing P Test 
statistic 
A. Dementia
  BRSGAIN, ms mmHg-1 2.49 (2.05-3.34) [28] 3.34 (2.21-3.88) [13] 0.385 151
  BRSUP, ms mmHg-1 3.59 (2.59-5.42) [34] 3.88 (2.53-6.52) [15] 0.558 228
  BRSDOWN, ms mmHg-1 2.43 (1.66-4.40) [31] 3.20 (2.11-5.05) [13] 0.203 152
B. MCI
  BRSGAIN, ms mmHg-1 3.27 (2.37-4.86) [20] 3.72 (1.86-7.62) [6] 0.951 59
  BRSUP, ms mmHg-1 4.08 (3.33-6.53) [23] 6.06 (2.37-11.60) [8] 0.619 81
  BRSDOWN, ms mmHg-1 3.29 (2.30-5.50) [20] 4.76 (2.67-7.22) [6] 0.543 50
C. Controls
  BRSGAIN, ms mmHg-1 2.45 (2.03-3.76) [33] 4.35 (2.51-4.59) [3] 0.179 26
  BRSUP, ms mmHg-1 3.64 (2.39-6.12) [33] 4.27 (3.04-6.79) [4] 0.525 53
  BRSDOWN, ms mmHg-1 1.97 (1.64-3.06) [32] 6.92 (4.41-7.98) [3] 0.010 4
Values are presented as median (interquartile range) [n]. Test statistics is U-statistic (Mann-Whitney). P-values in bold 
indicate <0.05. There is a diﬀerence in BRSDOWN for the Controls with and without present BRS, but given the low 
number of subjects with missing BRS rest (3 subjects) distortion of results will be minimal. BRS = baroreﬂex sensitivity.
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Supplemental Figures
Figure S1  Representative recordings of blood pressure and cerebral blood ﬂow velocity. Example of 
blood pressure (A-E) and cerebral blood ﬂow velocity (F-J) recordings during rest (5 minutes sitting) 
(A, F), during orthostatic challenges (5 minutes of repeated sit-to-stand at a frequency of 0.05 Hz, 
i.e. 10 s sitting, 10 s standing) (B, G), during hyperventilation (30 s at a frequency of 0.5 Hz, i.e. 1 s 
breathing in, 1 s breathing out) (C, H), during 5% CO2 inhalation for 3 minutes (D, I) and during three 
repetitions of a single sit-to-stand manoeuvre (2 minutes sitting and 1 minute standing) (E, J). Beat-
to-beat mean arterial pressure and mean cerebral blood velocity are shown in black. Systolic and 
diastolic waveforms are shown in grey. HV = hyperventilation; BP = blood pressure; CBFV = cerebral 
blood ﬂow velocity.
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Figure S2 Outcomes gain and coherence of cerebral autoregulation during rest and during 
orthostatic challenges. Gain and coherence during rest are visualized as frequency plot with 95% 
CI, for dementia patients (dotted line), MCI patients (dashed line) and controls (solid line). Gain and 
coherence during orthostatic challenges are presented as scatter plots at the sit-to-stand frequency 
(0.04-0.06 Hz). Scatter plots: each dot represents one participant and bars indicate the mean and 
95% CI. MCI = mild cognitive impairment.
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Figure S3 Transfer function analysis frequency plots categorized by tertiles of the cerebral 
vasomotor reactivity. Frequency plots showing the mean TFA response with the 95% CI of gain, 
normalized gain, phase and coherence for the upper tertile of CVMR (≥51.5%, highest CVMR, solid 
line, n = 17) and lower tertile (≤40.5%, lowest CVMR, dashed line, n = 17). Data from dementia and 
MCI patients are pooled into one group. CVMR = cerebral vasomotor reactivity.
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Figure S4 Transfer function analysis frequency plots categorized by tertiles of systolic blood pressure 
recovery. Frequency plots showing the mean TFA response with the 95% CI of gain, normalized 
gain, phase and coherence for the upper tertile of systolic blood pressure recovery (≥105%, highest 
recovery, solid line, n = 29) and lower tertile (≤98%, lowest recovery, dashed line, n = 28). Data from 
dementia and MCI patients are pooled into one group.
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Figure S5 Fourier transform of the Biopac recording system (left), the Finapres system (middle) 
and Multi-Dop system (right) with sample rate of 5000 Hz. Frequency plots showing the fourier 
transform at a higher sampling rate. As can be observed the Biopac system functions as a ﬂat 
passband system. The frequency content in Finapres and Multi-Dop system is very low above 20 Hz 
and hence justifying the chosen sampling frequency of 200 Hz.
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Abstract
This study investigated whether treatment with nilvadipine (a calcium antagonist) could 
restore cerebral blood ﬂow (CBF) in patients with mild-to-moderate Alzheimer’s disease. 
In this double-blinded RCT study (NILVAD-substudy), change in CBF after six months was 
evaluated in whole brain grey matter and in a priori deﬁned regions-of-interest: the 
posterior cingulate cortex and the left and right hippocampus, using MR arterial spin 
labeling. 22 patients in placebo-controlled and nilvadipine groups (72.8±6.2 years,  MMSE: 
20.4±3.4) were medication compliant over six months. The use of nilvadipine resulted 
(mean [95%CI]) in an increase in CBF to left (24.4mL/100g/min [4.3–44.5], p=0.02) and 
(almost signiﬁcant) right hippocampus (20.1mL/100g/min [-0.6–40.8], p=0.06), whereas 
global CBF (5.4mL/100g/min [-6.4–17.2], p=0.36) remained stable. In conclusion, nilvadipine 
increased CBF to the hippocampal region, while ﬂow to other brain regions remained 
stable. These ﬁndings could point to beneﬁcial eﬀects of antihypertensive treatment.  
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Introduction
In the development of Alzheimer’s disease (AD), pathophysiological changes occur years 
to decades prior to the ﬁrst onset of clinical symptoms.1 These changes encompass 
accumulation of aggregated amyloid-β and tau, but also the less investigated early cere-
brovascular pathophysiological changes.2 Such a cerebrovascular pathology includes 
structural changes to the cerebrovascular bed and amyloid deposition in vascular walls, 
leading to a reduction in cerebral blood ﬂow (CBF).3-5 This reduction in CBF is predictive 
for disease progression6 and has also been linked to diminishing cognitive capacities.7, 8 
 Cerebrovascular changes are thought to form the mechanistic link between mid-life 
hypertension - the major risk factor for cerebrovascular disease - and late life AD.9, 10 
Indeed, in an animal model for AD, hypertension in middle-aged animals led to reductions 
in CBF.11 Importantly, in that same mouse model, anti-hypertensive treatment was able to 
restore CBF, speciﬁcally in the hippocampus.12 However, translational evidence is limited 
as research on cerebrovascular interventions in patients with AD is scarce.13
 Nilvadipine is a dihydropyridine calcium-channel blocker that has speciﬁc properties 
that could target some of the cerebrovascular pathophysiology in AD. In addition to its 
blood pressure-lowering properties, it was shown in in-vitro and animal studies that 
nilvadipine blocks amyloid-β induced vasoconstriction, both by decreasing amyloid 
deposition and by antagonizing the vaso-active properties of amyloid.14, 15 Furthermore, 
in small human pilot studies nilvadipine increased regional CBF.16, 17
 The aim of this study was to investigate whether nilvadipine could increase CBF in 
patients with AD dementia. 
Methods
Trial design and treatment
The current study was a pre-planned sub-study  of the Nilvad trial (NCT02017340; EudraCT 
No: 2012-002764-27), which was a multicentre, randomized, double-blind, placebo- 
controlled study (RCT) of nilvadipine compared with placebo in AD patients approved 
by relevant authorities.18 Patients were randomly assigned at baseline to receive either 
8mg of nilvadipine or placebo (1:1), with block randomization stratiﬁed by site, using 
an online system. Patients took a trial treatment capsule once a day after breakfast for 
78 weeks. Trial assessment measures, comprising cognitive and blood pressure (BP) 
measurements, were done at baseline, week 13, week 52 and week 78. The measurements 
speciﬁc for this CBF sub-study were collected at baseline and week 26, and consisted of 
1 week of home blood pressure measurements (HBPM), MR-imaging and hemodynamic 
measurements.19
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Participants
Inclusion criteria for participation in the CBF sub-study encompassed a diagnosis of 
probable mild-to-moderate AD (based on the NIA-AA criteria20), age > 50 years, blood 
pressure between 100/65 and 159/99 mmHg, without other severe medical conditions or 
clinical abnormalities such as tumor, infarction, etc and/or use of calcium channel blockers 
or β-blockers.18 Patients were recruited from two memory clinics, one academic (Radboud 
university medical center, Nijmegen, The Netherlands) and one large teaching hospital 
(Rijnstate, Arnhem, The Netherlands). All participants and caregivers gave written informed 
consent. The sub-study was approved by the institutional review board (CMO, Arnhem- 
Nijmegen (no. 2012-508)) and was conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice. 
Data collection
General outcomes
At baseline, vascular comorbidities were summarized in a vascular comorbidity score (VCS; 
0-7), which included hypertension or use of anti-hypertensive medication, cerebrovascular 
diseases, peripheral artery disease, chronic heart failure, coronary heart disease, arrhythmias, 
and chronic kidney disease. Every three months BP (sitting and standing) was measured, 
new medication was dispensed and compliance was assessed by counting returned 
medication, where >80% was deemed compliant in that quartile (>75% in ﬁrst quartile). 
At baseline, week 13, week 52 and week 78, ADAS-Cog and clinical dementia rating scale 
(CDR) were measured.
Hemodynamic measurements and MR imaging
All data collection for the sub-study took place at the research center (Radboud university 
medical center). One week prior to the sub-study visit participants were asked to take 
their own BP readings twice daily (morning and evening) after 5 minutes of relaxation, 
using a HBPM monitor (Microlife Watch BP Home). From the evening prior to the visit 
participants were asked to refrain from caﬀeine and alcohol. During the visit, MRI and 
hemodynamic measurements were performed and blood samples were drawn for 
estimation of hematocrit. 
MRI protocol
All imaging was performed on a 3T Trio MRI (Siemens, Erlangen, Germany). 
 For registration purposes and segmentation of grey matter (GM) and brain structures 
a magnetization-prepared rapid gradient-echo 3D (MPRAGE) T1-weighted sequence was 
performed using the following parameters: repetition time/echo time (TR/TE) = 2300/4.71 
ms; matrix = 256 x 256; 192 slices; voxel size = 1x1x1 mm. Additional structural sequences 
included a ﬂuid-attenuated inversion recovery (FLAIR) (TR/TE: 12000/121ms; matrix 
250x250; 48 slices; 0.7x0.7x3mm), used for calculating white matter (WM) lesion volume, 
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and susceptibility weighted imaging (SWI) (TR/TE: 27/20ms; matrix 250x250; 144 slices; 
1x1x1mm) for assessment of microbleeds. 
 We used a multi-inversion time (TI) pulsed arterial spin labeling (ASL) sequence with 
ﬂow alternating inversion recovery (FAIR) labeling combined with a 3D-GRASE readout.21 
The parameters of the ASL-sequence were: 10 TIs (start: 500 ms, end 2750 ms, increment: 
250ms), 2 averages per TI, bolus length=1400ms. The 3D-GRASE readout parameters were: 
TR/TE: 4000/13.26ms; matrix of 220x165; 30 slices; 3.4x3.4x4mm; ﬂip angle=100°; turbo 
factor=23, echo planar imaging (EPI)-factor=12; partial Fourier (with zero ﬁlling in 
z-direction)= 6/8; Bandwidth = 2298 Hz/pixel. Additionally, a calibration image (without 
labeling) with TR=100 ms was acquired.  
Hemodynamic measurements
CBF was additionally assessed during ﬁve minutes of sitting and ﬁve minutes of standing, 
with transcranial doppler (TCD) ultrasonography using 2MHz probes (Multi-Dop, 
Compumedics DWL, Germany), recording cerebral blood ﬂow velocity (CBFV) in the 
middle cerebral arteries (MCA), captured continuously at 200 Hz (MP150, Biopac systems, 
Goleta, Ca, USA).
Data analysis
MRI measurements
CBF
ASL-MRI data were post-processed using packages from the FSL software (version v5.0.9, 
FMRIB, Oxford, UK).22 First, label, control, and calibration images were realigned using FSL 
(function mcﬂirt), based on the middle volume of the respective time series, and the 
rotations and translations were visually checked and if motion was large (>1.5 mm or >0.05 
rad) the image was excluded for further analysis. Subsequently, label and control images 
were subtracted to obtain perfusion weighed images. The calibration image was scaled 
back to obtain the M0 image (division by 1 –  ). Subsequently, the perfusion weighed 
images and the M0-image were ﬁtted to the General Kinetic Model,23 using the FSL 
function oxford_asl utility which estimates absolute CBF and arterial transit time (ATT) by 
Variational Bayesian inference,24 with parameter priors T1 tissue = 1331 ms,25 T1blood = 1/
(0.52*hematocrit+0.38),26 ATT = 700 ms, bolus-width = 1100ms and with options for spatial 
smoothing (using an adaptive method) and partial volume correction turned on.
 To obtain the GM mask, the T1 image was segmented using the FSL function FAST 
after brain extraction using a method optimized for pathological brains, OptiBET.27 
Hippocampal masks (left and right) were obtained using the longitudinal Freesurfer’s 
(version 6.0.0) automated subcortical processing stream. This longitudinal stream creates 
a template volume for each subject (using the “–base” option) which provides an unbiased 
segmentation of the hippocampus by taken all time points into account.28 The 
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hippocampal regions from this template volume served as the hippocampal masks. The 
PCC mask was obtained from the Harvard-Oxford cortical structural atlas and using the 
FSL function FNIRT, for non-linear registration, the PCC was registered from MNI to T1 
space. To obtain the transformation matrix for the GM, PCC and hippocampal masks from 
T1 to ASL space, the average control-image was co-registered with the skull-stripped T1 
image using a rigid transform. These masks were used to obtain the GM-CBF in the 
corresponding regions. 
Atrophy 
Brain volume and progress in brain atrophy were estimated from the T1-images using 
respectively the SIENAX and SIENA functions of FSL (default settings). Hippocampal volume 
and hippocampal atrophy were estimated using the longitudinal Freesurfer’s automated 
subcortical processing stream. After creating the previously mentioned template volume, 
the hippocampal volume was estimated for each T1 (using the “–long” option). 
Structural (vascular) lesions
WM lesions were segmented on the FLAIR images by the lesion prediction algorithm29 
using the LST toolbox version 2.0.15 for SPM12, with the T1 as reference images, where 
probability >0.5 were counted as lesions. SWI images at baseline and at week 26 were 
rated for microbleeds by two authors (DJ, JC) using the microbleed assessment rating 
scale (MARS).30 Infarcts were routinely assessed by trained radiologists.  
Hemodynamic measurements
All data were preprocessed using semi-automated custom-written Matlab scripts (version 
2014b, the MathWorks Inc. Natick, Massachusetts, USA), which resulted in beat-to-beat 
mean CBFV (MCBFV). After visual inspection for poor CBFV signal quality the remaining 
datasets were included for further analysis.31 For the sitting and standing position the 
5-minute averages of MCBFV were calculated. 
Statistical Analysis
All statistical analyses were performed on the per-protocol population based on complete 
cases using SPSS (version 22.0.0.1, IBM, New York, USA). 
 The a priori deﬁned primary outcomes were grey matter CBF (CBF-GM) at six months 
compared to CBF-GM at baseline in whole brain (WB), in the PCC and in both hippocampi. 
Secondary outcomes were systolic BP (SBP) and diastolic BP (DBP) at six months compared 
to baseline. Linear regression models with the outcome variable at six month as dependent 
variable and treatment group and baseline value as independent variables were used to 
estimate these changes in outcomes. Besides the analysis on the complete case dataset 
additional sensitivity analyses were performed on a multiple imputed dataset (see 
Supplementary material). The level of signiﬁcance was set at p<0.05.
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Sample size 
There have been very few RCTs using CBF as an outcome measure, none of which was 
done in an AD-population. Based on one RCT in an aged population, where regional CBF 
changed with 36%,32 we expect a CBF change in the range of 15-40%. To detect a 15% 
change in regional CBF between groups requires n=15 per group.33 Thus, a group size of 
20 was deemed suﬃcient to allow us  to reject the null hypothesis that the population 
means of each group are equal with probability (power) 0.8.19 
Results
Participants
Of 73 patients screened for eligibility between 1 June 2013 and 31 March 2015, 63 were 
included in the main NILVAD trial and therefore eligible for participation in this sub-study, 
of which 58 gave consent. These 58 patients were randomized, by which 29 patients 
received nilvadipine and 29 received placebo. At 6 months there were no dropouts. 
However, seven participants in both groups were not included for further analysis for this 
sub-study due to MR exclusion criteria (n=8), non-compliance (n=4) or discontinuation of 
the study medication (n=2), as a result of which these participants did not fulﬁll the criteria 
for the per-protocol analysis. The enrollment, the allocation process and reasons for 
exclusion for analysis are presented in Figure 1. 
 Baseline characteristics are listed in Table 1; participants had a mean age of 72.8± 
6.2 years and a mean MMSE of 20.4±3.4. There were no diﬀerences between patients 
included or excluded from analysis (Table s1). Compliance at 6 months was 98.9% for 
nilvadipine and 97.7% for placebo.
Missing data
The missing data rate for the primary and secondary variables ranged from 0-15.9%, with 
overall 89.8% of data available for analysis (Figure 1, Table s2). Missing data in the primary 
analysis were observed to be missing at random (Little’s missing at random test χ28=9.71; 
p=0.29), which is in line with the observed reasons why data was missing in this study 
(Table s2). 
Effects of nilvadipine vs placebo on blood pressure
Nilvadipine induced a signiﬁcant reduction in blood pressure recorded at the 6 months 
follow-up visit, compared to placebo (Figure 2). At 6 months, the decrease in SBP (Δ [95%-CI], 
p-value) was -11.5 mmHg [-19.7–-3.2], p<0.01). Blood pressure measured by patients at 
home using the HBPM device did not diﬀer between nilvadipine and placebo  (-1.9 mmHg 
[-8.8–5.1], p=0.59) (Table 2). 
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Effects of nilvadipine vs placebo on cerebral blood flow 
Nilvadipine led to an increase in blood ﬂow to the left hippocampus at 6 months (24.4 
mL/100g/min [4.3–44.5], p=0.02), while global CBF remained stable (5.4 mL/100g/min 
[-6.4–17.2], p=0.36) (Figure 2). Blood ﬂow to the right hippocampus showed a trend of 
20.1 mL/100g/min ([-0.6–40.8], p=0.06). There was no change in the posterior cingulate 
cortex (5.2 mL/100g/min [-16.5–27.0], p=0.92) (Table 2). The observations in the imputed 
data set are similar to the here presented complete case analyses (Table s3). 
Disease progression
Changes in parameters that relate to disease progression were not diﬀerent between 
groups (Table 3). The overall rates of atrophy in brain and hippocampi were respectively 
-1.2 % [-2.7–0.4] for brain and -2.0 % [-7.5–3.5] for left and -2.3 % [-6.7–2.0] for right 
hippocampus. MCBFV did not change over the six months in sitting (-0.4 cm/s [-16–15.3]) 
and standing position (-1.5 cm/s [-15.2–12.2]) and also ATT showed no change (-0.02 s 
[-0.08–0.05]). 
Figure 1  CONSORT-guideline based ﬂowchart.
73 patients screened  
for eligibility 
58 randomly assigned 
15 patients excluded: 
- MMSE outside limits (2) 
- Using exclusionary meds (4) 
- Unable to commit (4) 
- No consent for substudy(5) 
29 assigned  
to nilvadipine 
29 assigned  
to placebo 
22 cases analysed 22 cases analysed 
7 patients excluded: 
- MR exclusion criteria (4) 
-  off IMP (2) 
-  low compliance (1) 
7 patients excluded: 
- MR exclusion criteria (4) 
-  off IMP (2) 
-  low compliance  (1)  
14 complete cases 
analysed 
18 complete cases 
analysed  
ASL missing: 
-  Baseline (5) 
QC  (2) 
Logistics (2) 
Patient not cooperating (1) 
-  6 months (4) 
QC  (2) 
Patient not cooperating (2) 
ASL missing: 
-  Baseline (1) 
Logistics (1) 
- 6 months (3) 
QC (3) 
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Table 1  Participant characteristics.
Nilvadipine Placebo
n (%) 22 (50) 22 (50)
Gender (female), n (%) 14 (64) 12 (55)
Age (y), mean (95%CI) 72.6 (59.2–86.1) 72.9 (62–83.7)
Length (cm) , mean (95%CI) 168.7 (148.1–189.4) 167 (151.7–182.3)
Weight (kg) , mean (95%CI) 71.3 (42.9–99.8) 71.7 (50.2–93.1)
BMI (kg/m2) , mean (95%CI) 24.9 (17.8–32) 25.7 (18.2–33.2)
Smoking (Yes), n (%) 3 (14) 2 (9)
Cognitive function
MMSE, mean (95%CI) 19.7 (13.7–25.8) 21.1 (13.9–28.3)
CDR, n(%) 0.5 5 (23) 8 (36)
1 13 (59) 12 (55)
2 4 (18) 2 (9)
CDRsob, median [IQR] 6.0 [4.4-8] 4.5 [3.9-6.3]
ADAScog, median [IQR] 32 [26-38.5] 26.5 [25.8-34.3]
Medication, n(%)
Anti-hypertensive medication 7 (32) 7 (32)
Cholinesterase-inhibitors 20 (91) 19 (86)
Comorbidities, n(%)
Diabetes 3 (14) 0 (0)
Vascular comorbidity score (0-7),  
mean (95%CI)
1.2 (0–3.1) 1.6 (0–3.7)
Blood pressure, mean (95%CI)
SBP screening (mmHg) 136 (108–165) 140 (116–165)
DBP screening (mmHg) 78 (66–91) 78 (64–92)
Home-based SBP (mmHg) ) [n] 137 (104–170) [18] 135 (100–171) [21]
Home-based DBP (mmHg) ) [n] 79 (62–95) [18] 75 (56–94) [21]
Cerebral blood flow, mean (95%CI) ) [n]
MCBFV sit (cm/s) 36 (19.7–52.4) [19] 40 (17.1–62.9) [19]
MCBFV stand (cm/s) 35.3 (19.6–51.1) [17] 38.7 (19.8–57.6) [16]
CBF Global (mL/100g/min) 81.9 (38.3–125.5) [21] 87.2 (49.9–124.5) [17]
CBF posterior cingulate cortex (mL/100g/min) 107 (37.7–176.3) [21] 111.3 (52.9–169.8) [17]
CBF Hippocampus left (mL/100g/min) 107.2 (46–168.4) [21] 104.6 (52.4–156.7) [17]
CBF Hippocampus right (mL/100g/min) 107.7 (50.8–164.6) [21] 112.2 (66.4–158.1) [17]
ATT Global (s) 0.72 (0.65–0.78) [21] 0.7 (0.62–0.78) [17]
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Table 1  Continued.
Nilvadipine Placebo
ATT posterior cingulate cortex (s) 0.83 (0.7–0.97) [21] 0.81 (0.66–0.95) [17]
ATT Hippocampus left (s) 0.63 (0.52–0.75) [21] 0.62 (0.5–0.75) [17]
ATT Hippocampus right (s) 0.64 (0.51–0.78) [21] 0.62 (0.51–0.74) [17]
Structural brain outcomes 
Brain volume(*106mm3), mean (95%CI) ) [n] 1.37 (1.24–1.49) [22] 1.35 (1.23–1.48) [21]
Hippocampal volume left (*103mm3),  
mean (95%CI) [n]
2.8 (2.1–3.5) [20] 2.8 (2.1–3.6) [17]
Hippocampal volume right (*103mm3),  
mean (95%CI) [n]
2.9 (1.9–3.8) [20] 3 (1.9–4.1) [17]
White matter lesion volume  (*103mm3),  
median [IQR]  [n]
8.7 [3.6-26.9] [22] 9.2 [6.5-21.5] [19]
Infarcts, n(%) [n] 5 (23) [22] 4 (18) [21]
Microbleeds, n(%) [n] 5 (23) [21] 3 (14) [19]
Values are presented as mean (95% CI) for normally distributed variables, median [IQR] for non-normally 
distributed variables or n(%) for dichotomous variables. SBP and DBP were measured sitting position. 
Abbreviations: BMI, body mass index, MMSE, mini mental state examination range from 0 (severe impairment) 
to 30 (no impairment), CDR, clinical dementia rating range from 0 (no impairment) to 3 (severe impairment), 
CDRsob, clinical dementia rating sum-of-boxes range from 0 (no impairment) to 18 (severe impairment), 
ADAS, Alzheimer’s disease assessment scale - cognitive subscale range from 0 (no impairment) to 70 (severe 
impairment), SBP, systolic blood pressure, DBP, diastolic blood pressure, MCBFV, mean cerebral blood ﬂow 
velocity, CBF, cerebral blood ﬂow, ATT, arterial transit time.
Figure 2  Six month change in blood pressure and cerebral blood ﬂow. Estimated mean change, 
with standard error of the mean, over six months for nilvadipine (circle) and placebo (square) group. 
Abbreviations: SBP, systolic blood pressure, DBP, diastolic blood pressure, CBF, grey-matter cerebral 
blood ﬂow; Hipp-L, left hippocampus, Hipp_R, right hippocampus, PCC, posterior cingulate cortex. 
* indicates p<0.05 between the two groups, tested with ANCOVA
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Discussion
This study investigated the eﬀects of nilvadipine on CBF in patients with AD. In a double- 
blinded randomized controlled setting/design, grey-matter CBF was estimated with ASL- 
MRI at baseline and after 6 months use of either nilvadipine or placebo. In addition to 
global CBF, two regions of interest were deﬁned, known to show early changes in the AD 
disease process, the posterior cingulate cortex and the hippocampus.
 The main ﬁnding was that nilvadipine led to an increase of CBF to the left and a trend 
of increase to the right hippocampus, whereas global CBF and CBF in the posterior 
cingulate cortex did not signiﬁcantly change; also a reduction in SBP was found. 
 Given the antihypertensive properties of nilvadipine, the observed decrease in SBPVisit 
was expected. Moreover, the magnitude of decrease in SBP (~10 mmHg) is comparable to 
the eﬀect in antihypertensive trials34 and indicates that the dose of nilvadipine was 
eﬀective. 
 Despite this drop in BP, there was no decrease of CBF in any of the tested regions, 
which is similar to a previous study where BP was lowered in patients with mild cognitive 
impairment (MCI).35 The MCBFV measurements, that have been performed in sitting and 
standing position, conﬁrm the absence of a decrease in CBF. Moreover, they show that 
these ﬁndings are independent from body position. Thus, despite the lowering of blood 
pressure, CBF is maintained. 
 Moreover, there was an increase of CBF observed in the hippocampi, although only 
signiﬁcant in the left hippocampus. There are previous reports of an increase in regional 
CBF (left frontal lobe) with the use of nilvadipine,16, 17 but not in a (relatively normotensive) 
population with AD dementia. That the CBF increase was only observed in the hippocampi 
Table 3  Disease progression over six months in both groups and overall.
Change in: Placebo Nilvadipine Overall
MCBFV sit (cm/s) -1.0 (-17.1–15) 0.2 (-15.5–16) -0.4 (-16–15.3)
MCBFV stand (cm/s) -2.4 (-18.3–13.4) -0.6 (-12.1–10.9) -1.5 (-15.2–12.2)
ATT Global (s) -0.03 (-0.10–0.05) -0.01 (-0.06–0.05) -0.02 (-0.08–0.05)
Brain volume (%) -1.3 (-3.1–0.4) -1.1 (-2.4–0.3) -1.2 (-2.7–0.4)
Hippocampal volume left (%) -2.0 (-7.8–3.9) -2.0 (-7.2–3.2) -2.0 (-7.5–3.5)
Hippocampal volume right (%) -2.0 (-6.5–2.5) -2.6 (-6.9–1.6) -2.3 (-6.7–2)
White matter lesion volume  
(*103mm3)
1.0 [0.5-2.1] 0.6 [0.1-1.5] 0.8 [0.2-1.6]
Values are presented as mean (95%CI) for normally distributed variables, median [IQR] for non-normally 
distributed variables. Abbreviations: MCBFV, mean cerebral blood ﬂow velocity, ATT, arterial transit time.
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is in line with previous ﬁndings of an animal study, where, after BP lowering in a hyper- 
tensive AD mouse model, an increase in hippocampal CBF was observed.12 Yet, why this 
increase in CBF is only observed in the hippocampi remains speculative. The hippocampus is 
known to be a vulnerable region with regard to perfusion changes, since it relies strongly 
on the delivered glucose and oxygen.36 It may therefore be very sensitive for changes in 
perfusion pressure. This would also explain previously observed changes in hippocampal 
CBF in an early stage of AD.37, 38
 Previous studies reveal two possible mechanisms that could explain the stable to 
increasing CBF with the use of nilvadipine, despite the drop in BP. First, it suggests a stable 
functioning cerebral autoregulation in AD patients, which is in line with recent ﬁndings in 
AD.39 Moreover, there are indications that using antihypertensive drugs, the cerebral 
autoregulation curve is shifting, leading to an increase of CBF.40
 The second mechanism that could explain our ﬁndings are the eﬀects of nilvadipine 
on amyloid-β. First, nilvadipine has antagonizing properties to amyloid-β vasoactivity, 
shown both in vivo and in isolated arteries,14 resulting in dilation of the constricted vessels. 
Second, it decreases amyloid deposition by facilitating clearance of amyloid-β.15 These 
drug-speciﬁc properties would also explain previously observed diﬀerences in CBF 
response to nilvadipine and amlodipine in MCI subjects; where with the use of amlodipine 
global CBF did not change, with nilvadipine CBF increased.16 Further research is required 
to identify the contribution of each mechanism as most probable the combination of 
these two mechanisms explains the current ﬁndings. 
 Although ASL-MRI has, to our knowledge, not been used before in a RCT setting to 
evaluate CBF in AD patients, it has already proven its reliability and feasibility in longitudinal 
and cross-sectional studies.8, 37 We minimized variability in measurements by performing 
all measurements on the same MR-scanner and by correcting for diﬀerences in ATT, 
hematocrit and eﬀects of atrophy.41 Indeed, without correction for atrophy the observed 
eﬀect of nilvadipine was similar but non-signiﬁcant; moreover, without correction for 
hematocrit the increase in CBF is signiﬁcant for both left (p=0.03) and right (p=0.04) 
hippocampus (data not shown). 
 Furthermore, we validated the ASL-MRI outcomes with MCBFV measurements (using 
transcranial Doppler). Indeed, we observed a correlation (ρ=0.35, p=0.047) between the 
CBF-GM and MCBFV-sit (Figure s1). Nevertheless, whereas TCD can only assess global 
perfusion with a surrogate measure for ﬂow (velocity), ASL-MRI provides absolute estimates 
of regional ﬂow and is therefore superior in assessing localized changes in CBF. Thus, with 
carefully chosen acquisition and processing parameters ASL-MRI can be used to evaluate 
eﬀects of an intervention on regional and global CBF.  
 The retention of subjects was high, minimizing distortion of the results. However, 
there was approximately 10% missing data in the main outcomes. Since most missing data 
was due to logistic or technical problems rather than being patient-related (Table s2) data 
was predominantly missing completely at random. That the observed eﬀect is independent 
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from the missing data is conﬁrmed by the similar results on the imputed and complete-case 
datasets.
 Although these measurements were performed in a relatively small group of subjects, 
their characteristics were similar to the participants in the main NILVAD study (Table s1), 
thus diﬀerent results would not be expected in that population. The overall population 
consisted of subjects with a diagnosis of mild-to-moderate dementia due to AD. Since 
amyloid biomarker evidence was not required, this may have led to inclusion of patients 
without AD pathology. However, the diagnostic accuracy of clinical AD is approximately 
79%42 and with an observed progression of AD which is similar to previous ﬁndings of 
progression in AD, as indicated by the whole brain (1.2%)43 and hippocampal atrophy rate 
(2.0% and 2.3%),44 this group is likely representative for the overall patient group. 
Nevertheless, our ﬁndings cannot be translated to earlier stages of the disease, although 
a previous study in a small group of MCI patients showed similar results.16 Also, the group 
was (relatively) normotensive, in patients with hypertension the eﬀects are possibly 
diﬀerent. Previous ﬁndings indicate a more global increase in CBF.16, 40 Therefore, we expect 
that the results of this study can be generalized to a (relatively) normotensive mild-to- 
moderate AD population.  
Implications
This study shows that the use (of a low dose) of nilvadipine results in an increase in CBF 
to both hippocampi and stabilization in global CBF. Although interesting, the crucial question 
is whether the observed increase in CBF is beneﬁcial, as it may also be a compensatory 
eﬀect for functional decline. Unfortunately, sample sizes were too small  and follow-up 
time too short to study the eﬀects of the CBF increase on structural brain measures and 
cognitive measures (Table 3 and Figure s2). A study with larger groups and longer 
follow-up would be required to investigate these eﬀects. Furthermore, it would probably 
also be advisable to include subjects earlier in the course of AD (e.g. MCI stage), since the 
window of opportunity of recovery may have been expired. This is supported by the 
negative ﬁndings in the main NILVAD-trial, but with some indications of a positive eﬀect 
in the mild AD dementia subgroup (results under review).  
 Recently, it was acknowledged that it would be useful to also have multiple brain 
factors as endpoints in addition to cognitive biomarkers in evaluating treatment eﬀects in 
AD.2 With this sub-study we conﬁrm that additional measurements can provide valuable 
information on the physiological eﬀects of the intervention. Although the importance of 
CBF measurements in such trials still has to be proven, this study shows that with ASL-MRI 
changes in CBF, both global and regional, can be assessed in relatively small groups and 
with short follow-up periods. 
 That lowering of BP does not lead to a decrease in CBF is also a very relevant ﬁnding 
in light of treatment of hypertension in AD. Current hypertension guidelines lack speciﬁc 
advice regarding AD patients, since the ratio between safety and beneﬁt is not clear.45 
522648-L-bw-deJong
Processed on: 3-9-2018 PDF page: 161
Effects of nilvadipine on CBF in patients with AD | 161
6
One of the risks of BP lowering in this patient group is compromising CBF, since cerebral 
autoregulation might be aﬀected. Although we previously showed that dynamic cerebral 
autoregulation is still eﬀective in AD (Chapter 5), this study shows that also with blood 
pressure lowering, at least for nilvadipine, hypoperfusion is not likely. Yet, since nilvadipine 
also has a direct inﬂuence on cerebrovascular resistance, this cannot be extrapolated to 
other antihypertensive drugs. 
Conclusion
The use of nilvadipine led to an increase of CBF to left hippocampus, a trend of increase 
to right hippocampus, and a decrease in SBP. These ﬁndings indicate that the observed 
decrease in CBF in patients with AD can in some regions be reversed to some extent. 
In addition, this study demonstrates that ASL-MRI is feasible and valid for use to evaluate 
physiological changes in a relatively small sample of AD patients. 
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Figure S1  Scatter plot of the individual ﬂow outcomes at baseline as assessed with transcranial 
Doppler and arterial spin labeling. Each dot represents one participant and the solid line represents 
the linear regression curve with 95% CI (dashed curves). The x-axis shows the 5-minute average in 
mean cerebral blood ﬂow velocity in sitting (left) and standing(right) position and the y-axis shows 
the global CBF.
Figure S2  The mean (±SD) 18-month change in ADAS-cog (left) & CDRsob (right) for both treatment 
arms. ADAS, Alzheimer’s disease assessment scale - cognitive subscale range from 0 (no impairment) 
to 70 (severe impairment); CDRsob, clinical dementia rating sum-of-boxes range from 0 (no 
impairment) to 18 (severe impairment).
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Summary
Cerebral blood ﬂow (CBF), which is a net result of changes in the ratio between cerebral 
perfusion pressure (CPP) and cerebrovascular resistance (CVR), is reduced in Alzheimer’s 
disease (AD) and is predictive for disease progression. Causes for this reduction in CBF are 
only partly understood. Although this diminished CBF receives increasing attention in 
research, it still has a minor role in the total body of research in AD. Speciﬁcally, there has 
been very little attention to the possible disturbances in the regulation of CBF. Moreover, 
interventions that focus on reducing CBF deﬁcits are mostly absent, despite the proven 
importance of these CBF deﬁcits in disease progression. Therefore, the two research 
questions that have a central role in this manuscript are (1) Is there evidence for dysfunctioning 
of short-term regulation mechanisms of CBF in patients with AD and if so, does this dysfunction 
contribute to the observed decrease in CBF?  and (2) Can CBF deﬁcits in patients with AD be 
reduced by treating patients with nilvadipine?
 Cerebral autoregulation (CA) is the mechanism that aims to maintain adequate 
cerebral perfusion during changes in CPP. Transfer function analysis (TFA), the most widely 
used method to quantify dynamic CA (dCA), shows large between-study variability in 
outcomes. The aim of Chapter 2 was to investigate the role of measurement artifacts in 
this variation. The inﬂuences of three types of artifacts on TFA outcomes were modeled: 
loss of signal, head movement artifacts, and baseline drifts. This study showed that head 
movement artifacts should not be tolerated. Loss of signal distorted TFA outcomes, but if 
signal loss was less than 8%, the distortion was within acceptable ranges. The eﬀect of 
baseline drifts on TFA outcomes was negligible. All together, it is vital to validate signal 
quality to the deﬁned standards before interpreting TFA outcomes. 
 Whereas dCA reﬂects the response of CVR to short-term changes in CPP, the steady- 
state CA (sCA) reﬂects the CVR response to long-term changes in CPP. The relationship 
between the two mechanisms of dynamic and steady-state autoregulation was studied in 
Chapter 3, enabling correct application and interpretation of the CA measurements in 
research and in clinical care. In a group of healthy older adults, sCA was estimated by 
inducing stepwise increases and decreases in CPP (using infusion of the vaso-active drugs 
sodium nitroprusside and phenylephrine) and assess the resulting CBF. dCA was assessed 
in supine rest, analyzed with TFA and autoregulatory index (ARI), and during transient 
changes in CPP using a bolus injection of the same vaso-active drugs. There was variability 
between individuals in all (steady-state and dynamic) autoregulatory indices, ranging 
from low (almost absent) to highly eﬃcient CA. Comparison of sCA and dCA parameters 
demonstrated a lack of linear correlations between sCA and dCA measures. However, 
parameters within dCA and within sCA were correlated. These ﬁndings showed that 
assessment of a single CA parameter or a single set of parameters cannot be generalized 
to overall CA functioning. Thus, depending on speciﬁc research purposes, the choice for 
either steady-state or dynamic measures or both should be weighed carefully. 
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Besides CA, the baroreﬂex, which controls systemic arterial perfusion, is an important 
regulator for CBF homeostasis. A disturbed CBF homeostasis, e.g. the observed cerebral 
hypoperfusion in AD, elevates the risk of brain white matter (WM) lesions and cognitive 
impairment. Therefore, the purpose of Chapter 4 was to examine the associations among 
brain WM neuronal ﬁber integrity and baroreﬂex sensitivity (BRS) in older adults. Subjects 
with normal cognitive function or mild cognitive impairment (MCI) were included into this 
study. The neuronal ﬁber integrity of brain WM was assessed from diﬀusion metrics 
acquired by diﬀusion tensor MRI. BRS was measured in response to acute changes in 
blood pressure induced by bolus injections of vaso-active drugs. Since the WM diﬀusion 
metrics and BRS were not diﬀerent between the control and MCI groups, groups were 
combined in the analysis. Across WM, having ﬁber tracts with decreased integrity 
(in fractional anisotropy and radial diﬀusivity) was associated with also having lower BRS. 
In particular, the BRS assessed during hypotension was strongly correlated with lower 
WM integrity when compared with hypertension. Although the direction of these ﬁndings 
was not investigated, these ﬁndings suggest that baroreﬂex-mediated control of systemic 
arterial perfusion, especially during hypotension, may play a crucial role in maintaining 
neuronal ﬁber integrity of brain WM in older adults.
 If the previously discussed key control mechanisms for CBF, CA and BRS, are aﬀected 
in AD, antihypertensive treatment could increase the risk of cerebral hypoperfusion. 
Hence, in Chapter 5 we assessed whether CA and BRS are impaired in patients with MCI 
or dementia due to AD, by studying 53 patients with dementia, 37 patients with mild 
cognitive impairment and 47 controls. Beat-to-beat blood pressure, heart rate and CBF 
velocity (transcranial Doppler) were measured during 5 minutes rest (sitting) and 5 minutes 
of orthostatic challenges, using repeated sit-to-stand maneuvers. CA was assessed using 
TFA and the ARI. BRS was estimated with TFA and by calculating the heart rate response 
to blood pressure changes during the orthostatic challenges. Dementia patients had 
the lowest CBF velocity. During rest, neither TFA nor the ARI indicated impairments in CA. 
During the orthostatic challenges, higher autoregulatory index and lower TFA gain, 
indicating better CA, were found in dementia and mild cognitive impairment compared 
to controls. BRS measures did not diﬀer between groups. In conclusion, the key 
mechanisms to control CPP and CBF are not reduced in two stages of AD compared to 
controls, not in rest nor during orthostatic changes that reﬂect daily life challenges. 
 With the knowledge that the key control mechanisms for CBF are not aﬀected in AD, 
another question is whether the decline of CBF can be reduced. In Chapter 6 we 
investigated whether treatment with nilvadipine (a calcium-channel blocker) could 
restore CBF in AD. Patients with mild to moderate AD dementia were randomized to 
nilvadipine or placebo. At baseline and after six months CBF in grey matter was evaluated 
in the whole brain, the posterior cingulate cortex (PCC), the left and the right hippocampus, 
using arterial spin labeling MRI (ASL-MRI). Nilvadipine resulted in a signiﬁcant decrease in 
SBP compared to placebo. Also, following treatment there was an increase in CBF in both 
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hippocampi, whereas CBF in the whole brain and in the PCC remained stable. Thus, in 
these patients with AD, nilvadipine reduced blood pressure and increased CBF in the 
hippocampal region, while CBF in other brain regions remained stable. These ﬁndings 
could explain the beneﬁcial eﬀects of antihypertensive treatment on AD progression 
observed in some studies. 
Main findings
With the ﬁndings presented in this thesis answers can be formulated to the two research 
questions posed in the introduction of the thesis: 
1. Is there evidence for dysfunctioning of short-term regulation mechanisms of CBF in patients 
with AD and if so, does this dysfunction contribute to the observed decrease in CBF? 
We have assessed BRS and dCA as the most relevant short-term regulation mechanisms 
that control CBF, for which there were previous indications of malfunction in AD. However, 
in the present study, we observed no indication for deterioration of these regulation 
mechanisms with a broad range of measures, both during rest and during orthostatic 
challenges and in a large number of participants, in diﬀerent stages of the disease. Thus, 
although a longitudinal set-up could strengthen our ﬁndings, the currently available 
information points towards a normal functioning of the short-term CBF regulation 
mechanisms in patients with AD.  
2. Can CBF deficits in patients with AD be reduced by treating patients with nilvadipine 
The eﬀect of nilvadipine on CBF in patients with AD was isolated by performing a 
randomized controlled sub-study as part of a larger, randomized controlled, double 
blinded trial, which showed no eﬀect of nilvadipine on cognition. In this study CBF 
was assessed by means of ASL-MRI. With the use of nilvadipine global CBF remained 
stable, despite the decrease in systolic blood pressure. Moreover, hippocampal CBF, 
which usually is altered early in the disease process of AD, increased. Thus, nilvadipine 
is able to reduce CBF deﬁcits in AD, but only in some brain regions. 
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Research in context
Assessment of cerebral perfusion regulation
There are three ongoing debates in the ﬁeld of cerebral perfusion regulation to which the 
publications in this manuscript have contributed. The ﬁrst debate is on how to handle the 
large variability in the diﬀerent outcome measures. The second debate focuses on 
determining  the best measurement procedures to assess dCA. Similarly, the third debate 
relates to the best method to assess CBF.
 A substantial part of the overall variation in dCA outcome measures is related to 
diﬀerences in assessment and analysis procedures between research centers (i.e. analytic 
variability).1 In the past years the eﬀorts of the Cerebral Autoregulation Research network 
have resulted in more harmonization between centers in the assessment of the dynamics 
of CA.2 Yet, studying regulation of cerebral perfusion is speciﬁcally challenging in an older 
population. Older people, and especially older women, have a denser temporal bone, 
which impedes measurements using transcranial Doppler.3 In addition, subjects tend to 
be frailer and sometimes have problems with understanding or remembering test 
instructions. Therefore, the acquired signals are more prone to artifacts, such as loss of 
signal and movement artifacts. In Chapter 2 we showed how these artifacts aﬀect the 
measurement of CA parameters and deﬁned a clear set of criteria on how to identify and 
deal with these artifacts in the estimation of cerebral autoregulation parameters. Thus, 
when the work of chapter 2 would be added to the recently deﬁned criteria for acquisition 
and analysis2 the research ﬁeld can reduce the amount of analytic variability due to 
non-physiological sources, also in older adults, and therefore help to relate the overall 
variability to meaningful biological or physiological variability.
 Although our work did contribute to a reduction of the non-physiological variation in 
dCA measures, the issue of a high variation in dCA measures is far from resolved. The 
remaining unexplained physiological variation is still high, as was also revealed in Chapter 
3.  The overall biological variation can be divided in:  variation in parameters over time 
(intra-subject variability);4, 5 variation in parameters between (healthy) individuals 
(inter-subject variability);6 and diﬀerent outcomes between diﬀerently deﬁned dCA 
measures.7 Further research on how this variation can either be reduced or explained in 
terms of physiological mechanisms remains to be performed. 
 With regard to the second debate in the ﬁeld of cerebral perfusion regulation, the 
discussion is focusing on whether dCA assessment should be performed in rest8 or during 
induced CPP ﬂuctuations.9, 10 Inducing CPP ﬂuctuations may be helpful to reduce 
intra-subject variability, but in a vulnerable research population, i.e. patients at the 
intensive care unit, these ﬂuctuations may be diﬃcult to induce. Since this discussion is 
not yet resolved, in the current work measures derived from spontaneous as well as 
induced CPP ﬂuctuations were assessed. In chapter 3 these measures showed a correlation 
and also in Chapter 5, although not presented, there was a correlation between the ARI 
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measures in rest and during the sit-to-stand maneuver (ρ=0.3, p<0.01). Yet, the correlation 
was weak, indicating these measures cannot replace each other directly. Thus, results of 
studies with derived measures from spontaneous or induced ﬂuctuations should only be 
compared with caution. These ﬁndings stress the importance of further harmonization 
between research groups in assessment methodology.
 Similarly, diﬀerent measuring modalities of CBF are used in literature,11 and also in this 
thesis we employed TCD, color-coded duplex ultrasonography (CDUS) and ASL-MRI. In 
this thesis each modality was chosen to beneﬁt from its respective strength over other 
techniques and sometimes techniques were combined to reinforce each other. TCD has a 
high temporal resolution and is therefore superior in assessment of ﬂow oscillations and 
therefore suitable for assessment of the dynamic component of the regulation 
mechanisms. With CDUS, correction for changes in the diameter of the measured artery is 
possible, hence it is no longer a derivative of ﬂow (velocity), but actual ﬂow. Moreover, 
CDUS shares the ease-of-use with TCD, making this the best option to use when evaluating 
changes in ﬂow (over minutes to hours) where vessel diameters may not be constant, as 
may have been the case during the infusion of vaso-active drugs. However, it still lacks 
spatial information, since it provides only the aggregated information on the ﬂow territory 
of the respective artery. The ASL-MRI provides absolute estimates of ﬂow on a regional 
level (with a low temporal resolution), and is therefore most appropriate for CBF assessment 
in a longitudinal set-up. Indeed, in this thesis we demonstrated changes in hippocampal 
CBF, whereas CBFV as measured with TCD did not observe a change. Concluding, there is 
a range of options for assessment of CBF and the modality or combination of modalities 
need to be carefully chosen, depending upon the research aim. 
Cerebral perfusion (regulation) in Alzheimer’s disease
There is currently no complete overview of the role of cerebrovascular changes in disease 
progression in AD. Nevertheless, in the past few years study results  point towards a more 
causative role of cerebrovascular changes in AD progression.12, 13 Speciﬁcally, an increase 
of CVR was identiﬁed as one of the very early signs of developing AD.13 In line with changes 
in CVR, lower eﬃciency of short-term CBF regulation mechanisms were thought to be a 
reinforcing factor for causing periods of hypoperfusion.14-16 Chapter 5 showed that, 
opposite to previous ﬁndings, these mechanisms are not impaired in patients with AD 
within the range of normal hemodynamic oscillations. On the contrary, the data indicate 
that dCA in patients with AD may even be better functioning than in normal controls.  In 
summary, we provided with this thesis evidence that short-term CBF regulation 
mechanisms have no substantial role in AD progression. 
 To date, all phase-3 trials that aimed to delay the progression of AD, of which the vast 
majority of the investigated drugs intervene on the amyloid-β and/or tau aggregation 
cascade, have been negative.17-19 Also, the NILVAD study can be added to the list of 
negative studies (main results under review). The only positive trials so far have been trials 
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performed more than a decade ago, but these drugs, the acetylcholinesterase inhibitors, 
only temporarily relieved symptoms and did not mechanistically modify the course of the 
disease.19 Notably, precisely for these substances, increases in regional CBF have been 
observed,20, 21 and it has been hypothesized that this contributes to the beneﬁcial eﬀects 
of these cholinesterase inhibitors, the cholinergic-vascular hypothesis.22 The absence of 
any positive results on disease modifying drugs in the last decades shifts the research 
focus in two directions that ﬁt well with the ﬁndings in this thesis. 
 First, there is the trend to evaluate the eﬀect of medication in an earlier stage of the 
disease (e.g. MCI). Also, sub-group analyses in the NILVAD study hint towards a positive 
eﬀect of nilvadipine in mild AD (data not yet published). In addition, a previous preliminary 
open label phase-II study also suggested beneﬁcial cognitive eﬀects of nilvadipine in mild 
AD patients.23 Our new ﬁndings of improved hippocampal CBF could be causally related 
to such a beneﬁcial eﬀect by the physiological vaso-active eﬀect of the drug, and may 
support further hypotheses on beneﬁcial eﬀects of nilvadipine in either an earlier disease 
stage or after prolonged use.   
 Second, the argument for a broader research approach to understand and treat AD is 
growing stronger. The majority of previous trials focused on outcome measures based on 
cognition and/or amyloid aggregation. Recently, a modeling study showed that with the 
current study designs the chance for a type two error (not ﬁnding a positive eﬀect though it 
is present)  is very high.24 The major designs ﬂaws are the high variability in the mostly 
used cognitive outcome measure (the so called ADAS- COG: Alzheimer Disease Assessment 
Scale-Cognition), and the short duration of trials compared to the slow progression and 
the long preclinical stages of AD. This urgently calls for design innovation, in which more 
physiological, functional and quality-of-life measures should be used in concert. Moreover, 
with the multicausal origin of AD,25 combinatorial treatments probably are superior over 
the current single-target treatments.26 One might simultaneously target cerebral 
hypoperfusion, amyloid burden, oxidative stress and DNA mutations in the brain. However, 
to enable safe development of a multicomponent drug (a so called ‘poly-pill’), when new 
compounds are added, it is required to understand if and how diﬀerent drugs aﬀect 
various components of the brain function, including CBF, and the impact of the disease on 
these. This thesis presented ASL-MRI as a feasible and valid method to evaluate changes in 
regional and global CBF following an intervention. Hence, ASL-MRI may become a part of 
feature studies to potential AD drugs and AD drug combinations, both for measuring 
intermediate positive eﬀects, and for monitoring side-eﬀects on CBF. 
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Implications 
Assessment of cerebral perfusion regulation
When cerebral perfusion regulation is assessed, often only one of the CA measures is 
chosen. This is understandable, given the complex assessment procedures and diﬃcult 
interpretation of such measures. Nevertheless, although parameters are interpreted with 
caution, it remains a challenge to correctly interpret how each single indicator reﬂects the 
overall cerebral perfusion regulation functioning. Indeed, there is increasing evidence, this 
work included, that each measure for dCA reﬂects only one reductionist element of the 
CBF regulation,7 which provides little information about the other elements. Moreover, 
in Chapter 3 we have provided evidence that dCA measurements are not predictive for 
cerebral perfusion after long-term changes in CPP.
 Next to dCA, blood pressure regulation also plays a role in maintaining CBF, which is 
often neglected. Especially in aging, where the inverse relationship between BRS and CA 
functioning disappears,27, 28 this could be problematic. Possibly, in young adults the blood 
pressure and cerebral perfusion regulatory mechanisms are still able to compensate for 
each other, whereas in older adults functioning of both mechanisms is required for a 
stable CBF. Indeed, in Chapter 4 we provided evidence that the baroreﬂex functioning has 
eﬀects on white matter integrity, probably through causing periods of cerebral hypo-
perfusion. 
 Given this gained knowledge, there are consequences for the assessment of the CBF 
regulation mechanisms. Especially in older persons, where variability is high, it is important 
to assess a range of measurements that reﬂect diﬀerent elements of the overall CBF 
regulation mechanisms. In contrast with the assessment of steady state regulation of 
cerebral blood ﬂow, this does not need to be very complex for the dynamic regulation. 
With an assessment procedure of both 5 minutes during rest and 5 minutes repeated 
sit-stand maneuvers, various parameters for dCA (based on spontaneous and induced 
ﬂuctuations) and BRS can be estimated. Depending on the speciﬁc research aims, one of 
the measures can be chosen (a priori) as primary outcome, but for good understanding of 
the diﬀerent elements of the regulation mechanisms also the accompanying parameters 
should be presented. Especially more knowledge of the role of the BRS in CBF regulation, 
which is now often neglected, could help in gaining a comprehensive overview. However, 
to predict the eﬀects of long-term changes in BP to cerebral perfusion, actual assessment 
of sCA remains required.
Antihypertensive treatment in Alzheimer’s disease
The prevalence of hypertension in AD is high (at least 45%)29 and cerebrovascular diseases 
are among the major causes of death in AD.30 Considering that patients with mild or 
moderate AD have an average estimated survival rate of 3-9 years after AD diagnosis,31 
they may still beneﬁt from the positive eﬀects of antihypertensive drugs, if delay of disease 
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progression is indeed part of the individual treatment aims. However, two observational 
studies in patients with AD dementia showed a faster cognitive decline in the patient 
group using antihypertensive drugs.32, 33 Contrasting, other studies show a delay in 
cognitive decline when using antihypertensive drugs, possibly caused by the vasodilatory 
eﬀects, leading to better perfusion.34 This puts the physician in a diﬃcult position in 
deciding on treatment, especially with the new hypertension guidelines. These 
recommend a treatment goal of SBP less than 130 mmHg in older adults with few 
comorbidities and high physical ﬁtness. In patients with high frailty and comorbidity 
burden a higher SBP is acceptable (up to 150 or 160 mmHg), leaving a large group in the 
grey zone of uncertainty. In these cases, for example patients with mild stage of Alzheimer 
dementia without serious comorbidity, the decision on SBP treatment now has to be 
guided by wise and experienced clinical judgment linked to the individualized treatment 
preferences of the patients.35 In such cases, clinical monitoring of CBF and CA might help 
to evaluate the overall balance of risks and safety, especially if the next stage of CBF and 
CA measurements can be made suﬃciently reliable and simple to be carried out in daily 
geriatric practice. In this research we added new methodological knowledge that may 
indeed facilitate implementation and interpretation of such data in clinical practice, at ﬁrst 
in specialized Alzheimer Centers or memory clinics.
 With regard to the interpretation of measurement results, it is important that  we 
found no impairments in short-term cerebrovascular perfusion regulation mechanisms in AD 
patients (Chapter 5). In addition, our ﬁndings of a stable CBF after six months of treatment 
with nilvadipine add that also long-term regulation mechanisms are intact (Chapter 6). 
These results indicate that these patients do not have an inherently increased risk that lowering 
BP (with antihypertensive treatment) will lead to a (further) reduction in CBF or BP instability, 
negatively aﬀecting disease outcome. Notwithstanding, there could be other underlying 
mechanisms that explain the faster cognitive decline in patients using antihypertensive 
drugs; further research is required to elucidate these mechanisms. 
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Future perspectives
Interesting parallels can be made between the research ﬁeld of cancer and of AD, with the 
latter lagging behind a few decades (see also Figure 1 of the introduction). Cancer research 
was for a long time aimed at ﬁnding the ‘magic bullet’ that would cure the disease. Later, 
the big wins turned out to be found in prevention,36 and in combining diﬀerent therapies 
and drugs. Similar developments can be observed in the research ﬁeld of AD. As described 
in a previous section of this chapter (Changes in cerebral perfusion in Alzheimer’s disease), 
the argument for a more integrated view on AD is already growing stronger, with also 
including adequate assessment of cerebrovascular changes. Next to this, there is increased 
attention to other factors (e.g. sleep quality) that contribute to prevention of AD. Initially, 
the success of prevention for AD was a nice side-eﬀect resulting from prevention for 
cardiovascular diseases, but nowadays, programs are developed that speciﬁcally focus on 
how to maintain a healthy brain, e.g. the healthy brain cohort at the Radboud University 
and the ‘MijnBreinCoach app’ of the Alzheimer Centre Limburg. Possibly, the ASL-MRI can 
have a role in evaluating the eﬀects of these programs. By encompassing a multi-domain 
approach, such programs will hopefully contribute to further decline in AD incidence, and 
the ﬁrst signs for these multi-domain interventions are promising.37 Thus, the research 
ﬁeld of AD is, driven by the absence of success of pharmaceutical drug trials in the past 
two decades, preparing for a paradigm shift, which may be similar to paradigm shifts seen 
before in the ﬁeld of cancer. This will also require a methodological shift.
 In this thesis the main techniques to assess CBF were TCD and ASL-MRI. As discussed, 
TCD has a high temporal resolution, but it lacks spatial information. Vice versa, the ASL-MRI 
has a high spatial resolution, but temporal resolution is low. A method that could combine 
spatial and temporal information on CBF for the whole brain would provide much extra 
insight in the regulation of CBF. Other techniques, like near-infrared spectroscopy (NIRS), 
already provide information with a high temporal and spatial resolution, but only of a 
small region; global information is lacking. Nevertheless, in both methods there are 
developments that would ultimately allow measurements with a high spatial and temporal 
resolution. For ASL-MRI the non-averaged images may provide information of temporal 
information up to 0.1 Hz (data not published). However, a valid MR-compatible device to 
continuously measure BP is currently lacking, which is an obstacle in enabling assessment 
of CA with ASL-MRI. For TCD, the combination of contrast-enhanced ultrasound (with 
microbubbles) has the highest potential in gaining spatial information with a high temporal 
resolution.38 Further developments in these techniques will ultimately contribute to 
better understanding of regulation of CBF and could explain regional diﬀerences, such as 
the local increase we observed in hippocampal CBF. 
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Conclusion
Taken together, this thesis showed that in patients with AD, despite the known decrease 
of CBF and impaired cerebral vasomotor reactivity, two key mechanisms to control 
short-term stability of CBF, dCA and BRS, are well preserved. Considering these contrasting 
AD-related physiological eﬀects, predictions of long-term changes in BP on CBF, e.g. after 
starting antihypertensive treatment, are not straightforward; as demonstrated in this 
thesis, dCA does not linearly translate to sCA. Hence, CBF was also evaluated in AD patients 
after six-month of treatment with an antihypertensive drug (nilvadipine). Here we showed 
that CBF remained intact, indicating that also sCA was preserved. On top of that, CBF to 
the hippocampi increased, thereby reducing localized CBF deﬁciencies in AD patients. Yet, 
further research is required to study whether this observed increase in hippocampal CBF 
provides clinical beneﬁt, and further methodological improvements in CBF measurements 
are needed to warrant application in clinical practice of memory clinics.
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Nederlandse samenvatting
Hersendoorbloeding is verlaagd bij de ziekte van Alzheimer en de grootte van deze 
verlaging is voorspellend voor ziekteprogressie. De oorzaken van de daling in de hersen-
doorbloeding worden maar deels begrepen. Hersendoorbloeding wordt bepaald door 
de verhouding tussen de perfusiedruk en de weerstand van de vaten. Hoewel er steeds 
meer onderzoek gedaan wordt naar hersendoorbloeding bij de ziekte van Alzheimer, is 
dit marginaal vergeleken met het totale onderzoek naar de ziekte van Alzheimer. Of de 
mechanismen die de hersendoorbloeding stabiel houden, de regulatiemechanismen, 
aangedaan zijn is bijvoorbeeld niet duidelijk. Daarnaast zijn er vrijwel geen interventies 
voor de ziekte van Alzheimer die zich richten op het herstellen van de hersendoorbloe-
ding, ondanks de belangrijke rol voor hersendoorbloeding in de progressie van de ziekte. 
Om die reden staan de volgende twee vragen centraal in dit manuscript: (1) Is er bewijs 
voor het disfunctioneren van de korte-termijn regulatie-mechanismen voor hersendoorbloe-
ding bij patiënten met de ziekte van Alzheimer, en draagt deze disfunctie bij aan de bekende 
daling in hersendoorbloeding? (2) Kan een te lage hersendoorbloeding bij patiënten met de 
ziekte van Alzheimer hersteld worden door patiënten te behandelen met nilvadipine? 
 Cerebrale autoregulatie (CA) is het regulatiemechanisme dat de hersendoorbloeding 
op peil houdt tijdens schommelingen in de perfusiedruk. De meest gebruikte methode 
om de dynamische CA (dCA; de weerstandsrespons op kortdurende veranderingen in 
perfusiedruk) te bestuderen is de transfer-functie analyse (TFA). Echter, deze analyse laat 
veel variatie zien, onder andere tussen studies. Het doel van Hoofdstuk 2 was om de rol 
van meetartefacten in de variatie van TFA uitkomsten te onderzoeken. Speciﬁek zijn drie 
typen artefacten gemodelleerd: signaalverlies, hoofdbewegingen en baseline drift. Het 
bleek dat hoofdbewegings-artefacten veel invloed hebben op de uitkomst en daarom 
niet getolereerd moeten worden. Signaalverlies had ook eﬀect op de uitkomstmaten, 
maar zolang het verlies minder dan 8% van het totale signaal was waren de verstoringen 
nog acceptabel. De baseline drift had nauwelijks eﬀect op de TFA uitkomsten. Kortom, het 
is belangrijk om de signaalkwaliteit te veriﬁëren voordat de uitkomsten geïnterpreteerd 
worden. 
 Naast de dCA is er ook de stabiele-staat CA (sCA), die de weerstandsrespons op 
langdurige veranderingen in perfusiedruk beschrijft. De relatie tussen beide mechanismen 
(sCA en dCA) hebben we bestudeerd in Hoofdstuk 3, waarmee een juiste toepassing en 
interpretatie van deze maten mogelijk wordt gemaakt. In een groep gezonde ouderen 
hebben we het functioneren van sCA bepaald door het stapsgewijs laten stijgen en dalen 
van de perfusiedruk (via infusie van stoﬀen die zorgen voor vaatverwijding, sodium 
nitroprusside, en vaatvernauwing, phenylephrine). dCA werd bepaald tijdens een rust- 
meting in liggende positie, door de TFA en het bepalen van de autoregulatie-index (ARI), 
en tijdens snelle veranderingen in perfusiedruk door een bolus toe te dienen van eerder 
genoemde stoﬀen. We zagen veel variatie tussen de proefpersonen in alle CA uitkomst-
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maten, variërend van nauwelijks functionerende tot heel goed functionerende CA. Er was 
geen lineair verband tussen de sCA en dCA parameters, maar onderling waren sCA en 
dCA parameters wel gecorreleerd. Deze bevindingen laten zien dat het meten van één CA 
parameter niet vertaald kan worden naar een algeheel functioneren van de regulatie van 
hersendoorbloeding. 
 Naast CA is de baroreﬂex een belangrijk mechanisme voor een constante hersen-
doorbloeding, door de perfusiedruk te reguleren. Een verstoorde hersendoorbloeding, 
bijvoorbeeld de verlaagde doorbloeding bij de ziekte van Alzheimer, verhoogt het risico op 
witte stof schade in het brein en op cognitieve achteruitgang. Het doel van Hoofdstuk 4 was 
om de associatie tussen de baroreﬂex en de witte stof schade in ouderen te onderzoeken. 
Zowel gezonde ouderen als mensen met milde geheugenklachten werden getest. 
De witte stof schade werd bekeken met behulp van een MRI-techniek, de diﬀusie-tensor 
beeldvorming. De baroreﬂex werd bestudeerd door de respons te meten na een geïnduceerde 
acute bloeddrukverandering (met bolus-injectie van de eerder beschreven stoﬀen). Aangezien 
er tussen de ouderen zonder en met milde geheugenklachten geen verschillen waren in 
witte stof schade en baroreﬂex, zijn beide groepen samengevoegd in de analyse. Het 
hebben van aangetaste witte stof banen (in radiale diﬀusiviteit en fractionele anisotropie) 
was geassocieerd met een slechter functionerende baroreﬂex. Vooral de baroreﬂex tijdens 
dalingen in bloeddruk was sterk gecorreleerd aan lagere integriteit van de witte stof. 
Hoewel we niet onderzocht hebben in welke richting dit verband liep, suggereren deze 
observaties dat de regulatie van bloeddruk via de baroreﬂex, vooral tijdens dalingen in 
bloeddruk, een rol speelt in het behouden van de integriteit van de witte stof in ouderen. 
 Als de eerder besproken regulatiemechanismen voor hersendoorbloeding, de CA en 
baroreﬂex, aangedaan zijn in de ziekte van Alzheimer, dan zou het behandelen van 
hypertensie mogelijk leiden tot verlaagde hersendoorbloeding. In Hoofdstuk 5 hebben 
we gekeken of CA en baroreﬂex zijn aangedaan in patiënten zowel met milde geheugen-
klachten als dementie door de ziekte van Alzheimer. Hiervoor hebben we bij 53 patiënten 
met dementie, 37 patiënten met milde geheugenklachten en 47 controles deze regulatie-
mechanismen beschouwd. De bloeddruk, het hartritme en de hersendoorbloeding (met 
transcraniele Doppler) zijn slag voor slag gemeten tijdens vijf minuten zitten en vijf 
minuten van repeterend zitten en staan. Voor de CA werden zowel de TFA als ARI bepaald, 
de baroreﬂex werd bepaald met TFA en door de respons van het hartritme op de 
geïnduceerde bloeddrukschommelingen (tijdens het zitten en staan) te kwantiﬁceren. 
Zoals verwacht hadden de patiënten met dementie de laagste hersendoorbloeding. 
In rust waren zowel de TFA uitkomsten als de ARI uitkomsten normaal, tijdens het 
repeterend zitten en staan leek de CA zelfs wat beter bij patiënten met de ziekte van 
Alzheimer, zowel in de CA index als in de TFA uitkomst. De baroreﬂex maten verschilden 
niet tussen de groepen. Concluderend zijn de controle mechanismen niet verzwakt in 
twee fases van de ziekte van Alzheimer in vergelijking met gezonde oudere controles, 
zowel in rust als tijdens zitten en staan. 
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Met de kennis dat de controlemechanismen van hersendoorbloeding niet aangedaan zijn 
in de ziekte van Alzheimer, is de volgende vraag of de daling in hersendoorbloeding 
verminderd kan worden. In Hoofdstuk 6 hebben we onderzocht of behandeling met 
nilvadipine (een calcium antagonist) de hersendoorbloeding weer kan herstellen. 
Patiënten met een milde tot matige vorm van dementie door de ziekte van Alzheimer 
werden gerandomiseerd in behandeling met nilvadipine of met een placebo. Aan het 
begin en na zes maanden werd de hersendoorbloeding in de grijze stof gemeten met 
behulp van arterial spin labeling MRI; zowel in het hele brein als in de achterste cingulate 
cortex (PCC) en beide hippocampi. Nilvadipine zorgde voor een signiﬁcante daling van de 
systolische bloeddruk in vergelijking met de placebo groep. Ook was er als gevolg van de 
behandeling een stijging van hersendoorbloeding naar de hippocampi, maar de door- 
bloeding naar het hele brein en de PCC bleef constant. Oftewel, in patiënten met de ziekte 
van Alzheimer zorgt nilvadipine voor een bloeddrukdaling met een toename in door - 
bloeding van de hippocampi. Dit zou kunnen verklaren waarom sommige studies gunstige 
eﬀecten vinden bij de behandeling van hypertensie bij patiënten met de ziekte van 
Alzheimer. 
 Concluderend laat deze thesis zien dat bij patiënten met de ziekte van Alzheimer, 
ondanks de bekende daling van hersendoorbloeding, twee belangrijke mechanismen 
om de hersendoorbloeding op korte termijn te reguleren (CA en baroreﬂex) nog goed 
functioneren. Echter, deze thesis laat ook zien dat het functioneren van deze mechanismen 
niet automatisch door te vertalen is naar voorspellingen voor de hersendoorbloeding op 
lange termijn, bijvoorbeeld na een behandeling met bloeddrukmedicatie. Daarom hebben 
we ook de hersendoorbloeding geëvalueerd na een behandeling van zes maanden met 
een bloeddrukverlagend medicijn (nilvadipine). Hier zagen we dat de hersendoorbloeding 
constant bleef. Daar bovenop zagen we dat de hersendoorbloeding naar beide hippo- 
campi toenam, en er dus herstel was van de hersendoorbloeding. Toch is er nog vervolg-
onderzoek nodig om te kunnen zeggen of dit herstel van hersendoorbloeding in de 
hippocampi ook klinisch voordeel heeft. 
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Dankwoord
Hoewel alleen mijn naam op de cover van dit boekje staat, is dit werk allerminst 
gerealiseerd door alleen mijn inspanningen. Daarom wil ik hier alle mensen bedanken die 
direct of indirect hebben bijgedragen aan de totstandkoming van dit werk. En natuurlijk 
wil ik ook u als lezer bedanken. Of u nu het hele boekje gelezen heeft of alleen dit 
dankwoord, bedankt dat u hier de moeite voor neemt. Want iedereen die hier genoemd 
staat verdient op z’n minst dat kleine beetje aandacht. 
 Allereerst gaat mijn grote dank uit naar alle deelnemers van dit onderzoek. Zonder 
jullie was er niets mogelijk geweest van het werk dat ik gedaan heb. Echt geweldig dat u 
zich zo belangeloos inzet om de kennis rondom de ziekte van Alzheimer verder te 
brengen. En we hebben nogal wat van jullie gevraagd, variërend van stil blijven liggen in 
het lawaai van de MRI tot het vervelens aan toe gaan zitten en staan terwijl u vol hing met 
allerhande meetapparatuur. Dankzij uw volhardendheid is het ons gelukt om tot duidelijke 
conclusies te komen. Ik hoop van harte dat de wetenschap er uiteindelijk in slaagt dichter 
bij een goede behandeling te komen. Als we daar uiteindelijk komen, is dit zeker ook 
dankzij jullie. 
 Natuurlijk wil ook mijn begeleidingsteam bedanken. Marcel, dank voor de ruimte en 
mogelijkheden die je me geboden hebt. Heel erg ﬁjn om vanuit vertrouwen te kunnen 
werken en in combinatie met de kleine bijsturingen onderweg, ging het toch altijd de 
goede kant uit. Jouw gedrevenheid voor de oudere patiënt is een groot voorbeeld! Beste 
Jurgen, ook heel veel dank aan jou. Heerlijk om na elk overleg weer met nieuwe ideeën 
verder te kunnen en mijn onzekerheid weer wat kleiner gemaakt te hebben. Geen verzoek 
was gek genoeg voor jou, altijd was erover te praten. Thijs, wat ﬁjn dat je nog bij mijn 
project bent aangehaakt. Ik heb jouw feedback echt gewaardeerd, je hielp me enorm om 
scherp te blijven en kritisch te kijken naar wat ik nu aan het doen was. Zonder jouw 
expertise was dit boekje niet zoals het nu is. Olga, hoewel ik de eindstreep helaas niet met 
jou aan mijn zijde gehaald heb, heb ik wel ongelofelijk veel aan jouw begeleiding gehad. 
Jouw enthousiasmerende manier om mensen mee te krijgen is ongeëvenaard en een 
groot voorbeeld voor mij. Dit werk is er zeker ook dankzij jou!
 Naast het begeleidingsteam gaat mijn dank natuurlijk ook uit naar de andere leden 
van het NILVAD-team. Een dergelijke studie is niet alleen te doen, en ik denk dat wij als 
team elkaar enorm goed hebben versterkt. Geen enkele uitvaller, dat komt niet alleen 
door onze geweldige deelnemers, maar ook door goed teamwerk! Gerrita, dankzij jou 
liep de studie als een trein en was alles altijd op orde en georganiseerd. Ik heb hierin echt 
heel veel van jou geleerd, bedankt! Beste William, wat ben ik enorm jaloers op jouw 
omgang met patiënten, ongeëvenaard!  Al heb ik dat misschien niet vaak genoeg gezegd, 
je bent echt een onmisbare spil geweest in dit onderzoek. Anne, Angelina en Laura, wat 
ﬁjn dat jullie hebben kunnen aanhaken in verschillende fases van de studie. Zowel het 
verzamelen als verwerken van de data is dankzij jullie een stuk verder gekomen. 
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Dat ik elke dag weer met plezier naar het werk ging is te danken aan alle leuke collega’s. 
Allereerst natuurlijk aan al mijn kamergenoten. Doordat ik nogal eens van kamer verhuisd 
ben, zijn dat er nogal wat, maar met jullie allemaal was het een plezier om de kamer te 
delen. Dus veel dank Anke, Anne, Carlijn, Esther, Fokke, Gerrita, Marit, Minke, Noralie, 
Sanne en Sharon voor al de goede gesprekken en het tussentijdse plezier. Maar ook dank 
aan de vele andere collega’s van de afdeling, o.a. : Anke, Anouk, Carolien, Franka, Freek, 
Geke, Kim, Marieke, Marjolein, Miriam, Miriam, Jana, José, René, Roel, Teun en Thea. 
De lunchwandelingen, intervisies, borrels, bierweekenden, ﬁetstochten en wadloop- 
tochten; ik heb er van genoten.  
 Natuurlijk ook dank aan de mensen die mij kennis hebben laten maken met de 
geriatrie. Beste Aisha en Joep, dank voor alle lessen die ik als stagiair van jullie gekregen 
heb. Omgekeerd gaat mijn dank ook uit naar de mensen die ik als stagiair heb mogen 
begeleiden. Anniek, Anouk, Daan, Jasper en Karlijn, ik vond het een eer jullie te mogen 
begeleiden en jullie te zien groeien. Ik wil jullie ook bedanken voor de bijdrage die jullie 
aan dit werk geleverd hebben. 
 I have been fortunate enough to also collaborate with people abroad. I would like to 
thank Rong for his hospitality to have me at his department for some months. It has been 
a valuable experience to see a lab that is dedicated to science and science alone. Taka, 
thanks to you I did not only have a look at the lab, but could actually contribute something. 
Thank you so much for giving me the trust and providing me with these opportunities. 
Also I would like to express my gratitude to the entire NILVAD consortium, and in 
particular to Brian Lawlor, it was a pleasure to work in such a great team of health care 
professionals and researchers. Teemu, I really enjoyed to work with a real engineer, thank 
you for visiting us. And lastly all the people from CARNet, and speciﬁcally Ronney and 
David, it was a real pleasure to meet you every year and learn from all your experience.
 Mijn speciale dank gaat uit naar Frans, Thalijn, Pim en Erik. Dankzij jullie is het 
richting het einde van mijn promotie weer opwaarts gegaan. Dank jullie wel voor jullie 
goede zorgen en ook voor het schrijven van de mooie casus. 
 Gelukkig was er naast dit promotie ook nog genoeg ruimte voor andere activiteiten. 
Allereerst wil ik mijn bestuursgenoten binnen de NVvTG bedanken. Beste Abel, Juliëtte, 
Marjon, Marleen, Martijn, Martijn, Mats, Monique, Myrthe en René, ik vond het heel 
ﬁjn om met jullie samen de technisch geneeskundigen beter op de kaart te zetten. We 
hebben samen een stap weten te zetten, dat er nog maar veel stappen mogen volgen de 
komende tijd. Ook dank aan de nationale denktank 2016. Wat heerlijk om jullie te leren 
kennen en ook nog eens met jullie allemaal samen te mogen werken. In het speciaal dank 
aan Gerben, Hannah, Houssam, Jan, Melline, Ottilia en Rasila; dankzij jullie was het 
iedere dag weer een feestje op de kamer. 
 Naast de ‘serieuzere’ randactiviteiten was het ook ﬁjn om af en toe de ontspanning 
op te zoeken. Beste Bart, Simon, Joep, Sebastiaan, Kristian, Jasper, Cecile, Wouter en 
Johan, bedankt voor de leuke avonden en weekenden met bier, spelletjes, kroegpraat en 
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wat zo niet meer. Teamgenoten van Orion ses, seufe, agt en alf, bedankt voor de 
gezellige jaren. Fijn dat ik toch elke week weer de kans krijg om mijn ‘voetbalkwaliteiten’ 
tentoon te spreiden. Ook dank aan QHarmony, de Snoeptafel en Multivox voor de 
soms broodnodige aﬂeiding. 
 Lieve Robin en Yvette, ik vind het altijd weer genieten om met jullie te zijn. Ik houd 
ervan zoals we elkaar scherp houden. En hoewel ik de afgelopen tijd wat meer op mezelf 
gericht was, wil ik eigenlijk niets missen van wat jullie doen. Ik ben heel trots op wat jullie 
doen en bereiken. Steeds meer worden jullie, in plaats van mijn kleine zusje en broertje, 
persoonlijkheden waar ik veel van kan leren en die een voorbeeld voor mij zijn. 
 Gerard en José, papa en mama, avontuur is leuker als je weet dat er een stabiele 
haven is waar je op terug kunt vallen. Dat bewijzen jullie keer op keer, ook tijdens dit 
 promotieavontuur. Bedankt dat jullie er altijd voor me zijn. Ook jullie adviezen zijn altijd 
weer raak, en jullie zijn een geweldig voorbeeld om mezelf voor te houden. Dankzij jullie 
heb ik dit allemaal kunnen doen en bereiken. Mijn dank hiervoor is heel groot. 
 Lieve, allerliefste Rianne, ik had niet verwacht dat mijn promotietraject ook jou zou 
brengen. Maar dat is een nog mooiere opbrengst dan dit boekje! Bedankt voor al je steun, 
eerst alleen als collega en later ook als vriendin. Dankzij jou heeft alles, ondanks mijn 
tijdelijke afwezigheid, door kunnen lopen.  Dat we een van de artikelen in dit boekje delen 
vind ik geweldig, dat het zo’n plezier was het te schrijven een onderstreping van de 
synergie tussen ons. Ik vind het ﬁjn om bij jou en met jou te zijn. Ik kijk uit naar wat we nog 
allemaal samen mee gaan maken. 
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2015 CARnet, Southampton, UK (poster presentation, awarded with best 
student poster award)
0.5
Jan Beneken Conference, Nijmegen (participant) 0.6
2016 CARnet, Boston, USA (oral and poster presentation, awarded with 2nd prize 
Young Investigator Award)
1.2
ESMRMB, Vienna, Austria (oral presentation) 1.0
2017 CARnet, Berlin, Germany (poster presentation) 1.2
Other activities
2013 Organizing committee of NVvTG conference -
2013-2017 Lab coordinator of hemodynamic lab -
2014 Awarded with fellowship travel grant of ISAO -
2014-2016 Board Member of Dutch association of Technical Medicine (NVvTG) -
2014-2016 Supervision of internships -
2016 Participant at Nationale DenkTank -
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established 
the Donders Graduate School for Cognitive Neuroscience (DGCN), which was oﬃcially 
recognised as a national graduate school in 2009. The Graduate School covers training at 
both Master’s and PhD level and provides an excellent educational context fully aligned 
with the research programme of the Donders Institute. 
 The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
 The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, e.g. 
Stanford University, University of Oxford, University of Cambridge, UCL London, MPI 
Leipzig, Hanyang University in South Korea, NTNU Norway, University of Illinois, North 
Western University, Northeastern University in Boston, ETH Zürich, University of Vienna 
etc.. Positions outside academia spread among the following sectors: specialists in a 
medical environment, mainly in genetics, geriatrics, psychiatry and neurology. Specialists 
in a psychological environment, e.g. as specialist in neuropsychology, psychological 
diagnostics or therapy. Positions in higher education as coordinators or lecturers. A smaller 
percentage enters business as research consultants, analysts or head of research and 
development. Fewer graduates  stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT sector 
and management position in pharmaceutical industry. In general, the PhDs graduates 
almost invariably continue with high-quality positions that play an important role in our 
knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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